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Introduction 
 
1 Introduction 
In 2006, the World Health Organization (WHO) drew attention to the importance of the burden 
of neurological diseases for the public health.1 Hundreds of millions of people over the world 
suffer from neurological disorders like epilepsy, Alzheimer’s disease or dementia, Parkinson’s 
disease and depressions whereby more than 50 million people are affected by epilepsy 
globally.2,3 Epilepsy is defined as a chronical disorder of the brain and is characterized by 
having two or more unprovoked seizures over a period greater than 24 hours apart. Seizures 
are brief episodes of uncontrolled movement of part of the body or the entire body of a patient.4 
80 % of the epilepsy patient are living in low- or middle-income countries and 75 % do not 
receive necessary treatments.3 But also upon applying one of over 15 approved antiepileptic 
drugs (AEDs) more than 30 % of the patients continue to have seizures and up to the half of 
them are affected by psychiatric, cognitive and social side-effects.5 Hence, the development 
of more potent and lower-cost medications with minor side-effects are a huge field of interest 
for research.  
One key structure as starting point for the research of the mentioned neurological disorders 
and for the identification of novel drugs for the treatment is γ-aminobutyric acid (GABA, 1, 
Figure 1) as the major inhibitory neurotransmitter in the mammalian central nervous system 
(CNS).6 
 
Figure 1: Structure of γ-aminobutyric acid (GABA, 1). 
 
1.1  GABAerge Neurotransmission 
A summary of the neurotransmission of GABA in the mammalian brain is displayed in Figure 
2.7,8 GABA is synthesized in the presynaptic neurons through enzymatic decarboxylation of 
glutamate (Glu) – a potent excitatory neurotransmitter – by glutamic acid decarboxylase (GAD) 
and is then stored in synaptic vesicles by vesicular neurotransmitter transporter (vGAT). Due 
to depolarization of the presynaptic neuron the neurotransmitter GABA is released in the 
synaptic cleft where it can bind to the GABA receptors GABAA and GABAB.7 
The GABAA receptors are chloride ion channels mainly located on the postsynaptic membrane 
which enable the influx of chloride ions in the postsynaptic neuron upon the binding of GABA. 
This results in the hyperpolarization of the neuron and thus leads to an inhibition of the neural 
transmission. In contrast, the GABAB receptors are G-protein coupled receptors (GPCR) found 
on pre- and postsynaptic neurons which regulate the excitability of the cell in two location-
dependent mechanisms. Binding of GABA to the presynaptic GABAB receptors causes a 
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reduced calcium influx and therefore a reduction of the release of GABA in the synaptic cleft. 
Differently, postsynaptic GABAB receptors mediate a G-protein induced stimulation which 
causes the efflux of potassium through K+-ion channels and thus a hyperpolarization of the 
neuron. This leads to an inhibition of the GABAergic neurotransmission.9 
The inhibitory neurotransmission mediated by GABA is terminated by the reuptake of the 
neurotransmitter from the synaptic cleft in the presynaptic neurons or the surrounding glial cells 
by membrane-bound GABA transport proteins (GATs) subtype 1 and 3.10 Thereafter, GABA is 
either restored again in synaptic vesicles in the presynaptic neurons or is enzymatically 
degraded in the glial cells by GABA transaminase (GABA-T) to succinic semialdehyde.8 
 
Figure 2: GABAergic neurotransmission according to literature.7,8 γ-Aminobutyric acid (GABA) is 
synthesized through enzymatic decarboxylation of glutamine (Glu) and stored in vesicles by vesicular 
GABA transporter (vGAT). After release in the synaptic cleft due to an action potential it can interact 
with the receptors GABAA and GABAB. Reuptake of GABA in the presynaptic neuron or glial cells is 
accomplished by GABA transporters (GATs) subtype 1 and 3.  
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1.2 Pathology and Therapy 
An imbalance between inhibitory neurotransmission facilitated by GABA and glutamate 
mediated excitatory transmission caused by a reduced GABAergic neurotransmission8 are 
assumed to be associated with the development of neurological diseases like epilepsy11, 
Alzheimer’s disease or depression12. To reset the balance, the enhancement of the GABAergic 
signaling is one possible approach with different targets to address as e.g. the GABA 
receptors, GABA transaminase (GABA-T) and the GABA transporters (see Figure 2).  
Benzodiazepines are known positive allosteric modulators (PAMs) of the GABAA receptor 
which are in clinical use as medications for many years. Binding of the PAM to the GABAA 
receptor leads to a conformational change of the receptor. Thus, the required concentration of 
GABA is decreased for the opening of the ion-channel to enable the influx of chloride and 
therefore the inhibitory effect of GABA is increased. A prominent example of the 
benzodiazepine family is diazepam (Valium®, 2, Figure 3).13 
Furthermore, the GABAB selective agonist baclofen (Lioresal®, 3, Figure 3) enhances the 
GABAergic neurotransmission by activating GABAB receptors and has been used for the 
treatment of spasticity for many years.8 
Another possible approach to increase the extracellular GABA concentration is to block the 
degradation of GABA in the glial cells by irreversible inhibition of the GABA transaminase 
(GABA-T) using vigabatrin (Sabril®, 4, Figure 3).14 
By inhibition of the GABA transporters the reuptake of GABA from the synaptic cleft is 
suppressed and as a consequence the concentration of the neurotransmitter is increased. 
Tiagabine (Gabitril®, 5, Figure 3) is known as a drug for the reuptake inhibition which is in clinic 
use for the treatment of epilepsy.15 
 
Figure 3: Medications addressing different target in the GABAergic neurotransmission. 
However, all known therapeutics suffer from more or less severe side-effects like ataxia or 
dizziness so that the development of more potent and more selective antiepileptic drugs with 
lower side-effects is needed.8 
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1.3 GABA Transporters 
1.3.1 SLC6 Family 
The exchange of compounds which cannot permeate through membranes like ions, amino 
acids or signaling molecules between cells or cell compartments is realized by membrane 
proteins termed solute carriers or more general transporters. Many transport proteins are 
members of the solute carrier superfamily (SLCs) which is divided in 55 SLC families.16 These 
include the SLC6 gene family also known as neurotransmitter transporter (NTTs) of which 20 
different transporters are identified so far distributed into four subtypes: transporters for 
monoamine neurotransmitter e.g. serotonin, dopamine and norepinephrine transporters, the 
GABA transporters and two different amino acid transporters e.g. glycine transporters.17 All 
NTTs are Na+/Cl- dependent transporters as their transport of solutes is coupled to the 
cotransport of sodium in the same direction as a driving force for substrate transport against 
its chemical gradient.18 Therefore, the neurotransmitter transporters are also termed 
neurotransmitter-sodium-symporters (NSS).19 
 
1.3.2 Classification of GABA Transporters 
Four different subtypes of GABA transporters are known which are termed GAT1, BGT1, GAT2 
and GAT3 according to suggested nomenclature of the Human Genome Organization 
(HUGO).20 But other different designation for GABA transporter were also established over the 
time depending on the origin of cloning, e.g. the human GATs are named hGAT-1, hBGT-1, 
hGAT-2 and hGAT-3 and GATs derived from rat are designated as rGAT-1, rBGT-1, rGAT-2 
and rGAT-3, respectively. Differently, when cloned from mice the transporters are indicated as 
mGAT1 (=GAT1), mGAT2 (BGT1), mGAT3 (=GAT2) and mGAT4 (=GAT3).21 Since the GATs 
used in the following studies are cloned from mouse, the latter nomenclature for the GABA 
transporter subtypes of this species will be applied. All used designations are summarized in 
Table 1. 
Table 1: Different nomenclature of the four GABA transporter subtypes. 
Species Designation of GABA transporters  
HUGO GAT1 BGT1 GAT2 GAT3 
human hGAT-1 hBGT-1 hGAT-2 hGAT-3 
rat rGAT-1 rBGT-1 rGAT-2 rGAT-3 
mouse mGAT1 mGAT2 mGAT3 mGAT4 
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Both subtypes mGAT1 and mGAT4 are the only transporters present in the central nervous 
system in notable densities whereby mGAT1 is the most abundant transporter in the CNS 
mainly located on neurons and mGAT4 is predominantly responsible for the GABA uptake in 
glial cells.22 Consequently, these two subtypes are the key structures to address for an 
enhancement of the GABA concentration in the synaptic cleft. Besides, mGAT2 and mGAT3 
are predominantly expressed in the kidney and liver and therefore are not involved in 
termination of GABA signaling in the CNS.22,23 
 
1.3.3 Structure and Transport Mechanism of SLC6 Transporters 
The comprehension of the transport mechanism is dependent on the understanding of the 
molecular structures of the SLC6 transporter family. In the year 1990, the group around 
Guastella was able to clone the GABA transporter subtype 1 from rat brain tissue (rGAT-1) for 
the first time24 followed by the cloning of the monoamine neurotransmitter transporter for 
serotonin25, dopamine26 and norepinephrine27. By analysis of the amino acid sequences of the 
cloned transporters the claim was made that the transporters consist of 12 transmembrane 
helices28, which was confirmed in 2005 by the successful crystallization and X-ray analysis of 
the leucine transporter LeuTAa from the bacteria Aquifex aeolicus in the presence of leucine as 
its substrate and two sodium ions accomplished by Yamashita et al.29 As the amino acid 
sequence of LeuTAa responsible for the area of the substrate binding site is 55-67 % 
homologous compared to the other SLC6 family transporters30, the crystal structure of LeuTAa 
serves as a valid source for the comprehension of molecular structure and also the function of 
all other neurotransmitter transporters of the SLC6 family.  
LeuTAa consists of twelve transmembrane helices (TM1–TM12) with both N and C termini in 
the intracellular side. The first ten helices TM1–TM5 and TM6–TM10 are arranged in a C2-
pyseudosymmetrical order which is also named the 5 + 5 inverted repeat fold. The binding site 
for the substrate leucine (yellow triangle) and two sodium ions (blue circles, Figure 4) is located 
within the antiparallel arranged helices TM1 and TM6 which are broken into two parts (a and 
b). Through this unfolding of the helices additional binding sites for hydrogen bridges or ionic 
bonds are available for the binding of the substrate (Figure 4).29 
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Figure 4: Schematic secondary structure of LeuTAa according to Yamashita et al. The substrate leucine 
is depicted as a yellow triangle and the sodium ions are pictured as blue circles.29 
Since the crystallization of the leucine transporter many crystallographic and computational 
studies supported the assumption of the transport mechanism according to the alternating 
access model which describes the transport through a combination of global and local 
structural changes (Figure 5).31 
In the first step of one transport cycle, the transporter protein faces towards the extracellular 
side in an open conformation called outward-facing open state (OFo) which enables the 
binding of the substrate and ions in the S1 binding pocket. Upon binding of the substrate 
(outward-facing open, with substrate = OFo*) local changes of the conformation are initiated 
which leads to the closure of the extracellular gate (outward-facing closed, with substrate = 
OFc*). Subsequently, global conformational changes of the protein results in the inward-facing 
closed state (with substrate = IFc*) which opens to the intracellular media immediately (inward-
facing open, with substrate = IFo*). The bound substrate and ions are released into the 
cytoplasm and the inward-facing open state (without substrate = IFo) is transformed to the 
outward-facing open state whereby a new transport cycle starts again.32 
 
Figure 5: Postulated transport mechanism according to the „alternating access model“ by Yamashita et 
al.29 
7 
Introduction 
 
The first successful crystallization of LeuTAa in the outward-facing closed state (OFc*) 
containing two sodium ions and one leucine as substrate was accomplished by Yamashita et 
al..29 Shortly after the group of Gouaux had been able to crystalize the outward-facing open 
conformer (OFo*) in the presence of the competitive inhibitor tryptophan33 and recently they 
presented the resolution of the inward-facing open state (IFo) and outward-facing open state 
(OFo) without substrate34. These studies provided more detailed information of the different 
conformers for clarification of the molecular processes during the transport which finally 
confirmed the postulated transport mechanism of Yamashita et al.  
Based on molecular dynamics simulations and other experimental data, Shi and co-workers 
were able to identify a second binding pocket designated S2 which is located above the 
extracellular gate of LeuTAa.35 The existence of S2 was verified by many other studies 
regarding leucine transporter and other neurotransmitter transporter as e.g. dopamine 
transporter.36 Additionally, Shi et al. claimed that the occupation of S2 is required for the 
allosteric release of the substrate of the central binding site (S1) in the cytoplasm35, but this 
relevance of S2 for allosteric regulation is still questionable37,38. Further studies indicated that 
S2 is a binding site for non-competitive inhibitors of LeuT that prevent conformational changes 
of the transporter and therefore inhibit the transport of the substrate.37 
Meanwhile, further crystal structures of neurotransmitter transporters were obtained that 
confirm the structure of LeuT as a reliable tool for the understanding of the other SLC6 family 
transporters. In 2013, Penmatsa et al. reported the crystal structure of the eukaryotic dopamine 
transporter as a complex together with the tricyclic antidepressant nortriptyline39 and in a later 
publication the same group achieved the crystallization of the eukaryotic DAT with nisoxetine 
and reboxetine40. In the year 2016, the human serotonin transporter SERT was successfully 
crystalized together with the antidepressants paroxetine and (S)-citalopram by Coleman et al.41 
All published core structures were in good accordance with the crystal structure of the 
prokaryotic LeuTAa. Furthermore, in the structure of the human SERT an allosteric binding site 
located near the extracellular gate was identified which inhibit the release of the bound 
substrate from the central binding site.41 
All in all, these recently published crystal structures support and extend the understanding of 
the function of neurotransmitter transporter. 
 
1.3.4 Selective Inhibitors of murine GABA Transporter Subtype 1 (mGAT1) 
One possible way of treating neurological diseases like epilepsy caused by a disturbed 
regulation of GABA activity is the selective inhibition of the GABA transporter subtype 1 (GAT1) 
responsible for the reuptake of GABA in the presynaptic neurons.42  
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Since the late 1960, potent cyclic inhibitors for mGAT1 were discovered like (R,S)-nipecotic 
acid [(R,S)-6]43, guvacine (7)42, (R,S)-2-(pyrrolidin-3-yl)acetic acid [(R,S)-8]44 and (R,S)-
pyrrolidine-3-carboxylic acid [(R,S)-9]45. The determined pIC50 values of the mentioned 
compounds are summarized in Table 2. For the sake of better comparability, the inhibitory 
potencies of all compounds were determined by [3H]GABA uptake assays in our group in every 
case employing the same test system unless otherwise stated. Compared to the substrate 
GABA with an pIC50 values of 5.14 ± 0.0946, these small amino acids reveal even slightly higher 
pIC50 values in the case of (R,S)-2-(pyrrolidin-3-yl)acetic acid (pIC50 = 5.39 ± 0.05, Table 2)47 
and almost equal pIC50 values for (R,S)-nipecotic acid (pIC50 = 4.88 ± 0.07, Table 2)48 and 
guvacine (pIC50 = 4.87 ± 0.06, Table 2)49. In the case of (R,S)-pyrrolidine-3-carboxylic acid the 
inhibitory potency at mGAT1 is decreased by approximately one log unit (pIC50 = 4.17 ± 0.06, 
Table 2)50 compared to GABA itself. Except for mGAT2, these cyclic amino acids do not show 
selectivity for mGAT1 as the pIC50 values are in the same range regarding the other subtypes 
mGAT3 and mGAT4 (see Table 2). This and their inability to cross the blood brain barrier limit 
their prospective application for pharmacological treatment.  
 
Table 2: pIC50 values of GABA and small cyclic amino acid as GAT inhibitors. 
 
 
compound 
GABA uptake inhibition (pIC50 ± SEM)a 
mGAT1 mGAT2 mGAT3 mGAT4 
GABA (1) 5.14 ± 0.09 4.56 ± 0.06 4.94 ± 0.09 5.18 ± 0.13 
(R,S)-6 4.88 ± 0.07 3.10 ± 0.09 4.94 ± 0.07 4.70 ± 0.07 
7 4.87 ± 0.06 3.31 ± 0.03 4.59 ± 0.05 4.59 ± 0.05 
(R,S)-8 5.39 ± 0.05 3.78 ± 0.08 5.21 ± 0.06 5.42 ± 0.07 
(R,S)-9 4.17 ± 0.06 3.50 ± 0.06 4.25 ± 0.04 4.21 ± 0.10 
apIC50 values from [3H]GABA uptake assay performed with murine GABA transporters expressing HEK cells. The 
values represent the mean ± SEM of three independent experiments, each performed in triplicate. 
 
To enhance the ability for CNS penetration lipophilicity has been increased by attaching bulky 
aromatic residues via an alkyl chain bearing different functionalities to the nitrogen of the small 
amino acids. As a result, not only lipophilicity increased but also selectivity for mGAT1 with 
substantially enhanced inhibitory potential.  
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The pIC50 of some mGAT1 selective inhibitors are presented in Table 3. Lots of lipophilic 
derivatives of nipecotic acid are described in literature whereas tiagabine (5) is the most 
famous representative with a pIC50 value of 6.88 ± 0.12 for mGAT1 (Table 3)15,49. NO711 shows 
similar inhibitory potency at mGAT1 (10, pIC50 = 6.83 ± 0.06, Table 3)51 but the compound 
DDPM-2571 reveals an pIC50 value almost 1.5 log units higher as tigabine (11, pIC50 = 8.27 ± 
0.03, Table 3)52. Both examples are guvacine derivatives with an oxime functionality in the 
alkyl chain bearing different aromatic residues. (S)-12 represents one example of only few 
reported substances with 2-(pyrrolidin-3-yl)acetic acid substructure as a tiagabine-like 
derivative with pIC50 value only slightly lower than the value of tiagabine itself [(S)-12, pIC50 = 
6.69 ± 0.01, Table 3].49 
Compared to the corresponding unsubstituted amino acids it is apparent that the subtype 
selectivity for mGAT1 improved significantly as the pIC50 values for mGAT1 increased by 
approximately one log unit or even more whereas the inhibitory potencies for mGAT2 remained 
or increased only slightly over 4 and pIC50 values for mGAT3 and mGAT4 even decreased. In 
the cases of 5 and (S)-12, the results for the affinity towards mGAT2-4 are given as the 
percentage values of the remaining [3H]GABA uptake of the radioligand assay at an applied 
concentration of 100 µM of 10 and 10 µM of (S)-12, respectively.  
 
Table 3: pIC50 values of mGAT1 selective inhibitors. 
 
 
compound 
GABA uptake inhibition (pIC50 ± SEM)a 
mGAT1 mGAT2 mGAT3 mGAT4 
5 6.88 ± 0.12 50 % 64 % 73 % 
10 6.83 ± 0.06 3.20 ± 0.09 3.63 ± 0.04 3.07 ± 0.06 
11 8.27 ± 0.03 4.31 4.35 4.07 
(S)-12 6.69 ± 0.01 85 %b 89 %b 63 %b 
apIC50 values from [3H]GABA uptake assay performed with murine GABA transporters expressing HEK 
cells. The values represent the mean ± SEM of three independent experiments, each performed in 
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triplicate. Percentage values represent remaining [3H]GABA uptake in present of 100 µM test compound. 
bPercentage values represent remaining [3H]GABA uptake in present of 10 µM test compound. 
 
As already mentioned the majority of selective and potent mGAT1 inhibitors with lipophilic 
residues contains nipecotic acid as amino acid motif next to some guvacine derivatives. But 
only a few publications are known concerning mGAT1 inhibitors derived from 2-(pyrrolidin-3-
yl)acetic acid49,53 and no publication reported about pyrrolidine-3-carboxylic acid derivatives as 
potential mGAT1 inhibitors. So to say, tremendous amount of information about structure-
activity-relationships (SARs) for mGAT1 regarding diverse aromatic residues with various 
substituents attached via different linker regarding length and functionalities to the nipecotic 
acid and guvacine are available but SARs concerning different other amino acid substructures 
are rare. As a consequence, the expansion of SARs on the 5-membered cyclic amino acids 2-
(pyrrolidin-3-yl)acetic acid and pyrrolidine-3-carboxylic acid presents a huge step towards the 
identification of novel selective and potent inhibitors for the GABA transporter subtype 1.  
 
1.4 Drug Discovery 
In the beginning of the history of drug discovery, the identification of novel drugs was often 
only achieved by coincidence e.g. the discovery of penicillin, but nowadays target-oriented 
screening techniques are applied in the early stage of the drug discovery process in order to 
screen various substances to determine their affinity on a chosen target.54 The requirement to 
observe this affinity is the binding of the studied compounds so called ligands to the target. 
One possibility is the measurement of the changes of the target caused by the binding of ligand 
which can be detected by NMR or X-Ray crystallography. The advantage of this technique is 
that more information about the binding interactions (i.e. kinetics, mechanism) can be received 
with regard to one single ligand but with limited throughput. The second possibility is the 
detection of the bound ligand in the screening process using various assays. Thereby affine 
ligands can be identified out of a mixture of numerous compounds with a high throughput but 
without providing information about binding mechanism.55  
 
1.4.1 Ligand Binding Assays 
For the latter screening assays, the opportunities for the readout are manifold and can be done 
by optical sensors as in fluorescence-based assays or by mass spectrometry.54 Another way 
is the use of radioactively labelled reporter ligands to analyze ligand-target binding by 
scintillation counting.56 These so called radioligand binding assays have been developed in 
the 1970s and are still widely used for the screening in drug discovery processes. 57 In contrast 
to other ligand labels as fluorophores the effect of the insertion of a radioisotope as 3H, 125I or 
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32P in the ligand has only insignificantly impact on the binding affinity towards the target. 
Additionally, the detection method via scintillation counting is highly selective for the labeled 
ligand and has a high sensitivity. On the other hand, due to the radioactivity high costs for the 
radioligands as well for the disposal of the contaminated waste and increased health hazards 
for the operators have to be considered.  
Therefore, mass spectrometry (MS) Binding Assays have been developed for different targets 
as an alternative to radioligand binding assays.58 The differences between these two assay 
methods are, that the quantification of the reporter ligand is achieved by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) for the MS Binding Assays and no 
labeling of the reporter ligand which is also called MS marker is necessary, so every compound 
with an appropriate affinity towards the desired target is suitable. Thus, the costs for non-
labeled compounds is usually lower and there is no need for special disposal of the waste as 
necessary for radioactively labeled substances.  
 
1.4.2 Ligand Binding Experiments 
With either the radioligand as well as the MS binding assays, several experiments can be 
performed i.e. saturation, kinetic and competition experiments. Each of them based on the 
same simple and robust procedure which will be explained in the case of a competitive MS 
Binding Assay (Figure 6). Within these experiments the affinity of the competitor towards the 
target can be determined indirectly by the quantification of the marker bound to this target. This 
procedure offers the advantage to characterize various different test compounds with only one 
quantification method for one marker. The quantified amount of the marker represents the 
total-binding of the marker towards the target, which comprises the binding to the specific 
binding site of the target, termed specific binding and of the non-specific binding which is the 
binding of the marker to other binding sites e.g. lipid membranes in the protein preparation or 
filter materials used in the assay. The specific binding of the marker which is needed for the 
calculations of the affinity of the test compounds has to be determined by the subtraction of 
the non-specific binding from the total binding.56 
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Figure 6: Diagram of the procedure of MS Binding Assays. Marker and test compound are incubated 
with the target. After incubation unbound marker is separated from the marker-target complexes by 
filtration. Denaturation of the target upon drying is followed by elution of the formerly bound marker. 
Finally, the marker is quantified by LC-MS/MS.  
In the first step a defined concentration of the MS marker and different concentration levels of 
the test compound as competitor are incubated with the target. Upon equilibration, target-
ligand complexes are generated where the marker and the test compound are in competition 
for the binding site of the target. These complexes are than separated by filtration from the 
non-bound components of the incubation sample followed by the liberation of the bound marker 
by denaturation of the target protein by drying at elevated temperature and subsequent 
treatment with an organic solvent. After the elution of the formerly bound marker with methanol 
from the filter, the liberated marker is quantified by LC-MS/MS to determine the total binding.  
The higher the applied concentrations of the competitor the more the marker will be replaced 
from the target-ligand complexes and therefore the lower the amount of quantified marker will 
be. With the quantified amount of the marker competition curves in dependence of the applied 
concentrations of the competitor can be constructed as outlined in Figure 7. 
The non-specific binding has to be determined separately by incubation of the target and 
different concentration of the marker with a high excess of a highly affine inhibitor of the specific 
binding site of the target. Another possibility is to denature the specific binding site by heat 
shock.  
Figure 7: Schematic figure of typical competition curve in which specific binding of marker is plotted 
against applied concentrations of test compound. With increasing concentrations of competitor reduction 
of the specific binding of marker is observed. 100 % represents marker binding without competitor and 
log(IC50) is the concentration of the test compound which reduced the specific marker binding to 50 %. 
 
The competition curve is fixed to 100 % which represents the marker binding without 
competitor. The IC50 value – defined as the concentration of test compound which reduces the 
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specific binding of the marker to 50 % – describes the inhibitory potency of the corresponding 
test compound.  
Using the equation of Cheng-Prusoff (1) the IC50 values can be transformed into the inhibition 
constant Ki to reveal the affinity of the test compound towards the target.59 
𝐾i =
IC50
1 +
[L]
𝐾d
 (1) 
In this equation Kd is the equilibrium dissociation constant of the marker, which has to be known 
and [L] represents the free concentration of the ligand also termed marker, which can be 
substituted by the nominal concentration of the marker if marker depletion is negligible (<10 
%). Marker depletion occurs when significant amount of the marker is bound to the target (≥10 
%) but can be avoided easily by applying target concentrations which do not exceed 0.1·Kd of 
the marker.60 
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2 Aims and Scope 
Binding assays are useful tools for the identification of novel highly affine ligands for a certain 
target. This technique is used in form of MS Binding Assays for the determination of potent 
and selective mGAT1 inhibitors with NO711 (10) as MS marker in our group.58a This technique 
has been extended to the screening of substance libraries delineated from different amino acid 
key structures, whereby library generation and activity analysis are combined to a single step. 
This combinatorial screening concept is based on a simple condensation reaction known from 
dynamic combinatorial chemistry to obtain libraries with a broad range of structures with a vast 
variety of different functionalities. This was already published for pseudostatic hydrazone 
libraries with nipecotic acid substructure61 and stable oxime libraries with a guvacine motif52 by 
our group. In contrast to competitive MS Binding Assays in which the single test compounds 
are applied in different concentration levels to obtain a competition curve for those compounds, 
a set of different test compounds is employed in only one defined concentration. In the thus by 
means of MS Binding Assay performed library screening information about the potency of the 
whole library towards the target mGAT1 is obtained. The most potent libraries are then further 
subjected to so-called deconvolution experiments in which the individual compounds are 
screened once more at a single concentration level to identify the substance in the library 
responsible for the formerly observed potency at mGAT1. With this concept it is possible to 
quickly identify the most potent compounds out of a large set of different libraries. 
The aim of the present study was to transfer this screening concept to 5-membered cyclic 
amino acid substructures such as 2-(pyrrolidin-3-yl)acetic acid (8) and pyrrolidine-3-carboxylic 
acid (9) to identify novel potent and selective inhibitors of mGAT1 and to expand the known 
information about structure-activity-relationships of mGAT1 to other amino acid motifs. The 
focus was set on libraries with an oxime functionality due to their higher hydrolytic stability 
compared to the hydrazone moiety.62 Moreover, the oxime functionality might also contribute 
to the affinity of the new mGAT1 inhibitors as some highly affine inhibitors containing this 
function are already known (e.g. NO711 and DDPM-2571).  
Hence, stable oxime libraries should be examined within the MS Binding Assays which should 
be generated by the reaction of the respective amino acids 8 and 9 bearing a hydroxylamine 
functionality with different aldehydes 15 as outlined in Scheme 1.  
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Scheme 1: Condensation reaction of hydroxylamine derivative 13 (n = 1) and 14 (n = 0) with various 
aldehydes 15 to yield the corresponding oximes 16 (n = 1) and 17 (n = 0). 
In the case of hydrazone libraries61 it has been shown  that the generation of the libraries can 
be performed in the presence of the target protein, mGAT1. However, oxime formation is 
known to be very slow under physiological conditions. Hence, library formation and 
determination of the activity of the library by MS Binding Assays the latter requiring the 
presence of the target protein should be performed in separate steps. The same approach has 
already been applied before to the screening of related oxime libraries in our group.52 
Contrary to aforementioned study, the number of aldehydes 15 in a single library should be 
increased from four to eight compounds, which would improve the efficiency of the present MS 
Binding Assay. Therefore, the actual approach was conducted as follows: Oxime libraries are 
pre-generated in absence of the target mGAT1 by reaction of 28 different aldehyde libraries 
each consisting of eight different components with either hydroxylamine 13 or 14 to give the 
corresponding oxime libraries 16 and 17 as exemplarily outlined in Scheme 2. 
 
Scheme 2: Exemplary reaction of hydroxylamine 13 and 14 with aldehyde library 8 to yield 
corresponding oxime library 8. 
 
16 
Aims and Scope 
 
As the increase of the number of aldehydes (4 x 1 mM to 8 x 1 mM of each aldehyde) with 
constant concentration of the hydroxylamine (40 mM) changes the ratio of the reactants for the 
oxime generation (from 10:1 to 5:1), the suitability of the experimental conditions has to be 
proven which should be accomplished by 1H NMR studies.  
After the pre-generation the formed oxime libraries has to be diluted to concentrations suitable 
for the MS Binding Assays (1µM, 100 nM or 10 nM) and are subsequently incubated with the 
marker and the target protein mGAT1 for 4 hours. The stability of the diluted oxime libraries 
has to be examined over the subsequent incubation time. Due to the low concentration the 
measurements should be achieved by fluorescence detection.  
The affinity of the libraries can be indirectly measured by the quantification of the marker. 
Hence, the protein-ligand complexes, which were formed during incubation, have to be 
separated from the unbound oximes and marker, denatured and eluted with organic solvent. 
Afterward, the formerly bound marker is quantified by LC-MS/MS. If a library is able to reduce 
the specific binding of the marker under a certain level, this particular library should then be 
tested in deconvolution experiments in which each single oxime is examined in order to identify 
which oxime is responsible for the affinity of the library.  
After the deconvolution experiments the most potent oximes should be resynthesized to 
determine their binding affinities (pKi values) in full-scale competitive MS Binding Assays58a as 
well as their inhibitory activities (pIC50 values) in [3H]GABA uptake assays51. Finally, these 
compounds should be fully characterized regarding their subtype selectivity at all four murine 
GABA transporters.  
 
In the course of this study also an HPLC method for the enantiomeric purity determination of 
nipecotic acid (6) should be developed and validated. Furthermore, it should be used for the 
characterization of both enantiomers of nipecotic acid. This method should then enable the 
determination of the enantiomeric excess for other cyclic amino acids including those utilized 
in this work. 
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3 Results and Discussion 
3.1 First Publication 
Determination of enantiomeric excess of nipecotic acid as 1-(7-nitrobenzo- 
[c][1,2,5]oxadiazol-4-yl) derivatives 
 
3.1.1 Summary of the Results 
Nipecotic acid (piperidine-3-carboxylic acid) is an important precursor for the synthesis of novel 
enantiopure inhibitors of γ-aminobutyric acid transporters (GATs), for the enantiomers of which 
frequently quite different biological activities are found.42 One well-known example is tiagabine 
– a selective and highly affine GABA reuptake inhibitor for the transporter subtype GAT1 – for 
which the (R)-enantiomer is known to be distinctly more potent than the (S)-enantiomer.49 With 
the data of pharmacological testing being dependent on the enantiopurity of the studied 
samples, the knowledge of the enantiopurity of nipecotic acid serving as starting material for 
the synthesis of new GAT inhibitors is of fundamental importance.  
Several methods have been reported in the literature63 so far for enantiopurity determination 
of nipecotic acid but the only validated HPLC method was published in 1995 by Rustum et al. 
In that case, however, not the enantiopurity of the free amino acid but the ethyl ester using a 
Chiralcel-OG stationary phase (Daicel Corporation) with UV detection at 230 nm was 
analyzed.64 Due to the low absorption coefficient of the carboxylic acid ester function, 
sensitivity and selectivity of this method appears to be low, its suitability for an exact 
determination of highly enantioenriched samples of nipecotic acid ethyl ester thus being 
limited. Moreover, for this method the resolution of both enantiomers was specified to be 
around 1.3 though only for a resolution of ≥1.5, peaks with Gaussian shape can be assumed 
to be baseline separated. Hence, especially in higher concentration ranges and when tailing 
occurs the validity of % ee determination of the (S)-enantiomer in the presence of small 
amounts of (R)-enantiomer appears questionable.  
Therefore, a reliable new HPLC method for the determination of the enantiopurity of both 
enantiomers of nipecotic acid should be developed and validated. To this end, N-substituted 
derivatives of nipecotic acid provided with a suitable chromophore should be generated prior 
to chromatography. Due to the presence of the chromophore high wavelengths for UV-Vis 
detection would be expected, that should ensure a selective determination of high ee values 
of the individual enantiomers of the analyte. Additionally, due to N-substitution of the nipecotic 
acid ampholitic properties of the analyte were eliminated which should facilitate the 
development and optimization of the chromatographic conditions.  
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4-Fluoro-7-nitrobenzo[c][1,2,5]oxadiazole65 was used as a derivatization reagent as it enabled 
a detection wavelength of 490 nm. A Chiralpak ID-3 (250 x 4.6 mm, 3 µm, Daicel) in 
combination with a polar mobile phase consisting of acetonitrile with 20 mM of formic acid and 
20 mM of N,N-diisopropyethylamine was found suitable for enantioseparation after the 
chromatographic conditions such as flow rate, column temperature or injection volumes had 
been optimized. The final chromatographic conditions consisted of a flow rate of 1 mL/min, a 
column temperature of 40 °C and an injection volume of 10 µL (samples dissolved in the mobile 
phase) and enabled a separation of the enantiomers with a resolution of 5.44.  
The reliability of the optimized HPLC method was successfully demonstrated by validation of 
the parameters specificity, linearity, accuracy, precision and lower limit of quantification for 
both enantiomers. Due to the broad quantification range established for each enantiomer, 
enantiomeric excesses up to 99.87% ee for the (R)-enantiomer and 99.86% ee for the (S)-
enantiomer could be determined.  
In addition, by spiking of highly enantiopure samples of nipecotic acid derivatives with small 
amounts of racemic mixture, the newly developed method has been shown to even enable the 
detection of slight changes of ee values. 
 
3.1.2 Declaration of Contribution 
The idea of the publication was based on the bachelor thesis “Development of an HPLC 
Method for Enantiopurity Determination of Cyclic β-Amino Acids” by Marie Niedermeier 
prepared under my supervision. During this time, I derivatized racemic, (S)- and (R)-nipecotic 
acid using 4-fluoro-7-nitrobenzo[c][1,2,5]oxadiazole as derivatization reagent, which were 
used as analytes, respectively. Based on the preliminary experiments regarding stationary and 
mobile phase performed by Marie Niedermeier, I developed an HPLC method for the 
enantioseparation and the determination of the enantiomeric excesses of nipecotic acid as 1-
(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl) derivatives. Validation and the spiking experiments to 
verify the HPLC results were carried out by myself. I wrote the manuscript and generated all 
graphics and tables, assisted by Dr. Georg Höfner. The manuscript was corrected by Prof. Dr. 
Klaus T. Wanner. The cover image resulted in collaboration with Dr. Jörg Pabel.  
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For the enantiopure synthesis of novel chiral GABA uptake inhibitors, nipecotic acid
(1) is an important key precursor. To characterize accurately the pharmacological
activity of these interesting target compounds, the determination of the correct
enantiomeric purity of nipecotic acid as the starting material is indispensable. In this
report, a sensitive high‐performance liquid chromatography (HPLC) based method
for the separation and quantitation of both enantiomers of nipecotic acid as
1‐(7‐nitrobenzo[c][1,2,5]oxadiazol‐4‐yl) derivatives (5) on a Chiralpak ID‐3 column
(Daicel, Illkirch, France) was established. UV/Vis‐detection at 490 nm was chosen to
ensure a selective determination of even highly enantioenriched samples. Reliability
was demonstrated by validation of specificity, linearity, lower limit of quantification
(LLOQ), accuracy, and precision. By spiking highly enantiopure samples with small
amounts of racemic rac‐5, it was proven that the established HPLC method is able to
detect even slight changes in enantiomeric excess (ee) values. Thus, accurate
determination of ee values up to 99.87% ee for (R)‐5 and 99.86% ee for (S)‐5 over a
linear concentration range of 1–1500 μM for (R)‐5 and of 1–1455 μM for (S)‐5 could
be demonstrated.
KEYWORDS
amino acid, derivatization, enantiopurity, high performance liquid chromatography,
NBD‐F, validation1 | INTRODUCTION
Nipecotic acid (rac‐piperidine‐3‐carboxylic acid, 1) is a
nonnatural cyclic β‐amino acid that is a key precursor for
the synthesis of important inhibitors for γ‐aminobutyric acid
transporters (GATs1).2 For example, tiagabine [(R)‐2] and
SK&F‐89976A (3) are reuptake inhibitors for the subtype
GAT1 for which the (R)‐enantiomers are known to be more
potent than the (S)‐enantiomer [(S)‐2: pIC50 = 6.20 ± 0.13;
(R)‐2: pIC50 = 6.88 ± 0.12; (S)‐3: pIC50 = 4.97 ± 0.10;
(R)‐3: pIC50 = 5.49 ± 0.09].3,4 In contrast, the (S)‐enantiomer
DDPM‐1457 (4) is more active on the GABA transporter
subtype mGAT4 than its (R)‐enantiomer [(S)‐4: pIC50 =
5.87 ± 0.08; (R)‐4: pIC50 = 4.33 ± 0.05] (Figure 1).4,5
As can be seen from these examples and in the case of
even higher enantioselectivities, it is necessary to use only
highly enantiopure samples for the determination of thewileyonlinelpharmacological data of novel chiral GABA reuptake inhibi-
tors, as the false enantiomer will distort the resulting data the
more it is present. Especially when characterizing the phar-
macological activity of the distomer of a pair of biologically
active enantiomers exhibiting high enantioselectivity, the
presence of small amounts of the eutomer may significantly
falsify the results. Thus, in the case of the preparation of
novel target compounds derived from enantiopure nipecotic
acid (1), a reliable and sensitive determination of the precise
enantiomeric excess (ee) of nipecotic acid (1) is indispens-
able. As far as multistep syntheses are concerned, a determi-
nation of the enantiomeric purity of 1 may be sufficient,
when a racemization during the synthetic process can be
excluded which, e.g., can exemplarily be verified by chiral
analysis of a final product.
Several different methods have been reported in the
literature for the enantiopurity determination of nipecoticChirality 2017; 29: 48–56ibrary.com/journal/chir
FIGURE 1 Nipecotic acid (1) as key precursor
for the synthesis of novel GABA reuptake
inhibitors and important derivatives: tiagabine
[(R)‐2],3 SK&F‐89976A (3)3 and DDPM‐1457
[(S)‐4]5
SCHMIDT ET AL. 49acid (1). Besides an indirect method relying on separation of
diastereomers generated by derivatization with an
enantiopure isothiocyanate reagent on an RP column,6
several high‐performance liquid chromatography (HPLC)
methods in which the separation of both enantiomers of
nipecotic acid (1) after derivatization with achiral reagents
could be achieved on chiral stationary phases are known:
methods accomplished by employing carboxylic acid
esters,7–9 N‐carbamoyl,10 and N‐aminocarbonothioyl
substituted nipecotic acid,11,12 and nipecotic acid derivatives
with modifications at both functional groups.13,14
A validated HPLC method for the enantioseparation of a
nipecotic acid derivative has so far only been published for
the ethyl ester of 1, in 1995 by Rustum.9 This method is
based on Chiralcel‐OG stationary phase (Daicel, Tokyo,
Japan) and utilizes UV detection at 230 nm.9 But this method
was only validated for the quantification of (S)‐enantiomer in
the presence of (R)‐enantiomer, but not vice versa. The con-
centration range was reported to be linear from 0.1 to
1.0 mg·ml−1 for a 10 μl injection volume with a linear regres-
sion coefficient of >0.999 indicating the highest possible
quantification of 10% of the minor enantiomer in the pres-
ence of the major enantiomer. Because of the absorption
wavelength of 230 nm resulting from the carboxylic acid
ester function exhibiting a low absorption coefficient, the
selectivity and sensitivity of this method is to be regarded
as low and thus of limited suitability for the determination
of highly enantioenriched samples of the ethyl ester of 1.
Moreover, the resolution of the two enantiomers was
specified to be only around 1.3. Considering that only for a
resolution of ≥1.5, Gaussian peaks will be baseline sepa-
rated,15 a reliable ee determination especially for highly
enantioenriched samples appears questionable. Accuracy of
the method was concluded by standard addition yielding
good recoveries of the (S)‐enantiomer of 100.5 ± 0.8%
(mean ± relative standard deviation [RSD]).9
For the chiral separation of underivatized nipecotic acid,
methods based on chiral ligand‐exchange16 or zwitterionic
chiral stationary phases17–19 have been reported. One disad-
vantage of the latter approach is that most of these stationary
phases are not commercially available, but have to be pre-
pared, which is time‐consuming and therefore not appropriate
for most of the potential users.17,18 Recently, a zwitterionic
stationary phase based on quinine derivative fused with achiral sulfonic acid, which can be purchased under the trade
name Chiralpak ZWIX(+) (Daicel), was reported to allow
the separation of the nipecotic acid enantiomers with a reso-
lution of 14.87.19 But this approach has the disadvantage that
for the analysis, because nipecotic acid (1) is devoid of a
chromophore, detectors such as an ELSD (evaporating light
scattering detector) or a CAD (corona charged aerosol
detector) are required. Due to the limited accessibility of
ELSDs and CADs, we focused on UV/Vis‐detection in order
to enable application with standard HPLC equipment.
Overall, employing derivatives of 1 appears in particular
a promising approach for the development of an efficient
method for the chiral analysis of this compound. Providing
the amino function of 1, for example, with a chromophore
would increase the sensitivity of detection of the derivative
and as a consequence the upper limit of ee that can be
determined. In addition, the elimination of the ampholitic
properties of 1 in the derivative could ease the optimization
of the chromatographic conditions required for the chiral
separation. By being more common, also the use of UV as
compared to fluorescence detection appears to be more
favorable.
In 1993, derivatization of nipecotic acid with the fluores-
cence reagent 6‐aminoquinolyl‐N‐hydroxy‐succinimidyl
carbamate (AQC) to give an N‐carbamoyl nipecotic acid
derivative was described. On a γ‐cyclodextrin stationary
phase, the enantiomers could be separated with an Rs= 2.26.
10
However, the same derivative seems less suitable for UV/
Vis‐detection at the wavelength used for the excitation in
fluorescence detection (226 nm). For short wavelengths, the
interference resulting from contaminants are more likely,
which would hamper ee determination.
Therefore, we deemed derivative of 1 1‐(7‐nitrobenzo[c]
[1,2,5]oxadiazol‐4‐yl)nipecotic acid (rac‐5) more suitable
for chiral analysis (Scheme 1).20 The low‐cost reagent 4‐
fluoro‐7‐nitrobenzo[c][1,2,5]oxadiazole (6, NBD‐F)21
required for the preparation of 5 is widely used for the analy-
sis of amino acids like proline by HPLC, as it is known to
allow the formation of stable derivatives under mild reaction
conditions and to give rise to products with absorption wave-
lengths around 470 nm, allowing a reasonably selective UV/
Vis‐detection.22,23 In this report, we disclose an HPLC
method for the chiral analysis of 1 via nipecotic acid deriva-
tive 5, which allows the determination of ees up to at least
SCHEME 1 Preparation of rac‐5 from rac‐1 and 4‐fluoro‐7‐nitrobenzo[c]
[1,2,5]oxadiazole (6, NBD‐F)
50 SCHMIDT ET AL.99% (ee) for both enantiomers by means of calibration
functions and the validation of said procedure.2 | MATERIALS AND METHODS
2.1 | Derivatization: General experimental procedures
2.1.1 | Chemicals
HPLC‐grade acetonitrile and formic acid were purchased
from VWR International (Darmstadt, Germany). N,N‐
Diisopropylethylamine was purchased from TCI Europe
(Zwijndrecht, Belgium) and was freshly distilled prior to
use. Rac‐Nipecotic acid (≥98%) was from Sigma Aldrich
(Steinheim, Germany), (+)‐(S)‐nipecotic acid (98.4%,
99.6% ee, (−)‐(R)‐nipecotic acid (99.6%, 99.9% ee), and
2,6‐difluoroaniline (> 97%) from TCI Europe were used
as purchased. The deuterated solvents chloroform‐d
(99.8% D) and methanol‐d4 (99.8% D) were purchased
from Euriso‐top (Saint‐Aubin, France).
2.1.2 | Analytical data
NMR spectra were recorded with an Avance III HD 400 MHz
Bruker BioSpin (Billerica, MA) and Avance III HD 500 MHz
Bruker BioSpin spectrometer. The digital resolution is stated
with an accuracy of ±0.15 Hz. MestreNova (v. 10.0.1) was
used for further analysis of the spectra. IR spectra were
recorded with a FT‐IR spectrometer Paragon 1000 (Perkin‐
Elmer, Rodgau, Germany) and Spectrum v2.00 software
(Perkin‐Elmer). High‐resolution mass spectra were measured
on a Thermo Finnigan LTQ FT instrument for electrospray
ionization (ESI). Specific rotations ∝½ TD (c = g·cm−3 in
solvent) given as deg·cm3·g−1·dm−1 were measured
(pathlength l of 1 dm) on a Perkin Elmer 241 polarimeter
with a sodium vapor lamp. For weighing, an ALC‐80.4
ACCULAB and a MC 21S from Sartorius Group (Göttingen,
Germany) were used.
2.1.3 | Synthesis
4‐Fluoro‐7‐nitrobenzo[c][1,2,5]oxadiazole (6, NBD‐F) was
synthesized according to the literature.24 The synthesis of 5
from 1 with 6 (NBD‐F) was accomplished in analogy to the
procedure published by Min et al. for the reaction ofpyrrolidine‐3‐carboxylic acid with 7‐fluoro‐N,N‐
dimethylbenzo[c][1,2,5]oxadiazole‐4‐sulfonamide (DBD‐
F).24 The applied reaction conditions are given in the general
procedure (GP, Scheme 1).2.2 | General procedure (GP)
NBD‐F (6, 1.1 eq.) in CH3CN was added to a solution of
nipecotic acid (1 eq.) in aqueous Na2CO3 solution
(0.0625 M). The reaction mixture was stirred at 0°C for
7 min under protection from light. The aqueous layer was
extracted once with Et2O (1 × 50 ml), and after adjustment
of the pH to 3–4 with aqueous HCl solution (2 M) four addi-
tional times (4 × 100 ml). The combined organic layers were
dried (Na2SO4), filtered, and concentrated in vacuo. The res-
idue was resuspended in CH2Cl2 and after repeated evapora-
tion dried under high vacuum to yield the desired product as a
red solid.
rac‐1‐(7‐Nitrobenzo[c][1,2,5]oxadiazol‐4‐yl)piperidine‐
3‐carboxylic acid (rac‐5): According to GP with rac‐
nipecotic acid (rac‐1) (26.0 mg, 0.201 mmol) in aqueous
solution of Na2CO3 (9.6 ml) and NBD‐F (40.5 mg,
0.221 mmol) in CH3CN (3 ml). Yield: 57 mg (98%), red
amorphous powder. TLC: Rf = 0.12 (CH3CN/
CH3OH = 95:5). IR (KBr): ν = 3427, 2928, 1608, 1553,
1293 cm−1. 1H NMR (500 MHz, CD3OD, δ): 1.85–1.75
(m, 1H, CH2), 2.02–1.94 (m, 2H, CH2), 2.22–2.15 (m, 1H,
CH2), 2.80 (tt, J = 9.1/4.1 Hz, 1H, CH), 3.78 (ddd,
J = 13.4/10.1/3.0 Hz, 1H, CH2), 4.01 (dd, J = 13.7/9.1 Hz,
1H, CH2), 4.49 (br d, 1H, CH2), 4.72 (dd, J = 13.7/3.1 Hz,
1H, CH2), 6.60 (d, J = 9.1 Hz, 1H, CH), 8.48 (d,
J = 9.1 Hz, 1H, CH). 13C NMR (126 MHz, CD3OD, δ):
25.4 (CH2), 28.1 (CH2), 42.6 (CH), 51.7 (CH2), 52.8
(CH2), 104.4 (CH), 123.4 (Cq), 137.1 (CH), 146.4 (Cq),
146.5 (Cq), 147.0 (Cq), 176.1 (Cq). Mr calcd. for
C12H12N4O5, 292.0808; HRMS (ESI, m/z): [M – H]− calcd.
for C12H11N4O5, 291.0735; found, 291.0733. (R)‐1‐(7‐
Nitrobenzo[c][1,2,5]oxadiazol‐4‐yl)piperidine‐3‐carboxylic
acid [(R)‐5]: According to GP with (−)‐(R)‐nipecotic acid
[(R)‐1] (26.0 mg, 0.201 mmol) in aqueous solution of
Na2CO3 (9.6 ml) and NBD‐F (40.5 mg, 0.221 mmol) in
CH3CN (3 ml). Yield: 56 mg (96%), red amorphous powder.
[α]D22 = −118.0 (c = 0.245 in CH3OH). Mr calcd. for
C12H12N4O5, 292.0808; HRMS (ESI, m/z): [M – H]− calcd.
for C12H11N4O5, 291.0735; found, 291.0738.
(S)‐1‐(7‐Nitrobenzo[c][1,2,5]oxadiazol‐4‐yl)piperidine‐
3‐carboxylic acid [(S)‐5]: According to GP with (+)‐
(S)‐nipecotic acid [(S)‐1] (26.0 mg, 0.201 mmol) in aqueous
solution of Na2CO3 (9.6 ml) and NBD‐F (40.5 mg,
0.221 mmol) in CH3CN (3 ml). Yield: 54 mg (93%),
red amorphous powder. [α]D22 = +122.8 (c = 0.25 in
CH3OH). Mr calcd. for C12H12N4O5, 292.0808; HRMS
(ESI, m/z): [M – H]− calcd. for C12H11N4O5, 291.0735;
found, 291.0733.
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Rf value of (R)‐5 and (S)‐5 were in accord with data obtained
for rac‐5.
2.2.1 | Chemical purity
The water content of rac‐5, (S)‐5 and (R)‐5 obtained by deriv-
atization was determined by coulometic Karl‐Fischer titration
using a KF‐coulometer 684 (Metrohm, Herisau, Switzerland)
(solvent CH3OH, n = 3). Other impurities like solvent resi-
dues or grease were identified by 1H NMR spectroscopy.
Water content was found to be lower than 1.5% (m/m) for
rac‐5, 1.5% (m/m) for (S)‐5, and 2% (m/m) for (R)‐5. 1H
NMR spectra indicated impurities of 2.5% (m/m) for rac‐5,
2% (m/m) for (S)‐5, and 4% (m/m) for (R)‐5. Overall, the
chemical purity of rac‐5, (S)‐5, and (R)‐5 can be considered
as higher than 96%, 96.5%, and 94%, respectively.
2.2.2 | UV‐absorption measurement
The UV‐absorption spectrum of rac‐5 was measured in a
quartz fluorescence cuvette by a Spectra Max M2e plate
reader (Molecular Devices, Ismaning, Germany). The
spectrum was corrected by subtraction of the spectrum of
the pure solvent.2.3 | Chromatography
2.3.1 | Instrumentation
An Agilent 1100 HPLC system consisting of a vacuum
degasser, binary pump, column oven, variable wavelength
UV–Vis detector, autosampler (Agilent, Waldbronn,
Germany), and the stationary phase Chiralpak ID‐3 column,
250 × 4.6 mm, 3 μm (Daicel, Illkirch, France) was used. Data
analysis was performed by means of OpenLab CDS
EZChrom from Agilent Technologies.
2.3.2 | Preparation of samples
Samples were dissolved in the mobile phase consisting of
3.40 ml N,N‐diisopropylethylamine and 0.76 ml formic acid
filled up with CH3CN to 1000 ml. All concentrations of the
samples used for the validation procedure represent the
nominal concentration of isolated derivatized nipecotic acid
5. The samples for method development and validation were
prepared by diluting a 6 mM stock solution of 5 in the sample
solvent.
2.3.3 | Investigation of chromatograms
The obtained chromatograms were examined using the
following parameters calculated by OpenLab CDS EZChrom
from Agilent Technologies. Resolution, Rs, retention factor,
k, and symmetry factor, As, were calculated according to the
United States Pharmacopia (USP 39 – NF 34). Due to the
recommendation of the USP the following equation was
used for resolution calculations: Rs=1.18 · (tR1− tR2)/
(w1 , h/2+w2 , h/2) where tR1 and tR2 are the retention timesof the two compounds and w1,h/2 and w2,h/2 are the corre-
sponding widths of the peaks at 50% height. For the retention
factor k, void time of the stationary phase (t0,SP) was esti-
mated using following equation: t0;SP ¼ 5 ⋅10−4 Ld2c=F
 
where L is the column length in mm, dc is the column inner
diameter in mm, and F is the flow rate in ml ·min−1 and the
void time of the HPLC instrument without column (t0,I)
was measured to be t0,I = 0.097 min.
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2.4 | HPLC method and validation
Each sample was measured in triplicate unless stated other-
wise. Final chromatographic conditions were as follows:
The mobile phase consisted of 20 mM formic acid and
20 mM N,N‐diisopropylethylamine in CH3CN, the flow rate
amounted to 1 ml ·min−1, injection volume to 10 μl, and col-
umn temperature to 40°C. The samples were dissolved in the
mobile phase and chromatograms were recorded at a detec-
tion wavelength of 490 nm. The linearity was investigated
by measurement of 18 calibration levels (2, 2.5, 4, 5, 7.5,
10, 25, 50, 75, 100, 250, 500, 750, 1000, 1500, 2000,
2500, 3000 μM rac‐5). Accuracy was ascertained by determi-
nation of the recovery of quality control samples (QCs) of
rac‐5 in five different concentrations in five replicates.
Precision was validated regarding repeatability by different
dilutions leading to five QCs and different batches of the ana-
lyte rac‐5, (S)‐5 and (R)‐5, respectively and was calculated as
RSD. Additionally, validation of accuracy and precision was
extended to experiments with (S)‐5 and (R)‐5 samples of
high enantiopurity spiked with defined amounts of rac‐5.
Furthermore, the reliable detection of small changes in the
ee value was verified with the spiking experiments (sp‐ex).3 | RESULTS AND DISCUSSION
3.1 | HPLC method development
First, the detection wavelength was set to 490 nm, which
represented the absolute maximum of the UV absorption
spectrum of rac‐5 (100 μM in mobile phase, Figure 2a). As
chiral stationary phases for enantioseparation of rac‐5 Astec
Cyclobond I 2000 DM (Sigma Aldrich, 250 × 4.6 mm,
5 μm) and Chiradex Gamma (Merck, Darmstadt, Germany,
250 × 4.6 mm, 5 μm) were tested, both of which were run
with a mobile phase consisting of triethylammonium acetate
buffer in CH3CN, but only Chiralpak ID‐3 column (Daicel,
250 × 4.6 mm, 3 μm) showed promising results.
Consequently, all further experiments for method optimiza-
tion were undertaken using this stationary phase. When
CH3CN with 20 mM of formic acid and 20 mM of N,N‐
diisopropylethylamine was used as eluent with a flow rate
of 1 ml∙min−1, the resulting resolution observed for rac‐5
appeared to be sufficient to ensure a sensitive determination
of the ee for both enantiomers. By varying column tempera-
ture (room temperature, 30°C, 35°C, and 40°C) it could be
FIGURE 2 Chromatogram of (A) 3000 μM rac‐5 (1500 μM of each enantiomer); insert shows the absorption spectrum of rac‐5 (100 μM in the mobile phase)
with the absolute maximum at 490 nm; (B) remaining residue of derivatization reaction without nipecotic acid dissolved in the mobile phase; (C) 1455 μM of
(S)‐5; (D) 1500 μM of (R)‐5 (from TCI Europe). (E) LLOQ at 1 μM for each enantiomer (S)‐5 and (R)‐5 (2 μM rac‐5). All chromatograms were recorded on
a Daicel Chiralpak ID‐3 (250 × 4.6 mm, 3 μm), with a mobile phase of 20 mM formic acid and 20 mM N,N‐diisopropylethylamine in CH3CN at a flow rate
of 1 ml·min−1 at 40°C
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decreased, which reduced the analysis time, but at the same
time the peak widths narrowed, which led to an increased
resolution. When studying the effects of injection volume, it
was found that the chromatographic parameters worsened,
i.e., the symmetry factor AS increased and the resolution
decreased, when the volume was varied from 10 to 20 μl.
Nonetheless, a reduction of the injection volume to 5 μl,
although it should result in an improved resolution, was
considered not appropriate, as this would most likely alsolimit the quantitation range and thus also the maximal height
of the ee values that can be determined. Accordingly, the
injection volume was set to 10 μl, representing a good
compromise between chromatographic resolution and quanti-
fication range. Thus, the final optimized chromatographic
conditions consisted of 20 mM formic acid and 20 mM N,
N‐diisopropylethylamine in CH3CN as mobile phase, a flow
rate of 1 ml ·min−1 at a column temperature of 40°C, and
an injection volume of 10 μl with the samples being dissolved
in the mobile phase. For the chromatograms received under
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obtained. The resolution was found to be Rs = 5.44, when
determined at 3000 μM of rac‐5. As the sample at this
concentration had led to a chromatogram with the broadest
peaks and the highest symmetry factors (As((S)‐5) = 1.73;
As((R)‐5) = 1.67), this value can be considered the lowest res-
olution for the whole concentration range studied (Figure 2a).
From the same chromatogram the retention factors k for (S)‐5
and (R)‐5 were calculated to be 3.39 and 5.13, respectively.
Additionally, blank samples containing only the mobile phase
were injected during method development and validation.
According to the lack of peaks at the retention time of
rac‐5, the method is free of sample carryover effects (data
not shown).
3.2 | Validation
To validate the described HPLC method the following
parameters were examined: specificity, lower limit of
quantification (LLOQ), linearity, quantitation range, accu-
racy (i.e., recovery), and precision (i.e., repeatability, calcu-
lated as RSD) for both enantiomers of nipecotic acid. To
this end, the particular chromatograms of rac‐5 were ana-
lyzed. Additionally, for determination of accuracy and preci-
sion experiments with enantiopure samples of (S)‐5 and (R)‐5
were performed.
3.2.1 | Specificity
To exclude any interference of unreacted reagents resulting
from the formation of rac‐5 from rac‐1 or other components
in the analytical samples, the procedure used for the synthesis
of rac‐5 was repeated under identical conditions, except that
rac‐1 was left out. When the thus obtained residue was
subjected to the same analytical procedure as rac‐5
(see Figure 2b), the resulting chromatogram showed only a
peak eluting near the void time. But neither any other peak
nor a peak at the retention times of the enantiomers of
rac‐5 could be detected, which were determined by injection
of pure (S)‐ or (R)‐enantiomers of 5. (Figure 2c,d). Accord-
ingly, the method can be considered as being specific.
3.2.2 | Linearity, range, LLOQ
Calibration functions for both enantiomers were generated
based on the data obtained from the analysis of 18 concentra-
tion levels of rac‐5 in the concentration range from 2 to
3000 μM (for details, see Materials and Methods), by
applying linear regression with 1/x2 weighing. For the (S)‐
enantiomer, the calibration function found was
y = 264479× + 9186 (r2 = 0.9994, y‐intercept corresponding
to 3.37% of the area obtained at the LLOQ) and for the (R)‐
enantiomer y = 262519× + 16276 (r2 = 0.9995, y‐intercept
corresponding to 5.88% of the area obtained at LLOQ). For
both enantiomers, the quantitation range reached from 1 to
1500 μM. Thus, determination of enantiopurities of nipecotic
acid 1 up to 99.87% ee should be feasible, considering thatone enantiomer may be reliably quantified at a concentration
of 1500 μMwhen the other enantiomer, in this case the minor
isomer, is present at a concentration of 1 μM. The signal to
noise (S/N) ratio was recorded for three 1 μM concentrations
of (S)‐5 and (R)‐5. It was found to be ≥22 for (S)‐5 and ≥11
for (R)‐5 (Figure 2e), which could be regarded as suitable for
the purpose of determining ee values up to 99%.3.2.3 | Accuracy, precision
To determine accuracy and precision, quality control samples
were analyzed in replicates (n = 5) at five different concentra-
tion levels (2, 10, 750, 1500, 3000 μM of rac‐5). Concentra-
tions were calculated from the experimentally obtained areas
employing the particular calibration function. Mean concen-
trations, accuracy, and precision are given in Table 1. Recov-
ery was calculated as the ratio of the experimentally
determined concentration ± confidence interval (α = 0.05)
to the nominal concentration and precision as the RSD of
the measured concentrations. For the (S)‐enantiomer of 5,
recoveries between 98.8 ± 0.6% and 99.7 ± 0.9% and RSDs
between 0.26% and 0.73% and for (R)‐5 recoveries between
99.3 ± 0.6% and 100.2 ± 0.3% and RSDs between 0.26%
and 1.0% were found.
When accuracy and precision were examined for highly
enantioenriched material, samples of (S)‐5 and (R)‐5, with
the concentration of the major enantiomer not exceeding
1500 μM were prepared, the concentrations thus stayed still
in the previously defined linearity range. The found concen-
tration of the (S)‐5 sample (from TCI Europe) with a nominal
concentration of 1455 μM amounted to 1477 μM and resulted
in a recovery of 101.5 ± 1.7% and the RSD was 1.3% related
to the sum of both enantiomers (Table 2). According to the ee
value of 99.60% ee given by the supplier, TCI Europe, the
analyzed sample should contain the enantiomers (S)‐5 and
(R)‐5 in concentrations of 1452 μM and 2.910 μM, respec-
tively. With respect to the determined concentrations of
1474 μM for (S)‐5 and 3.014 μM for (R)‐5, for the latter
recovery it was found to be 103.6 ± 2.5% and RSD 1.9%
and for (S)‐5 recovery it was 101.5 ± 1.7% and RSD 1.3%.
The ee value calculated from these results amounts to
99.59%, which is in excellent agreement with the ee of
99.60% stated by the supplier.
In the case of the (R)‐5 sample (from TCI Europe) ana-
lyzed at a nominal concentration of 1500 μM, the concentra-
tions calculated by means of five replicates were 1468 μM
with a recovery of 97.8 ± 2.6% and RSD of 2.2% related to
the sum of both enantiomers (Table 2). For the
enantioenriched (R)‐5 (with 99.90% ee according to the sup-
plier) the nominal concentrations for each enantiomer were
expected to be 0.750 μM for (S)‐5 and 1499 μM for (R)‐5.
However, with the LLOQ being 1 μM for (S)‐5, this value
was too low for a reliable determination by our method. But
for (S)‐5, a concentration of 1.296 μM was found, which
was thus within the quantitation range. For this, recovery
TABLE 1 Results (mean values, n = 5) for QC samples at five different concentration levels of rac‐5 regarding accuracy (recovery ± confidence interval,
α = 0.05) and precision (relative standard deviation, RSD)
Concentration (μM)
Found (mean values) Recovery ± CI (%) RSD (%)
Nominal (S)‐5 (R)‐5 (S)‐5 (R)‐5 (S)‐5 (R)‐5
1500 1494 1503 99.6 ± 0.3 100.2 ± 0.3 0.26 0.26
750 746.0 749.3 99.5 ± 0.5 99.9 ± 0.5 0.43 0.44
375 370.6 372.4 98.8 ± 0.6 99.3 ± 0.6 0.51 0.52
5 4.974 4.980 99.5 ± 0.8 99.6 ± 0.9 0.62 0.75
1 0.9966 0.9954 99.7 ± 0.9 99.5 ± 1.3 0.73 1.0
TABLE 2 Results (mean values, n = 5) for samples of (S)‐5 and (R)‐5 regarding accuracy (recovery ± confidence interval, α = 0.05), precision
(relative standard deviation, RSD) and the error range of the determined ee values (calculated with concentration ± confidence interval, α = 0.05)
Concentration ee [%]
Nominal [μM] Found ± CI [μM] Recovery ± CI [%] RSD [%] Expectede Found ee rangef
(S)‐5 1455 1477 ± 24.4 101.5 ± 1.7c 1.3d
(S)‐5 (R)‐5 (S)‐5 (R)‐5 (S)‐5 (R)‐5 (S)‐5 (R)‐5
1452a 2.910a 1474 ± 24.5 3.014 ± 0.1 101.5 ± 1.7 103.6 ± 2.5 1.3 1.9 99.60 99.59 99.58–99.61
(R)‐5 1500 1468 ± 39.5 97.8 ± 2.6c 2.2d
(S)‐5 (R)‐5 (S)‐5 (R)‐5 (S)‐5 (R)‐5 (S)‐5 (R)‐5
0.750b 1499b 1.296 ± 0.1 1466 ± 39.4 172.8 ± 10.8 97.8 ± 2.6 5.1 2.2 99.90 99.82 99.81–99.84
aExpected concentration of a 1455 μM (S)‐5 sample with a given ee value of 99.60% ee stated by TCI Europe (Zwijndrecht, Belgium).
bExpected concentration of a 1500 μM (R)‐5 sample with a given ee value of 99.90% ee stated by TCI Europe (Zwijndrecht, Belgium).
cRecovery [%] ± CI was calculated regarding the combined concentration of (S)‐5 and (R)‐5 in the sample.
dRSD [%] was calculated regarding the combined concentration of (S)‐5 and (R)‐5 in the sample.
eee values [%] given by TCI Europe (Zwijndrecht, Belgium).
fee range represents the range of error of the found ee values calculated using the confidence intervals of the found concentrations. Upper limit of error range was calcu-
lated with mean concentration + CI of the major enantiomer and the mean concentration – CI of the minor enantiomer and the lower limit of error range was calculated
with mean concentration – CI of the major enantiomer and the mean concentration + CI of the minor enantiomer.
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(R)‐enantiomer (R)‐5, a concentration of 1466 μM was found
together with a recovery of 97.8 ± 2.6% and RSD of 2.2%.
The ee of 99.82% calculated from the experimentally deter-
mined concentrations is in very good agreement with the ee
of 99.90% indicated by TCI Europe. Figure 2c,d show the
chromatograms observed after injections of 1455 μM of
(S)‐5 and 1500 μM of (R)‐5. To visualize the small peaks of
the minor enantiomer of the enantioenriched samples, the
respective parts of both chromatograms have been enlarged.
To prove that the developed method is able to determine
small changes in the ee values in a reliable manner, the
above‐mentioned enantiopure samples of (S)‐5 with a con-
centration of 1477 μM (1474 μM of (S)‐5 and 3.014 μM of
(R)‐5) and (R)‐5) with a concentration of 1468 μM
(1466 μM of (R)‐5 and 1.296 μM of (S)‐5) were each spiked
with 5 μl (995 μl of (S)‐5 or (R)‐5 plus 5 μl of rac‐5, Table 3,
sp‐ex 1 and sp‐ex 3) and 8 μl (992 μl of (S)‐5 or (R)‐5 plus
8 μl of rac‐5, Table 3, sp‐ex 2 and sp‐ex 4) of a 1500 μM
solution of rac‐5. The concentrations of the spiked samples
measured in five replicates were calculated by means of the
aforementioned calibration curves. The results were verified
with the expected ee values for the spiked samples calculated
with the expected concentrations for both enantiomers basedon the experimentally determined concentrations of the
unspiked (S)‐5 and (R)‐5 solutions, which can be seen in
Table 3.
In the case of spiking (S)‐5 samples with 5 μM and 8 μM
of 1500 μM of rac‐5, concentrations of 1471 μM (S)‐5 and
6.749 μM (R)‐5 (Table 3, sp‐ex 1) and of 1469 μM (S)‐5
and 8.990 μM (R)‐5 (Table 3, sp‐ex 2) with ee value of
99.09% and 98.78% could be expected, respectively. For sp‐
ex 1 (Table 3), the found concentrations of 1420 μM for
(S)‐5 and 6.413 for (R)‐5 resulted in a recovery of
96.6 ± 0.2% and an RSD of 0.18% for the major enantiomer
(S)‐5 and a recovery of 95.0 ± 2.1% and an RSD of 1.8% for
the minor enantiomer (R)‐5. The concentrations regarding sp‐
ex 2 (Table 3) were found to be 1413 μM for (S)‐5 and
8.511 μM for (R)‐5. Thus, recovery is 96.2 ± 0.4% for (S)‐5
and 94.7 ± 1.1% for (R)‐5 and RSD is calculated to be
0.30% for (S)‐5 and 0.92% for (R)‐5. For both spiking exper-
iments, the experimentally found ee values of 99.10% for sp‐
ex 1 and of 98.80% for sp‐ex 2 matched the expected ee
values almost perfectly (Table 3). For enantioenriched sam-
ples of (R)‐5, spiking with 5 μM and 8 μM of rac‐5 would
lead to concentrations of 5.040 μM of (S)‐5 and 1463 μM
of (R)‐5 (Table 3, sp‐ex 3) and 7.286 μM of (S)‐5 and
1461 μM of (R)‐5 (Table 3, sp‐ex 4), respectively. The
TABLE 3 Validation results (mean values, n = 5) regarding accuracy (recovery ± confidence interval, α = 0.05) and precision (relative standard deviation,
RSD) after spiking a 1477 μM solution of (S)‐5 (99.59% ee) with small amounts of a 1500 μM rac‐5 solution and a 1468 μM solution of (R)‐5 (99.82% ee) with
small amounts of a 1500 μM rac‐5 solution, respectively. The error ranges of the determined ee values of (R)‐5 and (S)‐5 were calculated using the concen-
tration ± confidence interval (α = 0.05).
Concentration ee (%)
Expected (μM)b Found ± CI (μM) Recovery ± CI (%) RSD (%)
sp‐exa (S)‐5 (R)‐5 (S)‐5 (R)‐5 (S)‐5 (R)‐5 (S)‐5 (R)‐5 expectedg found ee rangeh
1c 1471 6.749 1420 ± 3.2 6.413 ± 0.2 96.6 ± 0.2 95.0 ± 2.1 0.18 1.8 99.09 99.10 99.08–99.12
2d 1469 8.990 1413 ± 5.2 8.511 ± 0.2 96.2 ± 0.4 94.7 ± 1.1 0.30 0.92 98.78 98.80 98.78–98.82
3e 5.040 1463 5.105 ± 0.2 1397 ± 12.9 101.3 ± 3.6 95.5 ± 0.9 2.9 0.74 99.30 99.27 99.24–99.30
4f 7.286 1461 7.302 ± 0.2 1383 ± 11.6 100.2 ± 2.6 94.6 ± 0.8 2.1 0.68 99.01 98.95 98.91–98.99
asp‐ex = abbreviation for Spiking Experiment
bExpected concentration calculated from the experimentally determined concentration for the enantioenriched (S)‐5 and (R)‐5, respectively and the added amount of rac‐5.
csp‐ex 1: spiking 995 μL of a 1477 μM (S)‐5 solution (99.59% ee) with 5 μL 1500 μM rac‐5 solution.
dsp‐ex 2: spiking 992 μL of a 1477 μM (S)‐5 solution (99.59% ee) with 8 μL 1500 μM rac‐5 solution.
esp‐ex 3: spiking 995 μL of a 1468 μM (R)‐5 solution (99.82% ee) with 5 μL 1500 μM rac‐5 solution.
fsp‐ex 4: spiking 992 μL of a 1468 μM (R)‐5 solution (99.82% ee) with 8 μL 1500 μM rac‐5 solution.
gExpected enantiomeric excess calculated with the expected concentrations of the spiking experiments sp‐ex 1–4.
hee range represents the range of error of the found ee values calculated using the confidence intervals of the found concentrations. Upper limit of error range was cal-
culated with mean concentration + CI of the major enantiomer and the mean concentration – CI of the minor enantiomer and the lower limit of error range was calculated
with mean concentration – CI of the major enantiomer and the mean concentration + CI of the minor enantiomer.
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be 99.30% and 99.01% (Table 3). With found concentrations
of 5.105 μM of (S)‐5 and 1397 μM of (R)‐5 in sp‐ex 3,
recovery amounted to 101.3 ± 3.6% for (S)‐5 with RSD of
2.9% and 95.5 ± 0.9% for (R)‐5 with RSD of 0.74%. For
sp‐ex 4, following concentrations were found: 7.302 μM for
(S)‐5 and 1383 μM for (R)‐5 which led to recovery of
100.2 ± 2.6% for (S)‐5 and 94.6 ± 0.8% for (R)‐5 with RSDs
of 2.1% for (S)‐5 and 0.68% for (R)‐5. Due to these results, ee
values of 99.27% for sp‐ex 3 and 98.95% for sp‐ex 4 could be
calculated, which are in excellent accord with the expected
values.
Additionally, the error ranges for the found ee values
listed in Tables 2 and 3 were calculated using the concentra-
tion and CI values obtained for both enantiomers in quintupli-
cate measurements (Tables 2 and 3). The best possible ee
value was calculated from the upper confidence limit of
concentration of the major enantiomer (mean concentra-
tion + CI) and the lower confidence limit of the concentration
of the minor enantiomer (mean concentration – CI). The
resulting ee value represents the upper limit of the error range
of the determined ee values. The lower limit of the error
range was calculated from the lower confidence limit of the
concentration of the major enantiomer (mean concentration
– CI) and the upper confidence limit of the concentration of
the minor enantiomer (mean concentration + CI) (Tables 2
and 3). For the unspiked samples an ee range from 99.58 to
99.61% for (S)‐5 and 99.81 to 99.84% for (R)‐5 was obtained.
Spiking experiments performed with enantiopure (S)‐5,
yielded an ee error range of 99.08 to 99.12% for sp‐ex 1
and an ee range of 98.78 to 98.82% for sp‐ex 2 (for (S)‐5)
both including the respective ee values (sp‐ex 1: 99.09%
ee; sp‐ex 2: 98.78% ee). The ee error ranges for sp‐ex 3and sp‐ex 4 performed for (R)‐5 were determined with
99.24 to 99.30% and 98.91 to 98.99% for (R)‐5, respec-
tively. For sp‐ex 3, the expected ee value was again within
the confidence limits and for sp‐ex 4 was very close to it
(sp‐ex 3: 99.30% ee; sp‐ex 4: 99.01% ee).
Overall, an excellent accordance between all experimen-
tally determined and expected ee values was found. Thus,
the method described in this article can be considered reliable
for the determination of the ee of nipecotic acid and for the
identification of small changes of ee values.4 | CONCLUSION
In this study, a reliable and sensitive HPLC method for the
analysis of highly enantioenriched samples of nipecotic acid
(1) on a chiral stationary phase has been presented. Using
UV detection at 490 nm ensures a very selective and versatile
method for the determination of the analyte, which should be
helpful for many others users. The method was demonstrated
to allow a reliable quantification of ee values up to 99.87%
for (R)‐5 and 99.86% for (S)‐5 over a concentration range
from 1 to 1500 μM for (R)‐5 and from 1 to 1455 μM for
(S)‐5. The determination of accuracy (i.e., recovery) and pre-
cision (i.e., repeatability) examined by QCs of rac‐5 led to
recoveries between 98.8 ± 0.6% and 99.7 ± 0.9% with RSDs
between 0.26 and 0.73% for the (S)‐enantiomer, as well as
recoveries between 99.3 ± 0.6% and 100.2 ± 0.3% with
RSDs between 0.26 and 1.0%, demonstrating the high
validity of the method. The ee values found for the
enantioenriched substances (S)‐5 and (R)‐5 were in very good
accord with the ee values referred by the supplier (99.59% ee
for (S)‐5 and 99.82% ee for (R)‐5) and even slight changes in
56 SCHMIDT ET AL.the ee values effected by spiking experiments could be
reliably quantified.
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3.2 Second Publication 
Identification of Pyrrolidine-3-acetic Acid derived Oximes as Potent Inhibitors of γ-
Aminobutyric Acid Transporter 1 through Library Screening with MS Binding 
Assays 
 
3.2.1 Summary of the Results 
In this study, the focus was set on the identification of prospective highly affine inhibitors for 
mGAT1 with a 2-(pyrrolidin-3-yl)acetic acid subunit by using LC-MS/MS binding assays. To 
obtain the desired oxime libraries an excess of a 2-(pyrrolidin-3-yl)acetic acid derivative with 
an aminooxy ethyl substituent attached to the amino nitrogen (40 mM) was incubated with 28 
libraries each consisting of eight different aldehydes (1 mM each) in phosphate buffer pH 6.0 
(12.5 mM Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value was adjusted with 1 M HCl) with 
40 % DMSO at 37 °C for 20 h. The above mentioned hydroxylamine was applied as 
dihydrochloride to which two equivalents of sodium hydroxide was added to compensate the 
acid equivalents. In contrast to the previously published method, the number of aldehydes for 
generation of the libraries was doubled from four to eight while maintaining the concentration 
of the applied hydroxylamine derivative. The completion of the oxime formation under these 
modified conditions and within the set time frame was exemplarily proven by 1H NMR studies. 
Except for aldehyde library 26, which contains three sterically highly encumbered 
tritylaldehydes instead of the common reaction (20 h at 37 °C) more forcing reaction conditions 
(45 h at 80 °C) had to be applied to accomplish oxime library formation.  
After their formation, oxime libraries were diluted with phosphate buffer pH 7.1 (12.5 mM 
Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value was adjusted with 1 M NaOH) and were 
applied in the MS Binding Assay at three different concentration levels (1 µM, 100 nM and 10 
nM).  
At the highest test concentration of 1 µM all oxime libraries were able to reduce the specific 
binding of the marker NO711 below 50 % and still 15 libraries below 20 % revealing a high 
affinity of all libraries to the target at this concentration. When using 100 nM test concentration 
ten libraries reduced marker binding under 50 % and still four libraries under 20 % whereas at 
a concentration of 10 nM only one library could reduce the marker binding below 50 %. It was 
decided to choose the four libraries reducing specific marker binding below 20 % at a test 
concentration of 100 nM for the deconvolution experiments.  
For deconvolution, single oximes of the mentioned libraries were generated individually under 
the same conditions as used for the library generation and after subsequent dilution to 100 nM 
studied for their binding affinities in MS Binding Assays. Eight oximes out of 32 analyzed ones 
were found to reduce marker binding below 50 % and were selected to be resynthesized in 
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order to determine their binding affinity (pKi values) in full-scale competitive MS Binding Assays 
at mGAT1 and their inhibitory activity (pIC50 values) using [3H]GABA uptake assays at all four 
GABA transporter subtypes (mGAT1-4).  
All oximes identified as most affine, were found to contain a 1,1’-biphenyl residue. Their pKi 
values ranged from 6.97 up to 7.87 for mGAT1 and were in good accordance with the data 
obtained from library screening and deconvolution experiments. The compound with the 
highest affinity is characterized by a 2’,4’-dichlorobiphenyl moiety and with a Ki values in the 
low nanomolare range (pKi = 7.87 ± 0.01). Furthermore, the pIC50 values determined in 
[3H]GABA uptake assays for mGAT1 were in accord with the high affinity and revealed high 
subtype selectivity of the tested oximes for mGAT1 as compared to mGAT2 – mGAT4 in the 
range of approximately one to almost three log units regarding pIC50 values. Hence, a set of 
new potent inhibitors of mGAT1 with a 2-(pyrrolidin-3-yl)acetic acid motif was identified again 
proving the concept of library screening by MS Binding Assays as a powerful tool in the drug 
discovery process.  
 
3.2.2. Declaration of Contribution 
Synthesis of the hydroxylamine derivative as a starting material for the oxime generation, all 
precursor molecules and the compounds for the biological testing as well as the evaluation of 
all corresponding analytical data were accomplished by myself. Some aldehydes were 
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NMR studies on the kinetics of the oxime formation and oxime exchange reaction were 
performed together with Dr. Lars Allmendinger and Claudia Glas. All binding experiments 
regarding library screening and deconvolution experiments were achieved and evaluated by 
me. pKi values and pIC50 values were determined by the technical assistants Silke Duesing-
Kropp and Miriam Sandner under the supervision of Dr. Georg Höfner. I wrote the manuscript 
and prepared all graphics and tables, supported by Dr. Lars Allmendinger. Prof. Dr. Klaus T. 
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Identification of Pyrrolidine-3-acetic Acid Derived Oximes
as Potent Inhibitors of g-Aminobutyric Acid Transporter 1
through Library Screening with MS Binding Assays
Simone K. Huber, Georg Hçfner, and Klaus T. Wanner*[a]
Introduction
The number of people throughout the world affected by neu-
rological disorders, such as epilepsy, Alzheimer’s disease, de-
mentia, Parkinson’s disease, and depression, is increasing sig-
nificantly.[1] In 2006, the World Health Organization (WHO)
drew attention to the importance of the burden of neurologi-
cal disorders on public health.[2] Hence, an understanding of
the abovementioned disorders and the development of more
potent medications with lower side effects are huge fields of
interest for research. Low concentrations of g-aminobutyric
acid (GABA)—one of the major neurotransmitters in the mam-
malian central nervous system (CNS)[3]—in the synaptic cleft
have been identified as being associated with diseases such as
epilepsy[4] or Alzheimer’s disease.[5] One approach to enhance
the level of GABA in the synaptic cleft is to block reuptake of
the neurotransmitter in presynaptic neurons and glia cells
through membrane-bound GABA transporters (GATs).[6]
Four different subtypes of human GATs are
known, which are named GAT1, BGT1, GAT2, and
GAT3 according to the nomenclature suggested by
the Human Genome Organization (HUGO).[7] Because
GAT1 and GAT3 are the only transporters present in
the CNS in notable densities, of which GAT1 is
mainly expressed in neurons and GAT3 predomi-
nantly located in glia cells,[8] both subtypes are the
key targets to address for the successful enhance-
ment of the GABA level in the synaptic cleft. There-
by, GAT1, in particular, plays a key role that has been intensive-
ly investigated over the last few years. Differently, BGT1 and
GAT2 are mainly expressed in the liver and kidney and are
therefore not regarded as having a significant role in the termi-
nation of GABA signaling in the CNS.[8, 9] Because the GABA
transporters used herein to characterize the biological activity
of the target compounds, that is, their potency to inhibit
GABA uptake at different GATs, are cloned from mice, the no-
menclature for the GABA transporter subtypes of this species
are applied hereafter, according to which murine GABA trans-
porters are termed as mGAT1–mGAT4.[10]
In the late 1960s, potent inhibitors for mGAT1 were discov-
ered, such as (R,S)-nipecotic acid ((R,S)-2),[11] guvacine (3),[6] and
(R,S)-pyrrolidine-3-acetic acid ((R,S)-4) ; Figure 1).[12] Relative to
the substrate GABA, with an pIC50 value at mGAT1 of 5.14:
0.09,[13] compounds (R,S)-2 and 3 are slightly less potent ((R,S)-
2 : pIC50 = 4.88:0.07,[14] 3 : pIC50 = 4.87:0.06[15]), whereas (R,S)-
4 is at least equally potent toward mGAT1 (pIC50 = 5.39:
0.05).[16] For the sake of better comparability, these inhibitory
potencies and the pIC50 values of all compounds shown in
Figure 2, except for compound (R,S)-8, were determined by
In this study, pyrrolidine-3-acetic acid derived oxime libraries
were applied to the concept of library screening by MS Bind-
ing Assays, as a powerful technique to reveal new potent
murine g-aminobutyric acid transporter subtype (mGAT1) in-
hibitors. Library generation was accomplished by condensation
of an excess of pyrrolidine-3-acetic acid bearing a hydroxyla-
mine unit with various libraries, each composed of eight differ-
ent aldehydes. The oxime libraries have been screened by
means of competitive MS Binding Assays and, as a conse-
quence, the most active libraries were further investigated
through deconvolution experiments to identify single oximes
responsible for the observed activity on the target mGAT1. All
identified hits were finally resynthesized to characterize them
with respect to their binding affinities, and a set of new potent
inhibitors with the pyrrolidine-3-acetic acid motif were found,
of which the most potent oxime, possessing a 2’,4’-dichlorobi-
phenyl residue, displayed a binding affinity in the low nano-
molar range (pKi = 7.87:0.01).
Figure 1. Structures of GABA and three different amino acids with high inhibitory poten-
cies toward the GABA transporter mGAT1.
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[3H]GABA uptake assays in our group by employing the same
test system for all compounds.
However, the application of these potent inhibitors for
mGAT1 as potential medications is limited because they are
not able to cross the blood–brain barrier. Hence, inhibitors
with more lipophilic character were developed over time;
these are characterized by the presence of a biarylic moiety
connected through an alkyl chain to the corresponding amino
acid. Thus, not only the lipophilicity and brain penetration
were raised, but also the inhibitory potency at mGAT1 rose by
several orders of magnitude.
A prominent selective inhibitor of mGAT1 is the nipecotic
acid derivative tiagabine (5), which is in clinical use (pIC50 =
6.88:0.12; Figure 2).[15, 17] Further examples with enhanced af-
finity toward mGAT1 are NO711[18] and DDPM-2571,[19] which
are derived from 3 with an oxime functionality in the alkyl side
chain (NO711: pIC50 = 6.83:0.06; DDPM-2571: pIC50 = 8.27:
0.03; Figure 2). DDPM-2571 was found to be even more potent
than 5 by almost 1.5 log units, and was applied recently in a
set of in vivo studies that showed promising anxiolytic, antide-
pressant, and antinociceptive properties.[20] Whereas various
studies describe inhibitors of mGAT1 with nipecotic acid and
guvacine substructures, only a few are known concerning
mGAT1 inhibitors derived from pyrrolidine-3-acetic acid (4).
Nevertheless, the preparations of miscellaneous pyrrolidine-3-
acetic acid derivatives containing different lipophilic residues
linked by alkyl, alkenyl, or alkynyl chains to the pyrrolidine ni-
trogen have been reported since the late 1980s; most exam-
ples are provided by a patent,[21] but the pharmacological char-
acterizations at GABA transporters are rather limited.[15, 22] One
example is the racemic N-(4,4-diphenylbut-3-en-1-yl) derivative
of pyrrolidine-3-acetic acid, (R,S)-8, and its enantiomer, (S)-8,
which were found to be potent and selective GABA uptake in-
hibitors of a GABA transporter corresponding to mGAT1 in the
case of (R,S)-8 and mGAT1 for (S)-8 ((R,S)-8 : IC50 = 0.12 (0.10–
0.15) mm determined on rat brain tissue, which is known to
preferentially contain the rGAT subtype 1;[22] (S)-8 : pIC50 =
5.99:0.11;[15] Figure 2). Additionally, (S)-pyrrolidine-3-acetic
acid containing a 4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl
residue, ((S)-9), was recently examined for its activity at
mGAT1, and showed also a high inhibitory potency ((S)-9 :
pIC50 = 6.69:0.01, Figure 2), whereby the pIC50 value of tiaga-
bine-like derivative (S)-9 is only slightly lower than that of 5
itself.[15] Thus, substances with a pyrrolidine-3-acetic acid motif
are interesting and promising scaffolds for new inhibitors of
mGAT1.
Within this study, the main focus was set on the examination
of lipophilic N-substituents carrying pyrrolidine-3-acetic acids
as possible high-affinity inhibitors of mGAT1. To gain access to
a broad range of structures with many different lipophilic moi-
eties for structure–activity relationships regarding the inhibito-
ry activity of pyrrolidine-3-acetic acid derivatives toward the
target mGAT1, we decided to use the combinatorial screening
concept previously published by our group.[23] This concept is
based on a simple condensation reaction of the respective
amino acid scaffold through a hydroxylamine function with dif-
ferent aldehydes to generate oxime libraries,[19] which are sub-
sequently investigated with a competitive LC–MS/MS Binding
Assay.[24] With NO711 as a native marker,[24] the LC–MS/MS
Binding Assay allows the indirect determination of binding af-
finities of the applied competitors.[23] This concept is exempli-
fied in the screening of pseudostatic hydrazone libraries[23] and
stable oxime libraries;[19] both address the target mGAT1. It
was shown that the generation of libraries could be performed
in the presence of the target simultaneously generating the li-
brary upon incubation with the protein, as in the case of hy-
drazone libraries,[23] or in two separate steps in which the con-
ditions of library formation are not tolerated by the target, as
first implemented with oxime libraries.[19]
For the study of pyrrolidine-3-acetic acid containing inhibi-
tors, we focused on the identification of stable libraries with
the oxime functionality due to their higher hydrolytic stabili-
ty[25] over that of the hydrazone moiety. One additional reason
to focus on stable oximes is that some highly potent inhibitors
containing this function are already known (e.g. , NO711 and
DDPM-2571; Figure 2); this indicates that the oxime functional-
ity can undergo positive interactions with the mGAT1 protein,
which might increase the chances of identifying new active
mGAT1 inhibitors. Consequently, we focused on stable oxime
libraries with general structure 12 (Scheme 1).
Because oxime formation is known to be very slow under
physiological conditions, it was clear that this would require
the generation of libraries separately from the screening ex-
periments. Hence, the formation of oxime libraries should be
Figure 2. Inhibitors of mGAT1 based on different amino acid skeletons with lipophilic residues.
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accomplished by reacting the pyrrolidine-3-acetic acid as a hy-
droxylamine derivative, 10, with different aldehydes, 11, as out-
lined in Scheme 1.
Differently to the previously reported concept,[19] the
number of aldehydes 11 in one library was intended to be
doubled from four to eight to increase the throughput of the
screening concept. Additionally, the number of aldehyde libra-
ries should be increased to improve the chances of finding
potent inhibitors with new substitution patterns. To realize the
designated modifications, the suitability of the experimental
conditions used in a recently described study for library gener-
ation had to be adapted for the use of the new hydroxylamine
10.[19] Also, the stability of the generated oximes had to be en-
sured over the incubation time. The most potent libraries iden-
tified in the screening experiments should be tested in decon-
volution experiments to examine which single oximes were re-
sponsible for the affinity of the library. Subsequently, the iden-
tified single oximes should be resynthesized to determine their
binding affinities (pKi values) in full-scale competitive MS Bind-
ing Assays,[24] and their inhibitory activities (pIC50 values)
through [3H]GABA uptake assays,[18] to find the most active in-
hibitors for mGAT1 originating from the respective set of alde-
hydes. Finally, all identified hits should be characterized with
regard to their inhibitory potencies at all four murine GABA
transporters to determine their subtype selectivity.
Results and Discussion
Chemistry
Synthesis of hydroxylamine 10
The desired hydroxylamine 10 was synthesized by
using the synthetic pathway outlined in Scheme 2.
First, an E/Z mixture of 13[26] (E/Z ratio = 1:1) was
treated with hydrogen in the presence of Pd/C for
the hydrogenation of the C@C double bond and si-
multaneous deprotection of the benzyl group to
yield pyrrolidine-3-acetic acid as acetate salt 14
(97 % yield). Conversion of 14 into hydroxyethyl de-
rivative 15 (83 % yield) upon reaction with 2-bro-
moethanol, followed by a Mitsunobu reaction with
N-hydroxyphthalimide as a nucleophile in the pres-
ence of DMEAD at room temperature for 20 h, yield-
ed the corresponding N-hydroxyphthalimide deriva-
tive 16. Purification of 16 was accomplished by flash
column chromatography on silica gel pre-dried at 145 8C in
vacuo for 5 h. Thus, the hydrolytic instability of 16 observed
during flash column chromatography with regular silica gel
could be overcome. Subsequent hydrazinolysis with an aque-
ous hydrazine solution of 16 afforded hydroxylamine 17 in
very good yield (96 %). Finally, the ethyl ester was hydrolyzed
by using hydrochloric acid (1 m) to afford 10. The salt form of
10 was deduced from the results of elemental analysis per-
formed for 10.
Synthesis of oximes 12
For the determination of pKi and pIC50 values of the hit com-
pounds found through the screening process described below,
the individual oximes were synthesized as outlined in
Scheme 3. Following a previously reported method, a hydroxyl-
amine functionality containing a pyrrolidine-3-acetic acid deriv-
ative was reacted, such as ethyl ester 17, with aldehydes 11 in
equimolar concentrations to yield the oxime esters 18 as E/Z
mixtures, of which the Z isomer is the minor isomer (1–7 %, rel-
Scheme 1. Condensation reaction of hydroxylamine derivative 10 with vari-
ous aldehydes 11 to yield the corresponding oximes 12.
Scheme 2. Synthesis of 2-{1-[(2-aminooxy)ethyl]pyrrolidine-3-yl}acetic acid di-
hydrochloride 10 : a) H2, Pd/C, AcOH, EtOH, 50 bar, 24 h, RT, 97 %; b) 2-bro-
moethanol, K2CO3, KI, THF, 24 h, reflux, 83 %; c) N-hydroxyphthalimide, PPh3,
di-2-methoxyethyl azodicarboxylate (DMEAD), THF, 20 h, RT, 90 %; d) hydra-
zine (50–60 % solution), EtOH, 2 h, RT, 96 %; e) aqueous solution of HCl (1 m),
3 h, 90 8C, 87 %.
Scheme 3. Synthesis of oximes 12 : a) absolute EtOH, RT, 18 h, 48–90 %; b) aqueous solu-
tion of NaOH (2 m), EtOH, RT, 24 h; c) aqueous solution of HCl (2 m) then CH2Cl2, 41–94 %
(over two steps).[19, 27]
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ative to the E isomer).[19] Flash column chromatography of the
E/Z mixture yielded the pure E form of esters (E)-18. After sub-
sequent cleavage of the ester function with an aqueous solu-
tion of NaOH (2 m) in EtOH, acidification with an aqueous solu-
tion of HCl (2 m), and extraction with dichloromethane, the hy-
drochloric acid salts, 12, of the desired oximes were ob-
tained.[27]
Aldehydes 11
The required aldehydes were purchased from Sigma Aldrich
(Steinheim, Germany), TCI (Zwjindrecht, Belgium), Acros (Geel,
Belgium), or ABCR (Karlsruhe, Germany) and used without fur-
ther purification, or synthesized through Suzuki–Miyaura cou-
pling according to a method published previously.[28, 29] The set
of aldehydes used for oxime generation and screening is given
in Figure 3.
Library generation
Twenty-eight different aldehyde libraries were applied in the
screening, each consisting of eight aldehydes (Figure 3). For
broad structural variation, libraries contained aldehydes differ-
ing with respect to their gross structure, substituents, and sub-
stitution patterns; major classes represent aromatic (e.g. , in li-
braries 6, 7, 8, 9, 16), heteroaromatic (e.g. , in libraries 1, 3, 10,
13, 24, 25, 28), and arylaliphatic aldehydes (e.g. , in libraries 15,
18, 26).
Figure 3. Aldehyde libraries 1–28 applied within the screening experiments.
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Analogously to the previously published method for the MS
Binding Assay based on screening of oxime libraries derived
from 3,[19] we pre-generated the oximes in the absence of the
target mGAT1 by treating each library of aldehydes (1 mm
each) with an excess of the pyrolidine-3-acetic acid containing
a hydroxylamine function (40 mm) at 37 8C in phosphate buffer
(pH 6.0, 12.5 mm Na2HPO4, 12.5 mm NaH2PO4, 1 m NaCl, pH
value was adjusted with 1 m HCl) with a high DMSO concentra-
tion, 40 %, to guarantee the solubility of all reactants.
Different from the previously described protocol, hydroxyla-
mine 10 was applied as the dihydrochloride. To compensate
for the two additional equivalents of acid introduced with 10,
two equivalents of sodium hydroxide were added to the phos-
phate buffer (pH 6.0) used for the incubation system. With this
modification, decomposition of the free form of 10, the prepa-
ration of which required ion-exchange chromatography with
an aqueous solution of ammonia for elution, could be avoided.
Moreover, the number of aldehydes contained in one library
was doubled from four to eight to increase the throughput,
and hence, efficiency of the assay (Scheme 4). However, upon
increasing the number of aldehydes, and thereby, maintaining
a concentration of 1 mm for each aldehyde, the 10-fold excess
of hydroxylamine used in the original screening protocol is re-
duced to 5-fold. 1H NMR spectroscopy studies with reaction
mixtures, by applying a reactant ratio of 1:5, confirmed that
oxime formation under the newly chosen conditions was ach-
ieved within 20 h, except for library 26. For this library, contain-
ing the three sterically highly demanding tritylaldehydes
11 gw, 11 gy and 11 gz, 1H NMR spectroscopy studies showed
that these compounds could not be converted into the corre-
sponding oximes within the original reaction time, 20 h, at
37 8C. Hence, for library 26, the abovementioned procedure for
oxime generation had to be adjusted. If the components were
allowed to react at an elevated temperature of 80 8C, leaving
the buffer system (phosphate buffer with pH 6.0, 40 % DMSO)
and concentration levels of the aldehydes (1 mm each alde-
hyde) and hydroxylamine (40 mm) unchanged, the formation
of oximes in library 26 was complete within 45 h, as revealed
by monitoring the reaction through 1H NMR spectroscopy.
Before use in the screening process, all formed oxime libra-
ries had to be diluted with phosphate buffer (pH 7.1, 12.5 mm
Na2HPO4, 12.5 mm NaH2PO4, 1 m NaCl, pH value was adjusted
with 1 m NaOH) to the required test concentrations (1 mm,
100 nm, and 10 nm in the assay for each oxime), thereby war-
ranting that the concentration of DMSO in the incubation mix-
ture with the target mGAT1 at 37 8C did not exceed 1 %. The
Figure 3a continued.
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stability of the oximes in the diluted mixture was verified
through fluorescence spectroscopy measurements performed
immediately after the dilution step. Fluorescence measure-
ments had the advantage that they could be rendered selec-
tive for the oxime derivatives by choosing the appropriate ex-
citation and emission wavelengths. All applied oximes were
stable for the incubation time of 4 h because the fluorescence
signal remained unchanged. Additionally, an oxime exchange
experiment monitored by means of 1H NMR spectroscopy was
performed. For this experiment, two equivalents of aldehyde
11 t (2 equiv, 2 mm) were added to separately prepared oxime
12 ao (1 mm), the mixture was diluted with phosphate buffer
(pH 7.1; 12.5 mm Na2HPO4, 12.5 mm NaH2PO4, 1 m NaCl, 10 %
D2O, 1 % [D6]DMSO), kept at 37 8C in an NMR tube, and sub-
jected to 1H NMR spectroscopy measurements every 4 h for a
total of 64 h (see the Experimental Section for details). Within
this period of time, the 1H NMR spectra remained unchanged,
which indicated that oxime 12 ao was stable in the presence
of free aldehyde 11 t because no exchange reaction occurred.
Library screening
The affinity of the libraries was determined in competitive MS
binding experiments for mGAT1 with NO711 as a reporter
ligand. Experiments were performed at single points, that is,
the concentrations of the test compounds were set as limits
for minimal affinities. These screening experiments were per-
formed as follows: after dilution of the generated oxime libra-
ries to three different test concentration levels, namely, 1 mm
(1st experiment), 100 nm (2nd experiment), and 10 nm (3rd ex-
periment) with phosphate buffer (pH 7.1), the libraries were in-
cubated with the target protein, mGAT1 (10–20 mg protein per
sample in 250 mL), and the MS marker, NO711 (20 nm in the
assay), for 4 h at 37 8C in a shaking water bath. Then the pro-
tein–ligand complexes were separated by filtration, denatured
by drying at 50 8C for 1 h, and finally eluted with MeOH. The
amount of formerly bound, and now liberated, marker NO711
was quantified by means of LC–MS/MS (ESI). This amount of
marker was indicative of the affinity of the oxime libraries. Low
amounts of marker binding indicated high affinity of the
oxime library, which could possibly arise from a single com-
pound. All libraries were examined at three different concen-
tration levels (1 mm, 100 nm, and 10 nm) to ensure a reliable
differentiation of the affinity of the libraries, of which many ap-
peared potent at the highest test concentration (1 mm).
Control experiments in which only the aldehyde libraries,
without prior incubation with hydroxylamine 10 for the forma-
tion of the oximes, were applied to examine the potential in-
hibitory activity of the aldehydes themselves showed that they
did not have a significantly impact on marker binding; NO711
binding ranged from 82 to 100 % (aldehyde concentration
1 mm ; Table 1). In addition, different concentration levels of hy-
droxylamine 10 were screened to determine its affinity to the
target because, even after full conversion toward the oximes, a
high concentration of hydroxylamine, 32 mm, remained in the
sample solution. After dilution of the oximes to the desired
concentration for the screening experiments, the remaining
hydroxylamine concentrations were still 32 mm (oxime concen-
tration 1 mm), 3.2 mm (oxime concentration 100 nm), and
320 nm (oxime concentration 10 nm), respectively.
Fortunately, hydroxylamine 10 effected marker binding only
at concentrations above 40 mm to a significant extent (400 mm :
79:3 %; 4 mm : 37:1 %; Figure 4). At the concentration levels
prevalent in the assay, almost no reduction of marker binding
could be found (40 mm : 93:2 %; 4 mm : 93:1 %, 400 nm : 95:
2 %; Figure 4). Accordingly, free hydroxylamine 10 will not in-
Scheme 4. Reaction of hydroxylamine derivative 10 with eight different aldehydes to yield corresponding oxime library 8.
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terfere with marker binding in the screening experiments to
any reasonable extent.
The first series of screening experiments, applying the gen-
erated oxime libraries containing each oxime at a concentra-
tion of 1 mm in the assay, revealed that all libraries reduced the
specific binding of NO711 below 50 %, and for 15 libraries it
was below 20 % (libraries 2, 3, 5–10, 12–15, 19, 20, and 23;
Table 1). Because at a test concentration of 1 mm the affinity of
all tested libraries was quite high, we decided to study the li-
braries at a concentration of 100 nm and furthermore at
10 nm. Whereas at a test concentration of 10 nm, only one li-
brary was left reducing the marker binding below 50 % (library
8; Table 1), a distinctly broader, and hence, more useful differ-
entiation of library affinity occurred at a test concentration of
100 nm. In this case, 10 libraries reduced the marker binding to
below 50 % and was even below 20 % for 4 libraries (libraries
6–9; Table 1), which corresponded to an IC50 value of 25 nm if
the affinity was due to a single library component. With four li-
braries reaching this limit (20 % marker binding at 100 nm test
concentration), the decision was made to take only these four
libraries forward to the next step: the deconvolution experi-
ments.
Deconvolution experiments
To identify the oximes responsible for reduced marker binding
in each of the four most potent libraries identified, single
oximes were generated by reacting the respective aldehyde
(1 mm) with a large excess of hydroxylamine (40 mm) under
conditions identical to those of the library screening experi-
ments (phosphate buffer at pH 6.0 with 40 % DMSO, 37 8C,
20 h). Subsequent dilution of the deconvolution samples to
100 nm and analysis of these samples by means of LC–MS/MS
Binding Assays, with NO711 as a marker, provided the follow-
ing results, which are summarized in Table 2. Also, the corre-
sponding aldehydes alone without hydroxylamine were tested,
and once more no significant effect on marker binding could
be found for any of these compounds (83–101 %; Table 2).
Of the 32 oximes studied, 8 oximes were found to reduce
marker binding below 50 % (12 ao, 12 av, 12 aw, 12 ax, 12 be,
12 bf, 12 bj, and 12 bn ; Table 2, entries 1, 8, 9, 10, 17, 18, 22,
and 26), according to which results they could be expected to
possess a high affinity, with an IC50 value at or below 100 nm.
One of these oximes was even capable of reducing MS
marker binding below 20 % (12 bf of library 8, 10:1 %; Table 2,
entry 18); in which case, the affinity should even reach an IC50
value below 25 nm. The aforementioned compounds were
chosen for resynthesis to determine their pKi values in full-
scale competitive MS Binding Assays.[24]
Structure–activity relationships
Next, all eight oximes (12 ao, 12 av, 12 aw, 12 ax, 12 be, 12 bf,
12 bj, 12 bn) that were able to reduce the specific binding of
NO711 to below 50 % at a test concentration of 100 nm, and
hence, classified as hits, were subsequently resynthesized to
determine their binding affinities (pKi values) in full-scale MS
Binding Assays and their inhibitory potencies (pIC50 values) in
[3H]GABA uptake assays. The resynthesized oximes yielded pKi
values from 6.97 to 7.87 (Table 3). All determined pKi values
were in good accordance with the data obtained by library
and deconvolution experiments because, for example, oxime
12 bf, with the lowest value for the remaining bound NO711 of
Table 1. Results of the screening of aldehyde and oxime libraries.
Library Specific NO711 binding [%][a]
Aldehyde library Oxime library
1 mm 1 mm 100 nm 10 nm
1 95:1 22:1 74:7 91:6
2 93:1 8:1 30:2 81:2
3 93:3 17:1 66:4 89:4
4 96:2 34:3 69:8 95:7
5 82:1 7:1 31:2 85:6
6 96:3 2:1 21:2 84:6
7 94:2 2:1 18:2 80:6
8 91:1 <LLOQ[b] 6:1 44:4
9 97:4 <LLOQ[b] 11:1 57:3
10 97:4 6:1 41:6 99:1
11 99:2 33:1 80:4 87:6
12 99:1 2:1 33:4 89:3
13 93:4 11:1 55:2 91:3
14 100:2 2:1 29:1 90:3
15 96:5 17:2 65:5 94:6
16 95:1 48:6 73:1 85:2
17 93:7 28:3 65:3 87:4
18 88:7 44:5 72:5 100:5
19 96:7 7:1 54:2 92:5
20 94:2 2:1 32:1 70:3
21 89:4 27:3 97:3 98:3
22 95:3 45:4 82:6 90:6
23 87:3 20:1 76:3 93:4
24 99:3 27:1 88:2 94:3
25 92:6 43:5 77:4 92:2
26 88:1 28:3 59:2 89:6
27 91:7 32:3 71:1 90:6
28 83:5 41:2 80:4 94:7
[a] Percentage of remaining bound NO711; data represent the mean:
standard deviation (SD) of n = 4 experiments. [b] Level of quantified MS
marker NO711 is below the lower limit of quantification (LLOQ) of 50 pm.
Figure 4. Control experiment applying single hydroxylamine 10 in six differ-
ent concentration levels. Percentage of remaining specific bound NO711;
data represent the mean : standard deviation (SD) of n = 4 experiments.
Control represents the specific binding of NO711 in the absence of hydroxyl-
amine.
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Table 3. Binding affinities (pKi) from the competitive MS Binding Assay and inhibitory potencies (pIC50) from [
3H]GABA uptake experiments determined for
synthesized oximes with different substitution patterns.
Entry Compound pKi
[b] pIC50
[c]
(substitution pattern)[a] mGAT1 mGAT2 mGAT3 mGAT4
1 12 ao (2’-F,4’-F) 7.31:0.03 6.60:0.08 73 % 82 % 85 %
2 12 av (2’-OMe,6’-F) 7.12:0.03 6.57:0.05 100 % 88 % 89 %
3 12 aw (2’-Cl) 7.07:0.04 6.41:0.08 77 % 76 % 72 %
4 12 ax (4’-Cl) 6.97:0.04 6.29:0.07 4.87 73 % 4.63
5 12 be (2’-F,4’-Cl) 7.13:0.11 6.63:0.12 4.07 64 % 4.49
6 12 bf (2’-Cl,4’-Cl) 7.87:0.01 7.33:0.05 4.44 4.08 4.27
7 12 bj (2’-F,4’-F,6’-F) 7.23:0.03 6.55:0.06 89 % 82 % 58 %
8 12 bn (2’-Cl,4’-F) 7.57:0.08 7.06:0.12 71 % 77 % 61 %
[a] Individually synthesized oximes (see the Experimental Section). [b] Data points for specific binding of NO711 on mGAT1 (mean:SD, n = 3) in the pres-
ence of different concentrations of test compound resulted in binding curves for Ki determination by means of nonlinear regression. pKi values represent
the mean: standard error of the mean (SEM) of three independent experiments, each performed in triplicate. [c] pIC50 values from [3H]GABA uptake assay
performed with murine GABA transporter expressing HEK cells. The values represent the mean:SEM of three (mGAT1) or one (mGAT2-4) independent ex-
periments, each performed in triplicate. Percentage values represent remaining [3H]GABA uptake in the presence of 100 mm test compound.
Table 2. Results of the deconvolution experiments for libraries 6, 7, 8, and 9 at a concentration of 100 nm.
Entry Compound Specific NO711 binding [%] Entry Compound Specific NO711 binding [%]
(substitution pattern) Aldehyde 11[a] Oxime 12[b] (substitution pattern) Aldehyde 11[a] Oxime 12[b]
library 6 library 7
1 ao (2’-F,4’-F) 95:6 46:1 9 aw (2’-Cl) 98:1 48:6
2 ap (2’-F,5’-F) 97:4 95:1 10 ax (4’-Cl) 96:2 45:3
3 aq (2’-F,3’-F) 89:6 72:5 11 ay (3’-Cl) 95:5 81:8
4 ar (3’-F,5’-F) 92:5 94:2 12 az (2’-OMe) 86:4 75:2
5 as (2’-OMe,5’-F) 95:5 93:4 13 ba (3’-OMe) 95:4 74:7
6 at (2’-OMe,4’-F) 85:5 61:6 14 bb (4’-OMe) 91:7 76:1
7 au 93:5 94:4 15 bc (3’-Me) 89:3 82:4
8 av (2’-OMe,6’-F) 95:5 44:2 16 bd (4’-Me) 97:7 61:3
library 8 library 9
17 be (2’-F,4’-Cl) 100:1 33:4 25 bm (2’-Me) 94:4 65:5
18 bf (2’-Cl,4’-Cl) 101:2 10:1 26 bn (2’-Cl,4’-F) 92:2 30:2
19 bg (3-F) 90:6 67:3 27 bo (2’-CF3,4’-CF3) 90:2 86:6
20 bh (2-F) 98:3 70:2 28 bp (2’-Me,4’-Me) 93:4 66:5
21 bi (2’-F,6’-F) 83:1 60:4 29 bq (3-F,4’-Cl) 94:6 57:4
22 bj (2’-F,4’-F,6’-F) 98:5 43:1 30 br (2’-Ph) 90:6 78:5
23 bk (3-F,2’-F) 98:2 57:3 31 bs (3’-Ph) 93:5 76:3
24 bl (3-F,2’-Cl) 100:2 59:2 32 bt (4’-Ph) 92:5 89:3
[a] Percentage of remaining bound NO711 in the presence of pure aldehyde at 100 nm ; data represent the mean:SD of n = 4 experiments. [b] Percentage
of remaining bound NO711 in the presence of generated oxime in the deconvolution experiment with the respective aldehyde at 100 nm ; data represent
the mean:SD of n = 4 experiments.
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10:1 % (Table 2, entry 18), showed the highest pKi value of
7.87:0.01 (Table 3, entry 6) that could be determined under
these conditions.
Notably, all hits contain a 1,1’-biphenyl moiety, which was
derived from 1,1’-biphenyl-2-carbaldehyde with substituents at
the terminal phenyl ring. The unsubstituted 1,1’-biphenyl de-
rivative, 12 j, from library 2 was additionally applied as a single
substance in the deconvolution experiments (70:2 % remain-
ing bound NO711). According to a comparison of the value ob-
served for the regioisomeric unsubstituted biphenyl-3-carbal-
dehyde-derived oxime, 12 au (94:4 %; Table 2, entry 7), the
substitution pattern of the latter compound leads to a reduced
affinity toward mGAT1.
The substitution pattern of the hits can be divided into four
main groups of which all members show rather high affinity
toward mGAT1: oximes derived from biphenyl-2-carbaldehydes
containing only chlorine (12 aw, 12 ax, 12 bf ; Table 2, entries 9,
10, and 18), oximes containing only fluorine (12 ao, 12 bj ;
Table 2, entries 1 and 22), oximes containing both fluorine and
chlorine substituents (12 be, 12 bn ; Table 2, entries 17 and 26),
and one oxime containing a methoxy and a fluorine residue
(12 av ; Table 2, entry 8). Oximes with different substituents,
such as methyl groups (e.g. , monosubstituted: 12 bc, 12 bd,
12 bm ; disubstituted: 12 bp ; Table 2, entries 15, 16, 25, and
28), trifluoromethyl groups (e.g. , 12 bo ; Table 2, entry 27), or
additional phenyl groups (e.g. , 12 br, 12 bs, 12 bt ; Table 2, en-
tries 30–32) showed a diminished binding affinity.
Among the oximes with a single chlorine substituent, the 3’-
chloro-substituted oxime, 12 ay (81:8 %; Table 2, entry 11),
represents the compound with the lowest affinity and does
not reach the limit of 50 % in the deconvolution experiments.
For the ortho- and para-substituted derivatives, the affinity is
distinctly higher and roughly the same for both compounds;
pKi value for the 2’-substituted oxime, 12 aw, is 7.07:0.04 and
for the 4’-substituted oxime, 12 ax, is 6.97:0.04 (Table 3, en-
tries 3 and 4). In comparison, for oxime 12 bl, which also has a
2’-chloro substituent in the second phenyl moiety, for example,
12 aw, but an additional fluoro substituent in the 3-position of
the first ring, the affinity to target mGAT1 is distinctly dimin-
ished (59:2 %; Table 2, entry 24). The same trend, a reduced
binding affinity, is also found for oxime 12 bq with 3-fluoro-
and 4’-chloro substituents (57:4 %; Table 2, entry 29), relative
to that of 12 ax with only a 4’-chloro substituent. Accordingly,
ortho or para substitution in the second phenyl ring is favora-
ble and additional 3-substitution in the first phenyl ring leads
to a decrease in affinity.
If two chloro substituents are present in the terminal ring in
the 2’- and 4’-positions, a significant increase in the binding af-
finity, by almost one log unit, results (pKi = 7.87:0.01; Table 3,
entry 6). The 2’,4’-dichloro-substituted oxime, 12 bf, represents
the oxime with the best binding affinity of all compounds
studied. If, however, the first phenyl ring of the 2’,4’-dichloro-
substituted oxime, 12 bf, is replaced, for example, by a thio-
phene (12 bw, library 10; Table 1), pyridine (12 dh, library 14;
Table 1), or a furan ring (12 fy, library 23; Table 1), the mGAT1
affinity must have lowered because none of the libraries con-
taining those oximes were able to reduce the specific NO711
binding under the limit of 20 % to be selected for further ex-
periments (see Table 1).
By replacing monochloro- by monofluoro-substituted com-
pounds at the terminal ring, the negative effect on affinity is
apparent because library 5, containing monofluoro-substituted
oximes in the 2’-, 3’-, and 4’-positions (12 ak, 12 al, and 12 am,
respectively), is not able to decrease the remaining specific
binding of NO711 to below 20 % at the test concentration of
100 nm (31:2 %; Table 1, entry 5), and thus, it was not exam-
ined in the deconvolution experiments. A similar negative
effect could be observed for oximes monosubstituted at the
terminal ring with a methoxy residue. All three oximes 12 az,
12 ba, and 12 bb, with methoxy functions in the 2’-, 3’-, and 4’-
positions, respectively, lead to a similar weak reduction of spe-
cific NO711 binding (at 100 nm marker concentration) to ap-
proximately 75 % (Table 2, entries 12–14).
All oximes containing fluorine that reached the limit of
below 50 % in the deconvolution experiments carry one or two
additional substituents in the terminal biphenyl subunit.
Among the difluoro-substituted compounds, the 2’,4’-substi-
tuted oxime, 12 ao (pKi = 7.31:0.03; Table 3, entry 1), was the
most active oxime, and the 2’,6’-disubstituted oxime, 12 bi,
could almost reach the 50 % limit (60:4 %; Table 2, entry 21).
For the 2’,4’,6’-trifluoro-substituted oxime, 12 bj, with an addi-
tional 6’-fluoro substituent compared with 12 ao, the pKi value
of 7.23:0.03 (Table 3, entry 7) is only slightly lower than the
value of 12 ao. Oximes with a second fluoro substituent in the
meta position, in addition to the first fluorine atom in the 2’-
position, show a distinctly diminished binding affinity com-
pared with, for example, the 2’,4’-difluoro-substituted com-
pound, 12 ao (Table 2, entry 1). This is especially true for the
2’,5’-disubstituted system (oxime 12 ap ; 95:1 %; Table 2,
entry 2), whereas it is less pronounced for the 2’,3’-disubstitut-
ed compound (oxime 12 aq ; 72:5 %; Table 2, entry 3). The
3’,5’-difluoro-substituted oxime 12 ar (94:2 %; Table 2, entry 4)
shows a similar low affinity to that of the 2’,5’-difluoro-substi-
tuted compound, 12 ap (Table 2, entry 2). Hence, for all tested
compounds, meta-fluoro substitution has a negative effect on
the affinity of the oximes and ortho and para substitution is
generally favorable; this is most pronounced for the chloro-
substituted compounds.
A 2’,4’-disubsitution appears also favorable for mixed substi-
tuted oximes containing a fluorine and a chlorine residue.
Thereby, oxime 12 bn, with a chlorine in the 2’-position and a
fluorine in the 4’-position, leads to a higher affinity (pKi =
7.57:0.08; Table 3, entry 8) than that of regioisomeric oxime
12 be with an inverted substitution pattern (pKi = 7.13:0.11;
Table 3, entry 5). Considering that the affinity of oxime 12 ao,
containing two fluorine substituents in the 2’,4’-position,
slightly diminished if the 4’-fluoro substituent was replaced by
chlorine (12 be ; Table 3, entry 5), but increased upon replace-
ment of the 2’-fluoro substituent, a 2’-chloro substituent is
clearly beneficial for the binding affinity.
As already mentioned, among the difluoro-substituted com-
pounds, the 2’,4’-difluoro-substituted derivative, 12 ao (Table 2,
entry 1), has an increased affinity to mGAT1 than that of the
oxime with a 2’,6’-disubstitution pattern, 12 bi (Table 2,
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entry 21). However, the opposite is true for the mixed disubsti-
tuted oximes, 12 av and 12 at, exhibiting methoxy and fluorine
residues. Here, the 2’-methoxy-6’-fluoro-substituted oxime,
12 av (pKi = 7.12:0.03; Table 3, entry 2), is more active than
oxime 12 at with 2’-methoxy-4’-fluoro substitution (61:6 %;
Table 2, entry 6). Notably, if the 4’-fluoro substituent in 12 at is
shifted to the 5’-position, and hence, in the meta position and
resulting in oxime 12 as, the affinity decreases (93:4 %;
Table 2, entry 5) according to the results already found.
In comparison with the recently published mGAT1 inhibitors
obtained with oxime libraries using guvacine (3) as the amino
acid motif,[19] the lipophilic moieties with the same substitution
pattern also turned out to yield the most potent inhibitors in
this study. These guvacine-derived hits displayed slightly
higher pKi values, for example, the oxime with guvacine motif
DDPM-2571, with 2’,4-dichloro substitution, showed a pKi value
of 8.29:0.02, compared with 7.87:0.01 for the analogous
pyrrolidine-3-acetic acid derivative 12 bf. Interestingly, the me-
thoxy group was identified as an alternative substituent that,
as in oxime 12 av, gave rise to high mGAT1 affinity (pKi =
7.12:0.03). Hence, known substitution patterns, such as di-
chloro or mixed chloro/fluoro substitution, were also con-
firmed to be favorable for mGAT1 binding affinity for the pyr-
rolidine-3-acetic acid derivatives.
Subtype selectivity—GABA uptake assays
The newly identified hits were characterized for their subtype
selectivity by determining their inhibitory potencies (pIC50) at
all four murine GABA transporters, mGAT1–mGAT4, by means
of [3H]GABA uptake assays based on HEK cells (Table 3). If the
test compounds at a concentration of 100 mm were not able to
reduce [3H]GABA uptake below a limit of 50 % (pIC50,4.00),
the percentage value of the remaining [3H]GABA uptake was
given. In cases of reduction of [3H]GABA uptake below 50 %,
the pIC50 values were determined in triplicate.
Upon comparing pKi values determined in the MS Binding
Assay with the pIC50 values determined in [
3H]GABA uptake
assays on mGAT1, it appears that pKi values are approximately
up to one log unit higher, which is common in these assays
and thought to be due to differences in the applied NaCl con-
centrations in the assays. To ensure high affinity of the marker
NO711 for improved assay performance, 1 m NaCl is employed
in MS Binding Assays and, in contrast, a NaCl concentration of
120 mm is used in uptake assays to comply with physiological
conditions. In the present case, all pKi values are between 0.50
(12 be ; Table 3, entry 5) and 0.71 (12 ao ; Table 3, entry 1) log
units higher than the corresponding pIC50 values, and hence,
fully in the expected range.
All studied test compounds listed in Table 3 show the high-
est potencies as GABA uptake inhibitors at mGAT1, with pIC50
values between 6.29 (12 ax ; Table 3, entry 4) and 7.33 (12 bf ;
Table 3, entry 6). The potencies at GABA transporters mGAT2–
mGAT4 are much lower. In most cases, the compounds are not
even capable of reducing [3H]GABA uptake to 50 % or lower at
a test compound concentration of 100 mm. In other words, the
pIC50 values of these compounds at mGAT2–mGAT4 are below
4.0, which is also why these pIC50 values are not considered to
be worth determining.
In the case of oxime 12 bf—the compound identified with
the highest pIC50 value, 7.33:0.05, for mGAT1—the potencies
at the transporters mGAT2–mGAT4 are almost three log units
lower (mGAT2–mGAT4, pIC50 = 4.08–4.44; Table 3, entry 6). A re-
markable subtype selectivity is also found for compound 12 av,
although it displays a lower pIC50 at mGAT1 (pIC50 = 6.57:
0.05; Table 3, entry 2) than that of 12 bf. With 88–100 % of re-
maining [3H]GABA uptake (at 100 mm test compound concen-
tration), the pIC50 values of 12 ao at mGAT2–mGAT4 are far
below 4.0 (Table 2, entry 2). Compound 12 ax also deserves at-
tention. It shows the lowest inhibitory potency toward mGAT1
(pIC50 = 6.29:0.07; Table 3, entry 4) and, at the same time, the
highest pIC50 values of all tested compounds toward the other
transporters, mGAT2 and mGAT4 (pIC50 = 4.87 for mGAT2 and
pIC50 = 4.63 for mGAT4). The subtype selectivity in favor of
mGAT1 is thus markedly reduced. Overall, all test compounds
in Table 3 show a clear subtype selectivity in favor of mGAT1,
which is in the range of approximately one to almost three log
units.
Conclusions
The concept of stable oxime library screening by using a com-
petitive LC–MS/MS Binding Assay was successfully transferred
to lipophilic N-substituted pyrrolidine-3-acetic acid derivatives.
The synthesis of 10 as a hydrophilic amino acid precursor was
accomplished within five steps, with an overall yield of 61 %.
The number of different aldehydes applied per library to re-
ceive stable oximes was this time increased from four to eight
compounds to improve the throughput of this type of assay.
Upon subsequent screening at different concentrations, 4 libra-
ries out of a total of 28, containing 228 different members,
were identified as being highly active toward the target
mGAT1. These libraries were subjected to deconvolution ex-
periments and led to eight hit compounds. After resynthesis of
these oximes, all of which displayed a 1,1’-biphenyl moiety as
part of the lipophilic domain, full competitive MS Binding
Assays confirmed the identification of new potent inhibitors of
mGAT1. With pKi values ranging from 6.97 to 7.87, these com-
pounds represent mGAT1 inhibitors with a pyrrolidine-3-acetic
acid motif with the highest binding affinity toward mGAT1 re-
ported so far. The concept of library screening by using an
oxime functionality for library generation has again been suc-
cessfully applied, and the reliable application of an LC–MS/MS
Binding Assay in library screening for hit identification on a
specific target has been proven.
Experimental Section
Chemistry
Organic solvents used were of analytical grade and were freshly
distilled prior to use, except for DMSO and absolute EtOH. Pur-
chased reagents and reactants were used without further purifica-
tion. TLC was performed on precoated silica gel F254 aluminum
sheets (Merck). Flash column chromatography was performed on
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Merck silica gel 60 (mesh 0.040–0.063 mm). NMR spectra were re-
corded with an Avance III HD 400 MHz Bruker BioSpin (400 MHz)
spectrometer and Avance III HD 500 MHz Bruker BioSpin (500 MHz)
spectrometer equipped with a CryoProbe Prodigy attachment. 1H
chemical shifts were internally referenced to tetramethylsilane
(TMS) or 3-(trimethylsilyl)propionic-2,2,3,3[D4] acid sodium salt
(TSP) for samples dissolved in D2O. The digital resolution was
stated with an accuracy of :0.15 Hz. MestreNova (Version 12.0.0)
was used for further analysis of the spectra. IR spectra were record-
ed with a FTIR Paragon 1000 (PerkinElmer, Rodgau, Germany) spec-
trometer and Spectrum v2.00 software (PerkinElmer, Rodgau, Ger-
many) as either KBr pellets or as films on NaCl plates. HRMS was
measured on a Thermo Finnigan LTQ FT instrument for ESI or on a
Thermo Finnigan MAT 95 instrument for electron impact (EI). Melt-
ing points (in 8C, uncorrected) were determined with a Bechi melt-
ing point B-350 apparatus. Elemental analysis for 10 was per-
formed with an 888 Titrando (Metrohm) instrument to determine
the protonation state. Purity was determined by means of qNMR
spectroscopy on an Avance III HD 400 MHz Bruker BioSpin
(400 MHz) spectrometer with maleic acid as an internal standard
(Sigma Aldrich, Steinheim, Germany, LOT-No. BCBM8127V).[30]
Oximes 12 and 10 were +95 % pure. For weighing, an ALC-80.4
ACCULAB and a MC 21S scale from Sartorius Group (Gçttingen,
Germany) were used.
General procedure for the preparation of oximes (GP1)
Aldehyde 11 (1.0 equiv) in absolute EtOH (c = 0.1 m) was added to
a stirred solution of 10 (1.0 equiv) in absolute EtOH (c = 0.1 m), and
the resulting mixture was stirred at 60 8C for 18 h. After removal of
the solvent under reduced pressure, the residue was purified by
flash column chromatography (silica gel, n-pentane/ether = 9:1 to
0:1) to yield 18 as a colorless oil.
General procedure for the hydrolysis of oximes (GP2)
A solution of ester 18 (1.0 equiv) in absolute EtOH (c = 0.1 m) was
treated with an aqueous solution of NaOH (2 m, 3.0 equiv), and the
mixture was stirred at room temperature for 18 h. After cooling to
0 8C, an aqueous solution of HCl (1 m) was added until pH 1 was
reached. The aqueous phase was extracted with CH2Cl2 (3 V 20 mL),
the combined organic layers were dried with Na2SO4, and the sol-
vent was removed under reduced pressure. The resulting oil was
dissolved in double-distilled water and lyophilized to yield desired
product 12 as a hydrochloride salt.
Syntheses
Synthesis of 13 : Only the 1H NMR spectroscopy analytical data for
the E/Z mixture were reported in the literature.[26] Thus, additional
analytical data are given for the isolated isomers. (Z)-13 : Rf = 0.30
(n-hexanes/EtOAc 8:2); IR (film): ñ= 3028, 2979, 2935, 2792, 1712,
1668, 1370, 1370, 1215, 1037, 700 cm@1; 1H NMR (400 MHz, CDCl3,
TMS): d= 1.25 (t, J = 7.1 Hz, 3 H), 2.64 (s, 4 H), 3.65–3.71 (m, 4 H),
4.13 (q, J = 7.1 Hz, 2 H), 5.67–5.82 (m, 1 H), 7.22–7.27 (m, 1 H), 7.29–
7.35 ppm (m, 4 H); 13C NMR (100 MHz, CDCl3, TMS): d= 14.3, 33.9,
52.56, 59.1, 59.7, 60.4, 111.8, 127.1, 128.3, 128.8, 138.5, 163.5,
166.3 ppm; IR (film): ñ= 3028, 2978, 2789, 1712, 1665, 1370, 1214,
1146, 1037 cm@1; HRMS (EI+): m/z calcd for C15H19NO2 [M]
+ :
245.1416; found: 245.1423. (E)-13 : Rf = 0.40 (n-hexanes/EtOAc 8:2);
1H NMR (500 MHz, CDCl3, TMS): d= 1.26 (t, J = 7.1 Hz, 3 H), 2.73 (t,
J = 6.8 Hz, 2 H), 2.96 (tdd, J = 6.6, 2.5, 1.2 Hz, 2 H), 3.26 (q, J = 1.5 Hz,
2 H), 3.65 (s, 2 H), 4.15 (q, J = 7.1 Hz, 2 H), 5.74 (p, J = 2.3 Hz, 1 H),
7.26–7.29 (m, 1 H), 7.30–7.35 ppm (m, 4 H); 13C NMR (126 MHz,
CDCl3, TMS): d= 14.4, 32.0, 54.1, 59.7, 60.4, 60.5, 111.4, 127.2, 128.4,
128.8, 138.5, 163.1, 166.5 ppm; HRMS (EI+): m/z calcd for C15H19NO2
[M]+ : 245.1416; found: 245.1411.
Synthesis of 14 : Compound 13 (3.85 g, 15.7 mmol), Pd/C (10 %,
929 mg, 7.85 mmol), and glacial acetic acid (2.70 mL, 47.1 mmol) in
EtOH (abs., 15 mL) was introduced into an autoclave, and hydroge-
nation was performed at room temperature and 50 bar for 23 h.
The reaction mixture was filtered through Celite and the solid was
washed with EtOH (abs. , 15 mL). After removal of the solvent
under reduced pressure, the residue was dissolved in water
(20 mL) and the aqueous phase was washed with diethyl ether (3 V
20 mL) and lyophilized to afford 14 as a yellow oil (3.3 g, 97 %). IR
(film): ñ= 3405, 2982, 2755, 2472, 1731, 1563, 1402, 1199,
1029 cm@1; 1H NMR (400 MHz, CDCl3, TMS): d= 1.26 (t, J = 7.1 Hz,
3 H), 1.64 (dq, J = 13.0, 8.7 Hz, 1 H), 1.96 (s, 3 H), 2.15–2.25 (m, 1 H),
2.47 (d, J = 7.5 Hz, 2 H), 2.67 (hept, J = 7.5 Hz, 1 H), 2.82 (dd, J = 11.4,
8.4 Hz, 1 H), 3.14 (ddd, J = 11.4, 8.9, 7.7 Hz, 1 H), 3.24–3.35 (m, 1 H),
3.41 (dd, J = 11.4, 7.6 Hz, 1 H), 4.14 (q, J = 7.1 Hz, 2 H); 13C NMR
(100 MHz, CDCl3, TMS): d= 14.2, 23.6, 30.6, 34.7, 37.2, 44.1, 49.2,
60.8, 171.6, 178.4 ppm; HRMS (EI+): m/z calcd for C8H15NO2 [M]
+ :
157.1103; found: 157.1109.
Synthesis of 15 : K2CO3 (382 mg, 2.76 mmol), KI (3 mg, 0.02 mmol)
and 2-bromoethanol (83 mL, 1.1 mmol) were added to a solution of
14 (200 mg, 0.921 mmol) in THF (4 mL). The resulting mixture was
heated at reflux for 20 h. After cooling to room temperature, the
solids were removed by filtration and the solvent was removed
under reduced pressure. The residue was purified by column chro-
matography on silica gel (MeCN/NEt3 = 97:3) to yield 15 as a
yellow oil (153 mg, 83 %): Rf = 0.10 (MeCN/NEt3 97:3); IR (film): ñ=
3389, 2954, 1729, 1376, 1191, 1051, 880 cm@1; 1H NMR (400 MHz,
CDCl3, TMS): d= 1.26 (t, J = 7.1 Hz, 3 H), 1.40–1.54 (m, 1 H), 2.08
(dddd, J = 13.1, 9.1, 7.4, 5.9 Hz, 1 H), 2.30 (dd, J = 9.3, 6.2 Hz, 1 H),
2.39 (d, J = 7.4 Hz, 2 H), 2.50–2.80 (m, 6 H), 2.82 (dd, J = 9.3, 7.4 Hz,
1 H), 3.61 (t, J = 5.4 Hz, 2 H), 4.13 ppm (q, J = 7.1 Hz, 2 H); 13C NMR
(100 MHz, CDCl3, TMS): d= 14.3, 30.5, 33.8, 40.0, 53.4, 57.2, 59.5,
59.7, 60.3, 172.8 ppm; HRMS (ESI+): m/z calcd for C10H20NO3 [M +
H]+ : 202.1438; found: 202.1439.
Synthesis of 16 : Compound 15 (235 mg, 1.17 mmol), N-hydrox-
yphthalimide (324 mg, 1.98 mmol), and triphenylphosphine
(531 mg, 1.98 mmol) were dissolved in THF (5 mL) before DMEAD
(479 mg, 2.04 mmol) was added slowly and the solution was stirred
for 17 h at room temperature. After removal of the solvent under
reduced pressure, the residue was dissolved in CH2Cl2 (20 mL) and
the organic layer was washed with water (3 V 15 mL), dried over
sodium sulfate, and the solvent was again removed in vacuo. The
resulting oil was purified by column chromatography on silica gel,
which was pre-dried at 145 8C in vacuo for 5 h (diethyl ether/
NEt3 = 95:5), to afford 16 as a light yellow oil (364 mg, 90 %). Rf =
0.81 (diethyl ether/NEt3 95:5); IR (film): ñ= 3059, 2981, 1731, 1693,
1434, 1267, 1178, 1029 cm@1; 1H NMR (400 MHz, CDCl3, TMS): d=
1.25 (t, J = 7.1 Hz, 3 H), 1.37 (ddt, J = 12.7, 8.1, 6.4 Hz, 1 H), 2.01
(dddd, J = 13.0, 9.1, 7.7, 5.6 Hz, 1 H), 2.25–2.37 (m, 3 H), 2.45–2.56
(m, 1 H), 2.60 (td, J = 8.6, 5.7 Hz, 1 H), 2.64–2.73 (m, 1 H), 2.83–2.98
(m, 3 H), 4.12 (q, J = 7.1 Hz, 2 H), 4.32 (t, J = 5.5 Hz, 2 H), 7.72–7.81
(m, 2 H), 7.81–7.90 ppm (m, 2 H); 13C NMR (100 MHz, CDCl3, TMS):
d= 14.3, 30.6, 33.7, 40.0, 53.9, 54.1, 60.1, 60.2, 76.1, 123.5, 129.0,
134.4, 163.5, 172.7 ppm; HRMS (ESI+): m/z calcd for C18H23N2O5
[M + H]+ : 347.1601; found: 347.1607.
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Synthesis of 17: A solution of hydrazine (50–60 %, 21 mL,
0.33 mmol) was added to a stirred solution of 16 (57 mg,
0.17 mmol) in EtOH (abs. , 2 mL), and the solution was stirred for
2 h at room temperature. The resulting slurry was filtered, the fil-
trate was washed with ice-cold CH2Cl2 (10 mL), and the solvent
was removed in vacuo. Again ice-cold CH2Cl2 (10 mL) was added to
the residue and the resulting mixture was filtered. Evaporation
under reduced pressure afforded 17 as a colorless oil (34 mg,
96 %). IR (film): ñ= 2958, 2933, 2792, 1732, 1591, 1374, 1277, 1191,
1156, 1031 cm@1; 1H NMR (400 MHz, CDCl3, TMS): d= 1.25 (t, J =
7.1 Hz, 3 H), 1.46 (ddt, J = 12.6, 8.2, 6.2 Hz, 1 H), 2.09 (dddd, J = 13.0,
9.4, 7.8, 6.0 Hz, 1 H), 2.20 (dd, J = 9.3, 6.9 Hz, 1 H), 2.39 (d, J = 7.5 Hz,
2 H), 2.52 (td, J = 8.6, 6.0 Hz, 1 H), 2.56–2.63 (m, 1 H), 2.63–2.76 (m,
3 H), 2.91 (dd, J = 9.3, 7.8 Hz, 1 H), 3.78 (t, J = 5.6 Hz, 2 H), 4.12 ppm
(q, J = 7.1 Hz, 2 H); 13C NMR (100 MHz, CDCl3, TMS): d= 14.3, 30.5,
33.7, 40.0, 54.2, 54.9, 60.3, 60.4, 74.2, 172.8 ppm; HRMS (ESI+): m/z
calcd for C10H21N2O3 [M + H]
+ : 217.1547; found: 217.1548.
Synthesis of 10 : Compound 17 (57 mg, 0.26 mmol) was dissolved
in an aqueous solution of HCl (1 m, 2.6 mL, 2.6 mmol) and the reac-
tion mixture was stirred at 95 8C for 4 h. After cooling to room tem-
perature, the mixture was washed with CH2Cl2 (3 V 5 mL) and the
aqueous layer was lyophilized to yield the product as colorless
amorphous solid (60 mg, 87 %); in the NMR spectra two different
conformers in a ratio of 1:1.18 could be identified; mp: 58–64 8C;
IR (KBr): ñ= 3383, 2957, 2671, 1722, 1454, 1408, 1199, 1044,
1019 cm@1; HRMS (ESI+): m/z calcd for C8H17N2O3 [M + H]
+ :
189.1234; found: 189.1233. Conformer 1 (major): 1H NMR (500 MHz,
0.1 DCl in D2O, TPS): d= 1.90 (dddd, J = 13.7, 9.5, 7.9, 5.9 Hz, 1 H),
2.32 (dq, J = 13.7, 8.1 Hz, 1 H), 2.56–2.70 (m, 2 H), 2.70–2.80 (m, 1 H),
2.86–2.98 (m, 1 H), 3.31 (ddd, J = 11.8, 9.6, 7.2 Hz, 1 H), 3.64 (tt, J =
4.0, 1.5 Hz, 2 H), 3.77 (ddd, J = 14.1, 7.6, 5.3 Hz, 1 H), 3.96 (dd, J =
11.3, 7.0 Hz, 1 H), 4.45 ppm (ddd, J = 5.6, 4.3, 1.5 Hz, 2 H); 13C NMR
(126 MHz, 0.1 DCl in D2O, TPS): d= 31.1, 35.9, 39.4, 40.0, 55.4, 55.5,
56.8, 61.6, 72.6, 72.6, 178.8, 179.0 ppm; Conformer 2 (minor):
1H NMR (500 MHz, 0.1 DCl in D2O, TPS): d= 1.74 (dddd, J = 13.6,
11.6, 9.3, 7.5 Hz, 1 H), 2.42 (dtd, J = 13.7, 7.2, 2.1 Hz, 1 H), 2.56–2.70
(m, 2 H), 2.86–2.98 (m, 1 H), 3.21 (td, J = 11.5, 6.9 Hz, 1 H), 3.51 (d,
J = 8.2 Hz, 2 H), 3.64 (tt, J = 4.0, 1.5 Hz, 2 H), 3.81 (ddd, J = 11.2, 7.3,
1.9 Hz, 1 H), 4.45 ppm (ddd, J = 5.6, 4.3, 1.5 Hz, 2 H); 13C NMR
(126 MHz, 0.1 DCl in D2O, TPS): d= 32.4, 35.3, 39.4, 40.0, 55.4, 55.5,
58.0, 61.1, 72.6, 72.6, 178.8, 179.0 ppm.
Synthesis of 18 ao : According to GP1, compound 18 ao was ob-
tained as a colorless oil (84 mg, 87 %) from hydroxylamine 17
(50 mg, 0.23 mmol) and 11 ao (50.4 mg, 0.231 mmol). Rf = 0.17 (di-
ethyl ether 100 %); IR (film): ñ= 3066, 2960, 2790, 1732, 1620, 1509,
1270, 1141, 954 cm@1; 1H NMR (400 MHz, CDCl3, TMS): d= 1.24 (t,
J = 7.1 Hz, 3 H), 1.45 (ddt, J = 12.6, 8.1, 6.1 Hz, 1 H), 2.07 (dddd, J =
13.6, 9.3, 7.8, 6.0 Hz, 1 H), 2.20 (dd, J = 9.0, 7.2 Hz, 1 H), 2.38 (d, J =
7.5 Hz, 2 H), 2.47–2.65 (m, 2 H), 2.65–2.83 (m, 3 H), 2.91 (dd, J = 9.0,
7.9 Hz, 1 H), 4.11 (q, J = 7.1 Hz, 2 H), 4.24 (t, J = 5.9 Hz, 2 H), 6.84–
6.93 (m, 1 H), 6.93–6.99 (m, 1 H), 7.21 (td, J = 8.5, 6.5 Hz, 1 H), 7.24–
7.26 (m, 1 H), 7.37–7.45 (m, 2 H), 7.93 (d, J = 2.0 Hz, 1 H), 7.95–
8.01 ppm (m, 1 H); 13C NMR (100 MHz, CDCl3, TMS): d= 14.2, 30.5,
33.7, 40.0, 54.3, 55.0, 60.3, 60.4, 73.1, 104.2 (t, J(C,F) = 25.9 Hz), 111.5
(dd, J(C,F) = 21.0, 4.0 Hz), 123.3 (dd, J(C,F) = 16.4, 4.0 Hz), 125.9, 128.4,
129.5, 130.8, 132.6 (dd, J(C,F) = 9.5, 4.7 Hz), 134.6, 147.0, 159.6 (dd,
J(C,F) = 249.8, 12.4 Hz), 162.7 (dd, J(C,F) = 249.9, 11.8 Hz), 172.8 ppm;
19F NMR (376 MHz, CDCl3): d=@110.2 (p, J = 8.0 Hz), @110.3 ppm
(q, J = 8.6 Hz); HRMS (EI+): m/z calcd for C23H26F2N2O3 [M]
+ :
416.1911; found: 416.1909.
Synthesis of 18 av : According to GP1, compound 18 av was ob-
tained as a colorless oil (17 mg, 48 %) from hydroxylamine 17
(17.8 mg, 0.0825 mmol) and 11 av (19.0 mg, 0.0825 mmol). Rf = 0.08
(diethyl ether 100 %); IR (film): ñ= 3065, 2960, 2794, 1732, 1615,
1470, 1239, 1155, 1083 cm@1; 1H NMR (400 MHz, CD2Cl2, TMS): d=
1.22 (t, J = 7.1 Hz, 3 H), 1.39 (ddt, J = 12.5, 8.0, 6.2 Hz, 1 H), 2.01
(dddd, J = 13.4, 9.3, 7.8, 5.7 Hz, 1 H), 2.18 (dd, J = 9.2, 6.5 Hz, 1 H),
2.29–2.39 (m, 2 H), 2.44–2.56 (m, 2 H), 2.60 (td, J = 8.4, 6.2 Hz, 1 H),
2.63–2.77 (m, 2 H), 2.79 (dd, J = 9.2, 7.5 Hz, 1 H), 3.74 (s, 3 H), 4.08
(q, J = 7.2 Hz, 2 H), 4.17 (t, J = 5.9 Hz, 2 H), 6.74–6.87 (m, 2 H), 7.17–
7.28 (m, 1 H), 7.30–7.48 (m, 3 H), 7.78 (s, 1 H), 7.96 ppm (dd, J = 7.7,
1.6 Hz, 1 H); 13C NMR (100 MHz, CD2Cl2, TMS): d= 14.6, 31.1, 34.4,
40.5, 54.6, 55.3, 56.6, 60.7, 60.8, 73.6, 107.3 (d, J(C,F) = 2.9 Hz), 108.6
(d, J(C,F) = 23.0 Hz), 116.6 (d, J(C,F) = 19.4 Hz), 125.9, 128.6, 129.8, 130.4
(d, J(C,F) = 10.6 Hz), 132.0, 132.0, 132.2, 147.5, 158.6 (d, J(C,F) = 6.8 Hz),
160.9 (d, J(C,F) = 243.5 Hz), 173.2 ppm;
19F NMR (376 MHz, CD2Cl2):
d=@114.3 ppm; HRMS (ESI+): m/z calcd for C24H30FN2O4 [M + H]+ :
429.2184; found: 429.2181.
Synthesis of 18 aw: According to GP1, compound 18 aw was ob-
tained as a colorless oil (39 mg, 68 %) from hydroxylamine 17
(30 mg, 0.14 mmol) and 11 aw (30 mg, 0.14 mmol). Rf = 0.15 (dieth-
yl ether, 100 %); IR (film): ñ= 3061, 2958, 2791, 1732, 1467, 1188,
1155, 1034, 756 cm@1; 1H NMR (400 MHz, CD2Cl2, TMS): d= 1.21 (t,
J = 7.1 Hz, 3 H), 1.39 (ddt, J = 12.6, 8.2, 6.2 Hz, 1 H), 2.01 (dddd, J =
13.3, 9.3, 7.9, 5.7 Hz, 1 H), 2.17 (dd, J = 9.2, 6.5 Hz, 1 H), 2.29–2.38
(m, 2 H), 2.43–2.56 (m, 2 H), 2.59 (td, J = 8.3, 6.1 Hz, 1 H), 2.61–2.76
(m, 2 H), 2.79 (dd, J = 9.1, 7.6 Hz, 1 H), 4.08 (q, J = 7.1 Hz, 2 H), 4.17
(t, J = 5.9 Hz, 2 H), 7.18–7.30 (m, 2 H), 7.31–7.39 (m, 2 H), 7.39–7.47
(m, 2 H), 7.46–7.54 (m, 1 H), 7.76 (s, 1 H), 7.90–8.03 ppm (m, 1 H);
13C NMR (100 MHz, CD2Cl2, TMS): d= 14.5, 30.9, 34.2, 40.4, 54.5,
55.2, 60.5, 60.7, 73.6, 125.8, 127.2, 128.6, 129.7, 129.9, 130.7, 131.0,
132.1, 133.7, 138.8, 139.6, 147.1, 173.0 ppm; HRMS (ESI+): m/z calcd
for C23H28ClN2O3 [M + H]
+ : 415.1783; found: 415.1781.
Synthesis of 18 ax : According to GP1, compound 18 ax was ob-
tained as a colorless oil (48 mg, 72 %) from hydroxylamine 17
(35 mg, 0.16 mmol) and 11 ax (35 mg, 0.16 mmol). Rf = 0.17 (diethyl
ether, 100 %); IR (film): ñ= 3062, 2958, 2792, 1733, 1473, 1200,
1156, 1035, 761 cm@1; 1H NMR (500 MHz, CD2Cl2, TMS): d= 1.14 (t,
J = 7.2 Hz, 3 H), 1.33 (ddt, J = 12.7, 8.1, 6.3 Hz, 1 H), 1.94 (dddd, J =
13.4, 9.3, 7.9, 5.8 Hz, 1 H), 2.12 (dd, J = 8.9, 6.7 Hz, 1 H), 2.27 (d, J =
7.5 Hz, 2 H), 2.37–2.48 (m, 2 H), 2.49–2.57 (m, 1 H), 2.59–2.70 (m,
2 H), 2.73 (dd, J = 8.9, 7.7 Hz, 1 H), 4.00 (q, J = 7.2 Hz, 2 H), 4.13 (t,
J = 5.9 Hz, 2 H), 7.15–7.20 (m, 2 H), 7.22 (dd, J = 7.5, 1.5 Hz, 1 H), 7.30
(td, J = 7.6, 1.5 Hz, 1 H), 7.32–7.39 (m, 3 H), 7.85 (dd, J = 7.8, 1.3 Hz,
1 H), 7.90 ppm (s, 1 H); 13C NMR (126 MHz, CD2Cl2, TMS): d= 13.3,
29.8, 33.1, 39.2, 53.3, 54.0, 59.3, 59.6, 72.5, 125.3, 127.1, 127.7,
128.8, 129.2, 129.4, 130.3, 132.8, 137.4, 140.0, 146.4, 171.8 ppm;
HRMS (ESI+): m/z calcd for C23H28ClN2O3 [M + H]
+ : 415.1783; found:
415.1781.
Synthesis of 18 be : According to GP1, compound 18 be was ob-
tained as a colorless oil (60 mg, 75 %) from hydroxylamine 17
(50 mg, 0.23 mmol) and 11 be (54 mg, 0.23 mmol). Rf = 0.15 (diethyl
ether, 100 %); IR (film): ñ= 3065, 2958, 2791, 1738, 1731, 1607,
1277, 1156, 893 cm@1; 1H NMR (500 MHz, CDCl3, TMS): d= 1.24 (t,
J = 7.1 Hz, 3 H), 1.45 (ddt, J = 12.6, 8.2, 6.2 Hz, 1 H), 2.07 (dddd, J =
13.6, 9.3, 7.8, 6.0 Hz, 1 H), 2.19 (dd, J = 9.3, 6.9 Hz, 1 H), 2.38 (d, J =
7.5 Hz, 2 H), 2.52 (td, J = 8.7, 6.0 Hz, 1 H), 2.59 (dq, J = 9.2, 7.2 Hz,
1 H), 2.66–2.82 (m, 3 H), 2.90 (dd, J = 9.2, 7.8 Hz, 1 H), 4.11 (q, J =
7.1 Hz, 2 H), 4.24 (t, J = 5.9 Hz, 2 H), 7.14–7.23 (m, 3 H), 7.23–7.26 (m,
1 H), 7.37–7.46 (m, 2 H), 7.93 (d, J = 2.0 Hz, 1 H), 7.95–8.01 ppm (m,
1 H); 13C NMR (126 MHz, CDCl3, TMS): d= 14.2, 30.5, 33.7, 40.0, 54.3,
55.0, 60.3, 60.4, 73.1, 116.6 (d, J(C,F) = 25.8 Hz), 124.6 (d, J(C,F) =
3.7 Hz), 125.8 (d, J(C,F) = 16.4 Hz), 126.0, 128.5, 129.5, 130.6, 130.7,
132.6 (d, J(C,F) = 4.1 Hz), 134.4, 134.7 (d, J(C,F) = 9.9 Hz), 146.9, 159.3
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(d, J(C,F) = 250.5 Hz), 172.8 ppm;
19F NMR (376 MHz, CDCl3): d=
@112.1 ppm; HRMS (EI+): m/z calcd for C23H26FClN2O3 [M]+ :
432.1616; found: 432.1612.
Synthesis of 18 bf : According to GP1, compound 18 bf was ob-
tained as a colorless oil (48 mg, 77 %)from hydroxylamine 17
(30 mg, 0.14 mmol) and 11 bf (35 mg, 0.14 mmol). Rf = 0.11 (diethyl
ether, 100 %); IR (film): ñ= 3059, 2957, 2925, 1733, 1586, 1466,
1154, 1035, 762 cm@1; 1H NMR (400 MHz, CDCl3, TMS): d= 1.24 (t,
J = 7.1 Hz, 3 H), 1.44 (ddt, J = 12.6, 8.3, 6.1 Hz, 1 H), 2.07 (dddd, J =
13.5, 9.3, 7.7, 5.9 Hz, 1 H), 2.18 (dd, J = 9.3, 6.9 Hz, 1 H), 2.38 (d, J =
7.5 Hz, 2 H), 2.47–2.55 (m, 1 H), 2.55–2.64 (m, 1 H), 2.64–2.81 (m,
3 H), 2.90 (dd, J = 9.2, 7.6 Hz, 1 H), 4.11 (q, J = 7.2 Hz, 2 H), 4.22 (t, J =
5.9 Hz, 2 H), 7.14–7.21 (m, 2 H), 7.30 (dd, J = 8.2, 2.1 Hz, 1 H), 7.36–
7.44 (m, 2 H), 7.48 (d, J = 2.1 Hz, 1 H), 7.80 (s, 1 H), 7.90–8.06 ppm
(m, 1 H); 13C NMR (100 MHz, CDCl3, TMS): d= 14.2, 30.5, 33.7, 40.0,
54.2, 55.0, 60.2, 60.4, 73.1, 125.8, 127.1, 128.5, 129.4, 130.2, 130.6,
132.3, 134.3, 134.4, 137.0, 138.0, 146.7, 172.8 ppm; HRMS (ESI+): m/
z calcd for C23H27Cl2N2O3 [M + H]
+ : 449.1393; found: 449.1393.
Synthesis of 18 bj : According to GP1, compound 18 bj was ob-
tained as a colorless oil (48 mg, 82 %) from hydroxylamine 17
(29.3 mg, 0.135 mmol) and 11 bj (32.0 mg, 0.135 mmol). Rf = 0.14
(diethyl ether, 100 %); IR (film): ñ= 3065, 2959, 2792, 1732, 1463,
1274, 1233, 1154, 1034, 998, 788 cm@1; 1H NMR (400 MHz, CD2Cl2,
TMS): d= 1.22 (t, J = 7.1 Hz, 3 H), 1.40 (ddt, J = 12.7, 8.2, 6.3 Hz, 1 H),
2.02 (dddd, J = 13.5, 9.2, 7.9, 5.7 Hz, 1 H), 2.18 (dd, J = 9.2, 6.5 Hz,
1 H), 2.29–2.38 (m, 2 H), 2.51 (dtd, J = 14.2, 8.1, 7.4, 3.4 Hz, 2 H),
2.55–2.62 (m, 1 H), 2.62–2.76 (m, 2 H), 2.79 (dd, J = 9.0, 7.6 Hz, 1 H),
4.08 (q, J = 7.1 Hz, 2 H), 4.17 (t, J = 5.9 Hz, 2 H), 6.74–6.86 (m, 2 H),
7.22–7.33 (m, 1 H), 7.41–7.54 (m, 2 H), 7.87 (t, J = 1.2 Hz, 1 H), 7.91–
7.99 ppm (m, 1 H); 13C NMR (100 MHz, CD2Cl2, TMS): d= 14.5, 30.9,
34.3, 40.4, 54.5, 55.1, 60.5, 60.7, 73.7, 100.8 (ddd, J(C,F) = 28.5, 25.7,
2.5 Hz), 113.3 (td, J(C,F) = 21.5, 5.2 Hz), 126.8, 128.0, 129.5, 129.9,
131.9, 132.0, 146.6, 160.7 (ddd, J(C,F) = 248.3, 14.9, 10.2 Hz). 163.2
(dt, J(C,F) = 234.0, 15.8 Hz), 173.0 ppm;
19F NMR (376 MHz, CD2Cl2):
d=@108.6 (t, J = 6.2 Hz), @109.8 ppm (d, J = 6.7 Hz); HRMS (ESI+):
m/z calcd for C23H26F3N2O3 [M + H]
+ : 435.1890; found: 435.1888.
Synthesis of 18 bn : According to GP1, compound 18 bn was ob-
tained as a colorless oil (59 mg, 84 %) from hydroxylamine 17
(35 mg, 0.16 mmol) and 11 bn (38 mg, 0.16 mmol). Rf = 0.15 (diethyl
ether, 100 %); IR (film): ñ= 3064, 2958, 2792, 1733, 1601, 1257,
1156, 1060, 898 cm@1; 1H NMR (400 MHz, CDCl3, TMS): d= 1.24 (t,
J = 7.1 Hz, 3 H), 1.44 (ddt, J = 11.7, 8.2, 6.1 Hz, 1 H), 2.07 (dddd, J =
13.3, 9.4, 7.9, 6.0 Hz, 1 H), 2.19 (dd, J = 8.8, 7.3 Hz, 1 H), 2.38 (d, J =
7.5 Hz, 2 H), 2.51 (td, J = 8.4, 6.6 Hz, 1 H), 2.58 (dq, J = 9.1, 7.3 Hz,
1 H), 2.64–2.83 (m, 3 H), 2.90 (dd, J = 9.0, 7.9 Hz, 1 H), 4.11 (q, J =
7.1 Hz, 2 H), 4.23 (t, J = 5.8 Hz, 2 H), 7.04 (ddd, J = 8.4, 8.0, 2.6 Hz,
1 H), 7.14–7.24 (m, 3 H), 7.37–7.47 (m, 2 H), 7.80 (s, 1 H), 7.92–
8.05 ppm (m, 1 H); 13C NMR (100 MHz, CDCl3, TMS): d= 14.2, 30.5,
33.7, 40.0, 54.3, 55.0, 60.3, 60.4, 73.1, 114.1 (d, J(C,F) = 21.1 Hz), 116.9
(d, J(C,F) = 24.7 Hz), 125.7, 128.4, 129.4, 130.4, 130.7, 132.5 (d, J(C,F) =
8.7 Hz), 134.3 (d, J(C,F) = 10.3 Hz), 134.6 (d, J(C,F) = 3.7 Hz), 138.2,
146.9, 162.1 (d, J(C,F) = 250.4 Hz), 172.8 ppm;
19F NMR (376 MHz,
CDCl3): d=@112.2 ppm; HRMS (EI+): m/z calcd for C23H26FClN2O3
[M]+ : 432.1616; found: 432.1604.
Synthesis of 12 ao : According to GP2, compound 12 ao was ob-
tained as a colorless, amorphous powder (54 mg, 87 %) from 18 ao
(61.0 mg, 0.146 mmol) and NaOH (17.6 mg, 0.439 mmol, 220 mL);
mp: 60–62 8C; IR (KBr): ñ= 3416, 2950, 2618, 2562, 1719, 1618,
1508, 1419, 1269, 1140, 942, 764 cm@1; 1H NMR (500 MHz, 0.1 m
NaOD/CD3OD = 1:2, TPS): d= 1.46 (ddt, J = 12.9, 8.2, 6.3 Hz, 1 H),
2.04 (dddd, J = 13.8, 8.9, 7.6, 6.4 Hz, 1 H), 2.18 (dd, J = 9.6, 7.7 Hz,
1 H), 2.22 (dd, J = 14.2, 8.1 Hz, 1 H), 2.25 (dd, J = 24.0, 10.7 Hz, 1 H),
2.46–2.59 (m, 2 H), 2.67–2.83 (m, 3 H), 2.94 (dd, J = 9.6, 7.9 Hz, 1 H),
4.23 (t, J = 5.8 Hz, 2 H), 7.06–7.16 (m, 2 H), 7.27–7.37 (m, 2 H), 7.49
(td, J = 7.6, 1.5 Hz, 1 H), 7.54 (td, J = 7.5, 1.6 Hz, 1 H), 7.87 (dd, J =
7.7, 1.5 Hz, 1 H), 7.91 ppm (d, J = 2.2 Hz, 1 H); 13C NMR (126 MHz,
0.1 m NaOD/CD3OD = 1:2, TPS): d= 33.1, 37.6, 46.2, 56.9, 57.4, 63.2,
75.4, 106.6 (t, J(C,F) = 26.2 Hz), 114.5 (dd, J(C,F) = 21.5, 3.7 Hz), 126.3
(dd, J(C,F) = 16.4, 3.8 Hz), 129.0, 131.5, 133.0, 133.2, 133.8, 135.6 (dd,
J(C,F) = 9.7, 4.5 Hz), 137.7, 150.9, 162.5 (dd, J(C,F) = 247.4, 12.2 Hz),
165.9 (dd, J(C,F) = 248.2, 11.7 Hz), 183.9 ppm;
19F NMR (376 MHz,
0.1 m NaOD/CD3OD = 1:2): d=@111.5 (d, J = 7.6 Hz), @112.5 ppm (d,
J = 7.6 Hz); HRMS (ESI+): m/z calcd for C21H23F2N2O3 [M + H]
+ :
389.1671; found: 389.1671.
Synthesis of 12 av : According to GP2, compound 12 av was ob-
tained as a colorless, amorphous powder (41 mg, 89 %) from 18 av
(45.0 mg, 0.105 mmol) and NaOH (12.6 mg, 0.315 mmol); mp: 54–
59 8C; IR (KBr): ñ= 3441, 2942, 2622, 2562, 1719, 1616, 1469, 1238,
1074, 786 cm@1; 1H NMR (500 MHz, 0.1 m NaOD/CD3OD = 1:2, TPS)
d= 1.45 (ddt, J = 13.0, 8.0, 6.4 Hz, 1 H), 2.03 (dddd, J = 13.7, 9.0, 7.6,
6.4 Hz, 1 H), 2.17 (dd, J = 9.3, 8.0 Hz, 1 H), 2.21 (dd, J = 14.2, 8.0 Hz,
1 H), 2.24 (dd, J = 14.3, 7.6 Hz, 1 H), 2.45–2.60 (m, 2 H), 2.67–2.81 (m,
3 H), 2.93 (dd, J = 9.3, 8.1 Hz, 1 H), 3.75 (s, 3 H), 4.21 (t, J = 5.8 Hz,
2 H), 6.87 (t, J = 8.7 Hz, 1 H), 6.97 (d, J = 8.5 Hz, 1 H), 7.22 (dd, J = 7.6,
1.0 Hz, 1 H), 7.41–7.54 (m, 3 H), 7.78 (s, 1 H), 7.88 ppm (d, J = 7.7 Hz,
1 H); 13C NMR (126 MHz, 0.1 m NaOD/CD3OD = 1:2, TPS) d= 33.1,
37.6, 46.2, 56.9, 57.3, 58.6, 63.2, 75.3, 110.0 (d, J(C,F) = 2.8 Hz), 110.8
(d, J(C,F) = 22.8 Hz), 118.8 (d, J(C,F) = 19.3 Hz), 128.5, 131.2, 132.7, 133.3
(d, J(C,F) = 10.7 Hz), 133.7, 134.3, 134.8, 151.2, 160.9 (d, J(C,F) = 6.9 Hz),
163.1 (d, J(C,F) = 242.6 Hz), 183.9 ppm;
19F NMR (376 MHz, 0.1 m
NaOD/CD3OD = 1:2): d=@115.7 ppm; HRMS (ESI+): m/z calcd for
C22H26FN2O4 [M + H]
+ : 401.1871; found: 401.1868.
Synthesis of 12 aw: According to GP2, compound 12 aw was ob-
tained as a colorless, amorphous powder (23 mg, 81 %) from 18 aw
(28.0 mg, 0.0675 mmol) and NaOH (8.1 mg, 0.20 mmol); mp: 56–
60 8C; IR (KBr): ñ= 3444, 3054, 2924, 2854, 2616, 2553, 2480, 1716,
1467, 1429, 1201, 1069, 757 cm@1; 1H NMR (500 MHz, 0.1 m NaOD/
CD3OD = 1:2, TPS): d= 1.45 (ddt, J = 12.9, 8.1, 6.3 Hz, 1 H), 2.02
(dddd, J = 13.7, 9.1, 7.6, 6.4 Hz, 1 H), 2.16 (dd, J = 9.6, 7.9 Hz, 1 H),
2.20 (dd, J = 14.2, 8.1 Hz, 1 H), 2.24 (dd, J = 14.3, 7.3 Hz, 1 H), 2.45–
2.60 (m, 2 H), 2.66–2.81 (m, 3 H), 2.93 (dd, J = 9.6, 7.8 Hz, 1 H), 4.21
(t, J = 5.8 Hz, 2 H), 7.22–7.25 (m, 1 H), 7.25–7.30 (m, 1 H), 7.42–7.47
(m, 2 H), 7.47–7.51 (m, 1 H), 7.51–7.56 (m, 2 H), 7.76 (s, 1 H),
7.88 ppm (dd, J = 7.6, 1.5 Hz, 1 H); 13C NMR (126 MHz, 0.1 m NaOD/
CD3OD = 1:2, TPS): d= 33.1, 37.6, 46.2, 56.9, 57.3, 63.2, 75.4, 128.5,
130.1, 131.3, 132.3, 132.6, 132.8, 132.9, 133.1, 134.4, 135.8, 141.2,
142.3, 150.9, 183.9 ppm; HRMS (ESI+): m/z calcd for C21H24ClN2O3
[M + H]+ : 387.1475; found: 387.1473.
Synthesis of 12 ax : According to GP2, compound 12 ax was ob-
tained as a colorless, amorphous powder (22 mg, 77 %) from 18 ax
(28 mg, 0.068 mmol) and NaOH (8.1 mg, 0.20 mmol, 101 mL) ; mp:
59–65 8C; IR (KBr): ñ= 3443, 2945, 2622, 2562, 1720, 1473, 1201,
1089, 762 cm@1; 1H NMR (500 MHz, 0.1 m NaOD/CD3OD = 1:2, TPS):
d= 1.47 (ddt, J = 13.0, 8.1, 6.5 Hz, 1 H), 2.05 (dddd, J = 13.7, 9.1, 7.6,
6.5 Hz, 1 H), 2.19 (dd, J = 9.6, 7.8 Hz, 1 H), 2.22 (dd, J = 14.5, 8.0 Hz,
1 H), 2.25 (dd, J = 14.2, 7.4 Hz, 1 H), 2.47–2.61 (m, 2 H), 2.71–2.86 (m,
3 H), 2.96 (dd, J = 9.5, 7.9 Hz, 1 H), 4.26 (t, J = 5.8 Hz, 2 H), 7.22–7.31
(m, 2 H), 7.36 (dd, J = 7.6, 1.3 Hz, 1 H), 7.43–7.50 (m, 3 H), 7.52 (td,
J = 7.5, 1.4 Hz, 1 H), 7.86 (dd, J = 7.8, 1.0 Hz, 1 H), 8.00 ppm (s, 1 H);
13C NMR (126 MHz, 0.1 m NaOD/CD3OD = 1:2, TPS): d= 33.1, 37.6,
46.2, 56.9, 57.4, 63.2, 75.4, 129.2, 131.0, 131.4, 132.2, 133.0, 133.1,
133.9, 136.5, 141.1, 143.8, 151.4, 183.9 ppm; HRMS (ESI+): m/z
calcd for C21H24ClN2O3 [M + H]
+ : 387.1475; found: 387.1471.
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Synthesis of 12 be : According to GP2, compound 12 be was ob-
tained as a colorless, amorphous powder (38 mg, 71 %) from 18 be
(57.0 mg, 0.132 mmol) and NaOH (15.8 mg, 0.395 mmol, 198 mL);
mp: 69–72 8C; IR (KBr): ñ= 3422, 2945, 2477, 1718, 1606, 1474,
1402, 1211, 1078, 892, 765 cm@1; 1H NMR (500 MHz, 0.1 m NaOD/
CD3OD = 1:2, TPS): d= 1.46 (ddt, J = 12.9, 8.1, 6.3 Hz, 1 H), 2.04
(dddd, J = 13.8, 9.0, 7.7, 6.6 Hz, 1 H), 2.17 (dd, J = 9.6, 7.8 Hz, 1 H),
2.22 (dd, J = 14.2, 8.0 Hz, 1 H), 2.25 (dd, J = 14.3, 7.3 Hz, 1 H), 2.47–
2.62 (m, 2 H), 2.66–2.80 (m, 3 H), 2.94 (dd, J = 9.5, 7.9 Hz, 1 H), 4.21
(t, J = 5.9 Hz, 2 H), 7.26–7.38 (m, 4 H), 7.47–7.59 (m, 2 H), 7.85 (dd,
J = 7.6, 1.6 Hz, 1 H), 7.92 ppm (d, J = 2.1 Hz, 1 H); 13C NMR (126 MHz,
0.1 m NaOD/CD3OD = 1:2, TPS): d= 33.1, 37.6, 46.2, 56.9, 57.4, 63.2,
75.3, 119.0 (d, J(C,F) = 26.3 Hz), 127.8 (d, J(C,F) = 3.6 Hz), 129.0 (d, J(C,F) =
16.2 Hz), 129.2, 131.7, 133.0, 133.2, 133.6, 135.5 (d, J(C,F) = 4.0 Hz),
137.3, 137.6 (d, J(C,F) = 10.3 Hz), 150.9, 162.2 (d, J(C,F) = 248.5 Hz),
183.9 ppm; 19F NMR (376 MHz, 0.1 m NaOD/CD3OD = 1:2): d=
@112.6 ppm; HRMS (ESI+): m/z calcd for C21H23FClN2O3 [M + H]+ :
405.1376; found: 405.1374.
Synthesis of 12 bf : According to GP2, compound 12 bf was ob-
tained as a colorless, amorphous powder (19 mg, 58 %) from 18 bf
(32 mg, 0.071 mmol) and NaOH (8.6 mg, 0.21 mmol; 107 mL); mp:
50–55 8C; IR (KBr): ñ= 3422, 2942, 2794, 2462, 1702, 1586, 1466,
1203, 1101, 1069, 807, 763 cm@1; 1H NMR (500 MHz, 0.1 m NaOD/
CD3OD = 1:2, TPS): d= 1.46 (ddt, J = 12.9, 8.2, 6.4 Hz, 1 H), 2.03
(dddd, J = 13.5, 8.7, 7.6, 6.5 Hz, 1 H), 2.16 (dd, J = 9.3, 8.4 Hz, 1 H),
2.21 (dd, J = 14.2, 8.0 Hz, 1 H), 2.25 (dd, J = 14.2, 7.4 Hz, 1 H), 2.44–
2.58 (m, 2 H), 2.61–2.81 (m, 3 H), 2.92 (dd, J = 9.5, 7.9 Hz, 1 H), 4.18
(t, J = 5.8 Hz, 2 H), 7.20–7.25 (m, 1 H), 7.27 (d, J = 8.2 Hz, 1 H), 7.46
(dd, J = 8.2, 2.1 Hz, 1 H), 7.51 (pd, J = 7.4, 1.6 Hz, 2 H), 7.60 (d, J =
2.1 Hz, 1 H), 7.80 (s, 1 H), 7.84 ppm (dd, J = 7.6, 1.6 Hz, 1 H); 13C NMR
(126 MHz, 0.1 m NaOD/CD3OD = 1:2, TPS): d= 37.6, 46.2, 50.3, 50.5,
50.7, 50.8, 51.0, 51.2, 51.4, 57.3, 63.2, 75.3, 129.1, 130.3, 131.6,
131.9, 132.8, 133.1, 135.4, 150.6, 183.9 ppm; HRMS (ESI+): m/z
calcd for C21H23Cl2N2O3 [M + H]
+ : 421.1080; found: 421.1079.
Synthesis of 12 bj : According to GP2, compound 12 bj was ob-
tained as a colorless, amorphous powder (20 mg, 41 %) from 18 bj
(48 mg, 0.11 mmol) and NaOH (13 mg, 0.33 mmol, 166 mL) ; mp:
49–51 8C; IR (KBr): ñ= 3422, 2954, 2612, 2557, 1719, 1638, 1599,
1435, 1119, 1028, 997, 840 cm@1; 1H NMR (500 MHz, 0.1 m NaOD/
CD3OD = 1:2, TPS): d= 1.46 (ddt, J = 12.9, 8.0, 6.4 Hz, 1 H), 2.04
(dddd, J = 13.6, 9.2, 7.7, 6.1 Hz, 1 H), 2.16 (dd, J = 9.7, 7.7 Hz, 1 H),
2.21 (dd, J = 14.1, 8.0 Hz, 1 H), 2.25 (dd, J = 14.2, 7.5 Hz, 1 H), 2.46–
2.62 (m, 2 H), 2.62–2.80 (m, 3 H), 2.93 (dd, J = 9.7, 7.8 Hz, 1 H), 4.18
(t, J = 5.8 Hz, 2 H), 6.96–7.06 (m, 2 H), 7.27–7.36 (m, 1 H), 7.49–7.61
(m, 2 H), 7.81–7.91 (m, 1 H), 7.93 ppm (s, 1 H); 13C NMR (126 MHz,
0.1 m NaOD/CD3OD = 1:2, TPS): d= 33.1, 37.6, 46.2, 56.9, 57.3, 63.2,
75.4, 103.9–102.3 (m), 115.9 (td, J(C,F) = 21.3, 4.8 Hz), 129.9, 130.6,
132.2, 132.8, 134.0, 134.5, 150.5, 163.1 (ddd, J(C,F) = 247.3, 15.2,
9.9 Hz), 165.7 (dt, J(C,F) = 248.8, 15.5 Hz), 171.1, 183.9 ppm;
19F NMR
(376 MHz, 0.1 m NaOD/CD3OD = 1:2): d=@108.9 (t, J = 6.4 Hz),
@111.1 ppm (d, J = 6.3 Hz); HRMS (ESI+): m/z calcd for C21H22F3N2O3
[M + H]+ : 407.1577; found: 407.1577.
Synthesis of 12 bn : According to GP2, compound 12 bn was ob-
tained as a colorless, amorphous powder (44 mg, 92 %) from 18 bn
(47 mg, 0.11 mmol) and NaOH (13 mg, 0.33 mmol); mp: 64–67 8C;
IR (KBr): ñ= 3429, 2951, 2625, 2562, 1720, 1601, 1474, 1257, 1198,
1060, 897, 765 cm@1; 1H NMR (500 MHz, 0.1 m NaOD/CD3OD = 1:2,
TPS): d= 1.45 (ddt, J = 12.9, 8.1, 6.4 Hz, 1 H), 2.03 (ddt, J = 13.7, 9.4,
7.5 Hz, 1 H), 2.16 (dd, J = 9.6, 7.9 Hz, 1 H), 2.21 (dd, J = 14.3, 8.0 Hz,
1 H), 2.24 (dd, J = 14.2, 7.5 Hz, 1 H), 2.45–2.60 (m, 2 H), 2.64–2.84 (m,
3 H), 2.93 (dd, J = 9.4, 8.0 Hz, 1 H), 4.20 (t, J = 5.8 Hz, 2 H), 7.18–7.27
(m, 2 H), 7.31 (dd, J = 8.5, 6.1 Hz, 1 H), 7.38 (dd, J = 8.7, 2.6 Hz, 1 H),
7.46–7.56 (m, 2 H), 7.78 (s, 1 H), 7.86 ppm (dd, J = 7.6, 1.6 Hz, 1 H);
13C NMR (126 MHz, 0.1 m NaOD/CD3OD = 1:2, TPS): d= 33.1, 37.6,
46.2, 56.9, 57.3, 63.2, 75.4, 117.2 (d, J(C,F) = 21.4 Hz), 119.4 (d, J(C,F) =
25.1 Hz), 128.8, 131.5, 132.9, 133.2, 133.3, 135.6 (d, J(C,F) = 8.9 Hz),
136.8 (d, J(C,F) = 10.5 Hz), 137.8 (d, J(C,F) = 3.7 Hz), 141.2, 150.7, 165.2
(d, J(C,F) = 249.0 Hz), 183.9 ppm;
19F NMR (376 MHz, 0.1 m NaOD/
CD3OD = 1:2): d=@113.4 ppm; HRMS (ESI+): m/z calcd for
C21H23FClN2O3 [M + H]
+ : 405.1376; found: 405.1373.
Oxime exchange experiments
Phosphate buffer (990 mL, pH 7.1, 12.5 mm Na2HPO4, 12.5 mm
NaH2PO4, 1 m NaCl, pH value adjusted with 1 m NaOH, 10 % D2O)
was added to a solution of oxime 12 ao (0.477 mg, 1 mmol) and
11 t (0.272 mg, 2 mmol) in [D6]DMSO (10 mL) in an NMR tube.
1H NMR spectra (64 scans) were measured at 37 8C with water sup-
pression directly after the preparation of the sample and every 4 h
over a 64 h period. No changes to the spectra could be observed
over the duration of the experiment.
MS binding experiments
Generation of pre-equilibrated libraries : To obtain 10 as a free
base, an aqueous solution of NaOH (1 m, 2.0 equiv) in phosphate
buffer (pH 6.0, 12.5 mm Na2HPO4, 12.5 mm NaH2PO4, 1 m NaCl, pH
value adjusted with 1 m HCl) was added to 10 as a dihydrochloride
salt dissolved in phosphate buffer (pH 6.0) to a nominal concentra-
tion of 400 mm of 10. This solution (10 mL) was added to a mixture
containing eight solutions of individual aldehydes in DMSO
(20 mm, 5 mL each) and phosphate buffer (pH 6.0, 50 mL). These li-
brary mixtures were incubated for 20 h at 37 8C in a shaking water
bath to guarantee full conversion into the corresponding oximes.
Before binding experiments, all pre-equilibrated libraries were
freshly diluted with phosphate buffer at pH 7.1 (12.5 mm Na2HPO4,
12.5 mm NaH2PO4, 1 m NaCl, pH value adjusted with 1 m NaOH)
and DMSO to obtain the generated oximes in final concentrations
of 10 mm (1st experiment), 1 mm (2nd experiment), and 100 nm (3rd
experiment) in phosphate buffer (pH 7.1) containing 10 % DMSO
(v/v).
Generation of pre-equilibrated single oximes for deconvolution
experiments : The pre-equilibrated single oximes for deconvolution
were obtained in the same way as that described for pre-equili-
brated libraries, except that one solution of a single aldehyde in
DMSO (20 mm, 5 mL) and additional DMSO (35 mL) were used.
Before binding experiments, all pre-equilibrated deconvolution
batches were freshly diluted with phosphate buffer at pH 7.1
(12.5 mm Na2HPO4, 12.5 mm NaH2PO4, 1 m NaCl, pH value adjusted
with 1 m NaOH) and DMSO to obtain the generated oximes in final
concentrations of 1 mm in phosphate buffer (pH 7.1) containing
10 % DMSO.
Aldehyde libraries : Aldehyde libraries were obtained by dissolving
eight individual aldehydes in phosphate buffer (pH 7.1) containing
10 % DMSO to obtain final concentrations of 10 mm (1st experi-
ment), 1 mm (2nd experiment), or 100 nm (3rd experiment).
mGAT1 membrane preparation : Membrane preparations of
HEK293 cells stably expressing mGAT1[18] were prepared as de-
scribed previously and stored at @80 8C.[24, 31] On the day of the
assay, an aliquot was rapidly thawed and diluted in a 20-fold
volume of a cold 0.9 % (m/v) aqueous solution of NaCl. After centri-
fugation at 20 500 rpm and 4 8C for 20 min (CP56GII, P70AT, Hitachi
Ltd. , Tokyo, Japan), the resulting pellet was resuspended in ice-
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cold phosphate buffer at pH 7.1 to a protein concentration of ap-
proximately 0.1 mg mL@1, as previously described.[31]
Library screening : Library screening was performed in 1.2 mL
polypropylene deep-well plates (Sarstedt, Nembrecht, Germany)
analogously to a procedure previously described.[19, 23] Samples (n =
4) were prepared in phosphate buffer (pH 7.1) with 1 % DMSO in
total volume of 250 mL per sample containing the mGAT1 mem-
brane preparation (50 mL, approximately 20 mg protein per sample,
see above), NO711 (25 mL, final concentration in the assay 20 nm),
and the pre-equilibrated libraries (25 mL; final concentration one-
tenth of the corresponding stock solution containing the pre-equi-
librated libraries, as described above) and incubated for 4 h at
37 8C in a shaking water bath. Incubation was stopped by transfer-
ring aliquots (200 mL) of each sample to a 96-well filter plate
(Acroprep Advance, glass fiber, 1.0 mm, 350 mL, Pall, Dreieich, Ger-
many) with a 12-channel pipette followed by subsequent vacuum
filtration. After washing with an ice-cold aqueous solution of NaCl
(1 m, 5 V 150 mL per well) by using a 12-channel pipette, the filter
plate was dried (60 min, 50 8C) and cooled to room temperature.
Subsequently, the marker was liberated by elution of the filter
plate with MeOH (3 V 100 mL per well) into a 1.2 mL polypropylene
96-well plate (Sarstedt, Nembrecht, Germany). Each sample was
supplemented with 1 nm [2H10]NO711 (200 mL, in MeOH) as an in-
ternal standard. All samples were completely dried (17 h, 50 8C).
For quantification by means of LC–MS/MS (ESI), samples were re-
constituted in 10 mm ammonium formate buffer (200 mL; pH 7.0/
MeOH (95:5 v/v)). In the same way, aldehyde libraries (see above)
and 10 (final concentrations in the assay 40 mm, 4 mm, or 400 nm)
were investigated. Total binding and nonspecific binding of NO711
were determined in analogously constituted samples lacking any
inhibitor or in the presence of 100 mm GABA, respectively.
Deconvolution : The experiments were performed in the same
manner as the experiments described for the library screening,
expect that an aliquot (25 mL) of a pre-equilibrated batch of a
single oxime was employed.
LC–MS/MS (ESI) analysis : Quantification of NO711 by means of
LC–MS/MS (ESI) was performed as described by using an API 3200
triple-quadrupole mass spectrometer.[24, 31] To assure reliable quan-
tification, each day a binding experiment was performed, also
matrix blanks (generated analogously to that described for binding
samples, but in the absence of NO711 and [2H10]NO711), a zero
sample (matrix blank with 1 nm [2H10]NO711) and matrix standards
(generated by supplementing matrix blanks with different concen-
trations of NO711 (50 pm, 100 pm, 200 pm, 500 pm, 1 nm, 2.5 nm,
and 5 nm) and [2H10]NO711 (1 nm) were investigated and individual
calibration curves for marker quantification were generated there-
from. Derived from the external calibration curve, the LLOQ could
be determined to 50 pm and results below this limit were de-
scribed as <LLOQ in Table 1.[19, 23]
Competition experiments with isolated oximes : The experiments
were performed as described recently, but substituting the original
incubation buffer for phosphate buffer (pH 7.1, 12.5 mm Na2HPO4,
12.5 mm NaH2PO4, 1 m NaCl, pH value adjusted with 2 m
NaOH).[24, 31]
Analysis of competitive binding experiments : Marker depletion
was negligible (<10 %) in all binding experiments. Specific binding
was defined as the difference between the total and nonspecific
binding. Nonspecific binding less than 50 pm (LLOQ) was not de-
termined experimentally, but was extrapolated by linear regression
from nonspecifically bound NO711 concentrations of +50 pm. The
concentration of a competitor that inhibited 50 % of specific bind-
ing (IC50) was calculated from competition curves by plotting
NO711 specific binding concentrations versus the log of competi-
tor concentration (eight different concentrations per competitor)
with Prism 5.04 (GraphPad Software, San Diego, CA, USA) by using
the equation for one-site competition and nonlinear curve fitting.
Specific binding determined for control samples in the absence of
any competitor was set to 100 %, whereas the bottom level was
set to 0 % (corresponding to the nonspecific binding of NO711). Ki
values were calculated according to a report by Cheng and Prusoff
and expressed as pKi values.
[32] All results were expressed as the
mean:SEM (unless stated otherwise). pKi values were determined
in at least three separate experiments.
GABA uptake assays : [3H]GABA uptake assays were performed as
previously described.[18]
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Results and Discussion 
 
3.3 Third Publication 
Application of the Concept of Oxime Library Screening by Mass Spectrometry (MS) 
Binding Assays to Pyrrolidine-3-carboxylic Acid Derivatives as Potential Inhibitors 
of γ-Aminobutyric Acid Transporter 1 (GAT1)  
 
3.3.1 Summary of the Results 
Various publications about differently affine inhibitors for mGAT1 with nipecotic acid or 
guvacine motif are known, but with regard to compounds delineated from other amino acid 
moieties only few information is published so far. To reduce this gap of information, the concept 
of oxime library screening by means of LC-MS/MS binding assays was transferred to 
substances with a pyrrolidine-3-carboxylic acid substructure.  
The desired oximes libraries were prepared by reaction of 28 sub-libraries with eight different 
aldehydes (1 mM each) with an excess of an pyrrolidine-3-carboxylic acid derivative 
possessing a hydroxylamine functionality (40 mM) which had been synthesized in six steps 
with an overall yield of 43 %. The oxime library generation was accomplished in the absence 
of the target mGAT1 at 37 °C for 20 h using a non-physiological buffer system with a pH value 
of 6.0 (12.5 mM Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value was adjusted with 1 M HCl) 
containing 40 % DMSO. The completion of oxime formation was verified exemplarily by 1H 
NMR measurements. Only three sterically highly demanding tritylaldehydes of one library were 
not fully converted to the corresponding oximes within the reaction time of 20 h, but after raising 
the reaction temperature to 80 °C the oximes were successfully formed within 45 h.  
After formation, all 28 freshly prepared oxime libraries were diluted with phosphate buffer pH 
7.1 (12.5 mM Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value was adjusted with 1 M NaOH) 
to the desired screening concentration level of 1 µM. In the MS Binding Assay, eight libraries 
were able to reduce the specific marker binding under 50 % and three libraries still reduced 
the marker binding below 20 % which corresponds to an IC50 value of 250 nM at the 
concentration of 1 µM if only one oxime is responsible for the affinity. In order to identify the 
most potent oximes these three oxime libraries were forwarded to the next step – the 
deconvolution experiments.  
Therefore, each single oxime of the three active libraries was generated by reacting the 
respective aldehydes (1 mM) with an excess of hydroxylamine (40 mM) under conditions 
identical to these applied for oxime library formation. After dilution of the thus generated 
samples to the concentration of 1 µM applied in the screening assay with phosphate buffer pH 
7.1 the performed MS Binding Assays revealed that none of the single oximes was able to 
reduce marker binding to 20 % and only one compound was able to reach the limit of 50 % 
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marker binding. Hence, the three most potent oximes effecting the lowest remaining marker 
binding in the three sub-libraries were selected for resynthesis and determination of their 
binding affinities in full-scale competitive MS binding assays. Furthermore, their inhibitory 
activities in [3H]GABA uptake assays at all four GABA transporter subtypes (mGAT1-4) and 
thus their subtype selectivities were determined. All three compounds were found to contain a 
1,1’-biphenyl moiety with different substituents at the terminal phenyl ring. The oximes 
derivatives with a 2’,4’-dichloro (pKi = 6.41 ± 0.02) and a 2’-methoxy-4’-fluoro substitution (pKi 
= 6.39 ± 0.03) yielded the highest pKi values. When exchanging the chlorine in the 4’-position 
of the 2’,4’-dichloro derivative with a fluorine the affinity is reduced to a pKi values of 6.16 ± 
0.03. Interestingly, when compared to the corresponding oximes with 2-(pyrrolidin-3-yl)acetic 
acid motif for the three substances all determined pKi values were lower. For the 2’,4’-dichloro 
substituted oxime the difference amounts to approximately 1.5 log unit, but for the 2’-methoxy-
4’-fluorine derivative with pyrrolidine-3-carboxylic acid moiety the pKi value is roughly 0.7 log 
units lower indicating that substitution with a methoxy group has a favorable effect on the 
affinity for pyrrolidine-3-carboxylic acid derivatives. The pIC50 values for mGAT1 of the 
[3H]GABA uptake assays confirmed the affinity towards the target and pIC50 values for mGAT2 
– mGAT4 showed high subtype selectivity regarding mGAT1.  
Overall, three oximes with pKi values between 6.16 and 6.41 with a pyrrolidine-3-carboxylic 
acid motif were identified and structure-activity-relationships for mGAT1 inhibition were 
expanded in particular with regard to the amino acid moiety.  
 
3.3.2 Declaration of Contribution 
Synthesis of the hydroxylamine derivative as a starting material for the oxime generation, all 
precursor molecules and the compounds for the biological testing as well as the evaluation of 
all corresponding analytical data were accomplished by myself. Some aldehydes were 
synthesized by Hans Brabec during his bachelor thesis “Synthese neuer Aldehyde mit Biaryl-
Struktur mittels Suzuki-Miyaura-Kupplung” which was supervised by me and Tobias Hauke. 
NMR studies on the subject of kinetics and oxime exchange experiment were performed 
together with Dr. Lars Allmendinger and Claudia Glas. All binding experiments regarding library 
screening and deconvolution experiments were achieved and evaluated by me. pKi values and 
pIC50 values were determined by the technical assistants Silke Duesing-Kropp and Miriam 
Sandner under the supervision of Dr. Georg Höfner. I wrote the manuscript and prepared all 
graphics and tables, supported by Dr. Lars Allmendinger. Prof. Dr. Klaus T. Wanner corrected 
the manuscript.  
 
Third publication 
Application of the Concept of Oxime Library Screening by Mass Spectrometry (MS) Binding 
Assays to Pyrrolidine-3-carboxylic Acid Derivatives as Potential Inhibitors of γ-Aminobutyric 
Acid Transporter 1 (GAT1)  
 
Simone K. Huber, Georg Höfner, and Klaus T. Wanner* 
Department of Pharmacy – Center of Drug Research, Ludwig Maximilians-Universität München, Butenandtstr. 7, 
81377 Munich, Germany 
 
*corresponding author. E-mail address: klaus.wanner@cup.uni-muenchen.de 
 
Abstract 
In the present study, the concept of oxime library screening by MS Binding Assays was 
successfully extended to N-substituted lipophilic pyrrolidine-3-carboxylic acid derivatives in the 
pursuit of varying the amino acid motif in order to identify new inhibitors for GAT1 and to 
broaden structure-activity-relationships for this target, the most abundant GABA transporter in 
the central nervous system. For the screening, 28 different oxime sub-libraries were employed 
that were generated by simple condensation reaction of an excess of pyrrolidine-3-carboxylic 
acid derivatives carrying a hydroxylamine functionality with various sub-libraries each 
assembled of eight aldehydes with broadly varying chemical structures and functionalities. The 
compounds responsible for the activity of an oxime sub-library were identified by deconvolution 
experiments performed by employing single oximes. Binding affinities of the oxime hits were 
confirmed in full-scale competitive MS Binding Assays. Thereby, oxime derivatives with a 1,1’-
biphenyl moiety were found as the first inhibitors of mGAT1 comprising a pyrrolidine-3-
carboxylic acid motif with affinities in the submicromolar range. 
 
1. Introduction 
γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian central 
nervous system (CNS).1 A decreased GABAergic signaling and the resulting imbalance 
between excitatory neurotransmission effected by glutamate and inhibitory neurotransmission 
mediated by GABA2 is assumed to be the cause for severe neurological diseases such as 
epilepsy3, Alzheimer’s disease4, or depression5. Hence, as a rational approach for the 
treatment of the above mentioned diseases, the membrane bound GABA transporters (GATs) 
responsible for the reuptake of GABA in the presynaptic neurons and glia cells to enhance the 
level of GABA in the synaptic cleft may be blocked.6 
The GABA transporter proteins exist in four different subtypes which are termed mGAT1, 
mGAT2, mGAT3, and mGAT4 when cloned from mice,7 whereas according to the Human 
Genome Organization (HUGO)8, they are indicated as GAT1 (=mGAT1), BGT1 (=mGAT2), 
GAT2 (=mGAT3), and GAT3 (=mGAT4). Of these, only mGAT1 and mGAT4 are found in the 
CNS in densities high enough to play a significant role in the determination of GABAergic 
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neurotransmission. Thereby, mGAT1 is the predominant GABA transporter located in neurons 
and mGAT4 is mainly responsible for the reuptake of GABA in glia cells.9 Being predominantly 
expressed in the kidney and liver and only in very low densities and in specific areas of the 
brain, mGAT2 and mGAT3 are not likely to be notably involved in termination of GABAergic 
neurotransmission in the CNS.10  
Some cyclic analogues of GABA including 6-membered amino acids like nipecotic acid (1)11 
or 5-membered amino acids such as 2-(pyrrolidin-3-yl)acetic acid (2)12 and pyrrolidine-3-
carboxylic acid (3)13 have been found to be potent inhibitors of mGAT1. Although these small 
amino acids reveal good functional activities at the target mGAT1 with 2-(pyrrolidin-3-yl)acetic 
acid as the most potent inhibitor among these amino acids (pIC50 = 5.39 ± 0.05 in [3H]GABA 
uptake assays, Figure 1)14 followed by nipecotic acid (pIC50 = 4.88 ± 0.07, Figure 1)15 and 
pyrrolidine-3-carboxylic acid (pIC50 = 4.17 ± 0.06, Figure 1)16, their benefit for pharmacological 
treatment is limited due to their inability to cross the blood brain barrier. Derivatives of nipecotic 
acid and of the related unsaturated amino acid guvacine bearing aromatic residues linked with 
an all carbon or heteroatom carbon chain to the amino nitrogen appeared to possess in 
addition to an increased lipophilicity also an improved membrane permeability. For example, 
tiagabine (4) (pIC50 = 6.88 ± 0.12, Figure 1)17, which is in clinical use for the treatment of 
epilepsy and NO711 (5) (pIC50 = 6.83 ± 0.06, Figure 1),18 a widely used experimental drug with 
an oxime functionality in the alkyl chain are selective inhibitors for mGAT1 with substantially 
enhanced inhibitory activity and known to be capable of passing the blood brain barrier.  
 
Figure 1: Selected potent inhibitors of mGAT1. 
 
A whole plethora of additional substances with mainly nipecotic acid and guvacine as polar 
subunit have been developed. These are varying with respect to the structure of aromatic 
residues, substituents, and the length and the functionalities embedded in the linkers,19 
providing a tremendous amount of information regarding structure-activity-relationships 
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(SARs) of mGAT1 ligands.20 However, when it comes to SARs for mGAT1 inhibitors derived 
from amino acid moieties different from nipecotic acid (1) and guvacine, some, but only a 
limited amount of literature has yet been published which is for example true for 2-(pyrrolidin-
3-yl)acetic acid (2) derived inhibitors14, but in the case of compounds with a pyrrolidine-3-
carboxylic acid (3) subunit no publication is known so far.  
Hence, in the present study, we aimed at the generation of SARs for pyrrolidine-3-carboxylic 
acid (3) derived mGAT1 inhibitors by an extensive variation of the lipophilic domain linked to 
the amino acid subunit. To this end, a concept for combinatorial screening developed by us 
and used for the identification of potent inhibitors with a guvacine21 and 2-(pyrrolidin-3-yl)acetic 
acid14 subunit should be followed. This method comprises the generation of oxime sub-libraries 
and their screening by means of competitive mGAT1 MS Binding Assays.22 In the present 
case, the hydroxylamine containing pyrrolidine-3-carboxylic acid 6 should be reacted with a 
set of sub-libraries containing various aldehydes to give the corresponding oxime sub-libraries 
as outlined in Scheme 1 and thus giving easy access to a broad variety of potential mGAT1 
inhibitors.  
 
Scheme 1: Reaction of hydroxylamine derivative 6 with sub-libraries containing various 
aldehydes 7 possessing different lipophilic residues to afford corresponding oximes 8.  
 
As in related studies, also here competitive MS Binding Assays for mGAT1 with NO711 (5) as 
MS marker23 should be used to determine the binding affinities24 of the individual compound 
sub-libraries. 
In analogy to the screening of oxime sub-libraries derived from 2-(pyrrolidin-3-yl)acetic acid 
(2),14 in this study oximes sub-libraries should be generated by employing sub-libraries with 
eight different aldehydes in the absence of the target, mGAT1, to allow the use of a non-
physiological buffer system with a pH of 6.0 required for oxime formation in a reasonable period 
of time. Of course appropriate studies had to be performed to warrant completion of sub-library 
generation within the set time frame and also to ascertain the stability of the generated oximes 
over the incubation period. The oxime sub-libraries found most potent during the library 
screening would have to be subjected to deconvolution experiments, i.e. tests of single oximes 
in the same manner as the sub-library to identify hit compounds. For hit validation, the 
respective oximes should be resynthesized and characterized in full-scale competitive MS 
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Binding Assays24 providing their pKi values as well as in [3H]GABA uptake assays18 for all four 
murine GABA transporters to gain insights in their functional activity (pIC50 values) at mGAT1–
4. All in all, by this MS Binding Assays based screening of easily to generate oxime sub-
libraries an extension of structure-activity-relationships of pyrrolidine-3-carboxylic acid (3) 
derived mGAT1 inhibitors should be achieved.  
 
2. Results and Discussion 
 
2.1. Chemistry 
 
2.1.1. Synthesis of hydroxylamine building block 6 
 
Synthesis of hydroxylamine 6 was accomplished according to the synthetic sequence outlined 
in Scheme 2. At first, the benzyl protecting group of the pyrrolidine-3-carboxylic acid ester 925 
was substituted by a Troc protecting group using 2,2,2-trichloroethyl chloroformate to generate 
10 (yield 90%), which upon subsequent deprotection of 10 with zinc powder in acetic acid 
afforded pyrrolidine-3-carboxylic acid ethylester 11 as acetate salt in high yield (87%). 
According to literature26, this two-step procedure is required for the deprotection of the amino 
nitrogen in 9 as a hydrogenolytic procedure employing Pd/C as catalyst for the direct removal 
of the benzyl moiety gives rise to extensive decomposition. Employing 11 in a nucleophilic 
substitution reaction at 2-bromoethanol furnished alcohol 12 (yield 76%) which when subjected 
to a Mitsunobu reaction with N-hydroxyphthalimide as nucleophile in the presence of di(2-
methoxyethyl)azodicarboxylate (DMEAD) and triphenylphosphine provided the corresponding 
N-hydroxyphthalimide derivative 13 in very good yield (83%). Upon purification by flash column 
chromatography, 13 appeared to be hydrolytically labile. This problem could, however, be 
overcome when pre-dried silica gel was used (145 °C for 5 hours in vacuo). Treatment of 13 
with aqueous hydrazine solution to remove the phthalic acid protecting group afforded 
hydroxylamine 14, which was finally subjected to carboxylic acid ester hydrolysis by treatment 
with 1 M HCl to give 1-[2-(aminooxy)ethyl]pyrrolidine-3-carboxylic acid (6) as dihydrochloride 
salt with an overall yield of 43% over six steps.  
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Scheme 2: Synthesis of 1-[2-(aminooxy)ethyl]pyrrolidine-3-carboxylic acid (6) as 
dihydrochloride. Reagents and conditions: (a) 2,2,2-trichloroethyl chloroformate, K2CO3, 
CH3CN, 60 °C, 3 h, 90%; (b) Zn, AcOH, rt, 4 h, 87%; (c) 2-bromoethanol, K2CO3, KI, THF, 24 
h, reflux, 76%; (d) N-hydroxyphthalimide, PPh3, DMEAD, THF, 20 h, rt, 81%; (e) hydrazine 
(50–60% solution), EtOH, 2 h, rt, 92%; (f) aq. HCl (1 M), 3 h, 90 °C, 97%. 
 
2.1.2. Synthesis of oximes 8 
 
The individual oximes required for further hit characterization in MS Binding Assays (pKi) and 
[3H]GABA uptake studies (pIC50) were synthesized as described in Scheme 3 in analogy to the 
recently published approaches.14,21 Hence, hydroxylamine 14 was reacted with a single 
aldehyde, which gave the respective oxime 15 as an E/Z-mixture. The E-isomer as the major 
isomer (amount of Z-isomer was approximately 2–7% compared to E-isomer) was isolated via 
column chromatography followed by alkaline hydrolysis of the ester function using aqueous 
NaOH solution (2 M) in EtOH. Finally, acidification with aqueous HCl solution and extraction 
with dichloromethane yielded the desired oximes 8 as hydrochloric acid salts.27 
 
Scheme 3: Synthesis of oximes 8. (a) abs. EtOH, rt, 18 h, 69–81%; (b) aq. NaOH (2 M), EtOH, 
rt, 24 h; (c) aq. HCl (2 M) then CH2Cl2, 70–89% (over two steps).14,22,27  
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2.1.3. Aldehydes 7 
 
Aldehydes required for the formation of the oxime sub-libraries 1–28 (see e.g. sub-library 8, 
Scheme 4) were either purchased from Sigma Aldrich (Steinheim, Germany), TCI (Zwjindrecht, 
Belgium), Acros (Geel, Belgium), or ABCR (Karlsruhe, Germany) and used without further 
purification or synthesized via Suzuki-Miyaura coupling according to the method published 
previously.28,29,30 Aldehydes applied for the oxime generation and screening have been 
grouped in aldehyde sub-libraries 1–28, which are given in Figure 2 and each of which contains 
eight constituents.  
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Figure 2: Aldehyde sub-libraries 1–28 which were employed for oxime sub-library generation 
and subsequent screening experiments.  
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2.2. Library screening employing LC-MS/MS Binding Assays 
 
2.2.1. Sub-library generation 
 
For the generation of the oxime sub-libraries, which was performed in the absence of the target 
mGAT1, an excess of pyrrolidine-3-carboxylic acid derived hydroxylamine 6 (40 mM) was 
reacted with the individual aldehyde sub-libraries (1 mM each) at 37 °C in a 6:4 mixture of 
phosphate buffer (pH 6.0, 12.5 mM Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value was 
adjusted with 1 M HCl) and DMSO as exemplarily displayed in Scheme 4. The aldehyde sub-
libraries 1–28 employed in the present study were identical with those used in a former related 
study14, each containing the same eight constituents overall representing a broad variety of 
different chemical structures (Scheme 4). As attempts to purify and liberate the free 
hydroxylamine from its dihydrochloride salt by ion-exchange chromatography using aqueous 
ammonia solution as eluent led to decomposition of the compound, the dihydrochloride 
derivative 6 was directly employed for oxime generation, however, two equivalents of sodium 
hydroxide were added to reaction mixture (phosphate buffer, pH 6.0, DMSO = 6:4) to 
compensate for the two acid equivalents from the disalt 6. 
 
 
Scheme 4: Exemplary chosen reaction of hydroxylamine derivative 6 with aldehyde sub-library 
8 containing of eight different aldehydes to yield corresponding oxime sub-library 8. 
 
As verified by 1H NMR spectroscopy studies, oxime formation was complete within 20 h at 
37 °C applying the mentioned buffer system and a reactant ratio of 5:1 
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(hydroxylamine/aldehydes). This, however, did not apply for sub-library 26 containing the three 
sterically highly encumbered tritylaldehydes 7gw, 7gy, and 7gz. As these did not show any 
significant sign of oxime formation within the defined time, the reaction temperature was risen 
to 80 °C, while leaving all other parameters unchanged. Oxime formation was then completed 
within 45 h.  
The thus generated oxime sub-libraries were finally diluted to a concentration of 1 µM for 
individual oximes present in the sub-library with phosphate buffer (pH 7.1, 12.5 mM Na2HPO4, 
12.5 mM NaH2PO4, 1 M NaCl, pH value was adjusted with 1 M NaOH). That way also the 
DMSO content was reduced to ≤ 1%, thus matching conditions found earlier to be suitable for 
the incubation with the target mGAT1 (performed at 37 °C for 4 h).14,21 According to 
fluorescence spectroscopy measurements performed with single oximes generated with an 
excess of hydroxylamine as described before and diluted to the test concentration of 1 µM, the 
test compounds are stable over the incubation time of 4 h as no change of the intensity of the 
fluorescence signal occurs. Furthermore, exemplarily an oxime exchange experiment using 1H 
NMR spectroscopy was performed to determine the stability of oximes in the presence of a 
competing free aldehyde. For this purpose, 4-methoxybenzaldehyde 7t (2 mM) was added to 
a solution of oxime 8av (1 mM) in phosphate buffer pH 7.1 (12.5 mM Na2HPO4, 12.5 mM 
NaH2PO4, 1 M NaCl, 10% D2O) in an NMR tube kept at 37 °C. No change over a period of 64 
h of repeatedly taken NMR spectra occurred indicating that no exchange reaction took place.  
 
2.2.2. Sub-library screening 
 
For the determination of the activity of the oxime sub-libraries in competitive MS Binding 
Assays, the freshly diluted oxime sub-libraries were incubated with the target mGAT1 (10–20 
µg protein per sample in 250 µL) and the MS marker NO711 (final concentration in the assay 
20 nM) for 4 h at 37 °C. Thereafter, the protein-ligand-complexes were separated from the 
non-bound components by filtration and were dried for 1 h at 50 °C to improve the efficiency 
of the subsequent step, i.e. the treatment of the filter plates to denature protein-ligand 
complexes and elute the formerly bound MS marker. Quantification of the liberated MS marker 
NO711 by LC-MS/MS (ESI), finally revealed the affinity of a particular sub-library towards the 
target – the amount of formerly bound MS marker being inversely proportional to the sub-library 
affinity. In an already previously published screening study14, control experiments had revealed 
that the individual aldehyde sub-libraries (with 1 µM of each aldehyde) themselves do not have 
a significant effect on MS marker binding (reduction of bound NO711 from 82% to 100%; in 
oxime sub-libraries only neglectable amounts should be present).  
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When only hydroxylamine 6 which is present in excess in the screening experiments was 
studied for its potential to reduce MS marker binding towards the target, only marginal effects 
were detected (at 40 µM 6 leads to remaining marker binding of 98 ± 1%).  
 
Table 1: Results of the screening of oximes sub-libraries at a concentration level of 1 µM. 
Oxime sub-library 
Specific NO711 
binding [%]a 
Oxime sub-library 
Specific NO711 
binding [%]a 
1 66 ± 2 15 57 ± 3 
2 59 ± 1 16 87 ± 6 
3 65 ± 6 17 85 ± 3 
4 79 ± 2 18 91 ± 5 
5 49 ± 2 19 55 ± 4 
6 20 ± 2 20 36 ± 3 
7 34 ± 3  21 76 ± 3 
8 13 ± 2 22 81 ± 4 
9 19 ± 2 23 68 ± 2 
10 54 ± 3 24 84 ± 4 
11 85 ± 4 25 85 ± 1 
12 48 ± 2 26 69 ± 4 
13 69 ± 2 27 91 ± 5 
14 49 ± 4 28 89 ± 2 
a Percentage of remaining specific bound NO711; data represent the mean ± standard deviation (SD) 
of n = 4 experiments. 
 
As summarized in Table 1, with the test concentration for the oximes set to 1 µM, eight sub-
libraries were found to reduce marker binding below 50% (sub-library 5–9, 12, 14 and 20). 
Aiming at identification of only the most potent inhibitors out of the 28 sub-libraries studied, we 
decided to define the limit to 20% under which sub-libraries had to decrease the marker binding 
to be selected for further investigations, which correspond to an IC50 value of 250 nM provided 
the observed affinity results from a single constituent. The thus defined requirement, the 
reduction of the specific NO711 binding below 20% was fulfilled by three sub-libraries (sub-
library 6, 8 and 9, Table 1). These sub-libraries were subjected to deconvolution experiments, 
whereas all other sub-libraries, the MS marker binding values of which ranged from 34 ± 3% 
(sub-library 7, Table 1) to 91 ± 5% (sub-library 18, Table 1) were excluded from further studies.  
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2.2.3. Deconvolution experiments 
 
For the deconvolution experiments, single oximes of the three sub-libraries designated as 
active, sub-libraries 6,8, and 9, were generated by incubation of the respective aldehydes (1 
mM) with an excess of hydroxylamine 6 (40 mM) under conditions identical to those used for 
oxime sub-library generation (phosphate buffer pH 6.0 with 40% DMSO, 37 °C, 20 h) and then 
diluted to the test concentration of 1 µM (as in the assay with phosphate buffer pH 7.1). To 
examine that the single fragments of the oxime formation were not able to reduce the specific 
marker binding themselves, the individual aldehydes applied in the deconvolution experiments 
were tested in the absence of hydroxylamine whereby they showed no significant impact on 
the marker binding (87–98%, data not shown).  
The results of the deconvolution experiments are presented in Table 2. None of the screened 
oximes was able to reduce marker binding to the set limit of 20% or below, that had been used 
before as limit for the library screening. Even when adapting the limit for the reduction of MS 
marker binding to 50% corresponding to an IC50 value of 1 µM, only one oxime, 8bf, could 
almost reach this criterion (52 ± 2%, Table 2, entry 10). Hence, it was decided to resynthesize 
this compound to determine its pKi value in full-scale competitive MS Binding Assays23. In order 
to verify the validity of the results obtained from the deconvolution experiments and to gain 
insight into structure-activity-relationships for this class of compounds and to expand the SARs 
for mGAT1 in general, also the two most active oximes of sub-library 6 and 9 were selected 
for resynthesis and further evaluation of the binding affinity towards the target (sub-library 6, 
oxime 8av: 63 ± 1%, entry 8 and sub-library 9, oxime 8bn: 62 ± 2%, entry 18; Table 2). 
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Table 2: Results of the deconvolution experiments of oximes 8 of sub-library 6, 8 and 9 at a concentration level of 1 µM. 
 
Entry 
Oxime (substitution 
pattern) 
Specific NO711 
binding [%]a 
 
Entry 
Oxime (substitution 
pattern) 
Specific NO711 
binding [%]a 
 
Entry 
Oxime (substitution 
pattern) 
Specific NO711 
binding [%]a   
Sub-library 6  Sub-library 8  Sub-library 9 
1 8ao (2’-F,4’-F) 87 ± 2  9 8be (2’-F,4’-Cl) 78 ± 5  17 8bm (2’-Me) 83 ± 1 
2 8ap (2’-F,5’-F) 96 ± 4  10 8bf (2’-Cl,4’-Cl) 52 ± 2  18 8bn (2’-Cl,4’-F) 62 ± 2 
3 8aq (2’-F,3’-F) 95 ± 6  11 8bg (3-F) 77 ± 6  19 8bo (2’-CF3,4’-CF3) 88 ± 2 
4 8ar (3’-F,5’-F) 83 ± 5  12 8bh (2-F)  76 ± 2  20 8bp (2’-Me,4’-Me) 77 ± 1 
5 8as (2’-OMe,5’-F) 83 ± 2  13 8bi (2’-F,6’-F) 81 ± 3  21 8bq (3-F,4’-Cl) 79 ± 2   
6 8at (2’-OMe,4’-F) 76 ± 3  14 8bj (2’-F,4’-F,6’-F) 76 ± 2  22 8br (2’-Ph) 70 ± 5 
7 8au 94 ± 2  15 8bk (3-F,2’-F) 79 ± 3  23 8bs (3’-Ph) 69 ± 2 
8 8av (2’-F,6’-OMe) 63 ± 1  16 8bl (3-F,2’-Cl) 77 ± 3  24 8bt (4’-Ph) 86 ± 6 
aPercentage of remaining specific bound NO711 in the presence of generated oxime in the deconvolution experiment with the respective aldehyde at 1 µM; data represent 
the mean ± standard deviation (SD) of n = 4 experiments. 
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2.2.4. Structure-activity-relationships 
 
After resynthesis, the three selected oximes 8av, 8bf, and 8bn were characterized for their 
binding affinities for mGAT1 (pKi values) in full-scale MS Binding Assays and their inhibitory 
potencies at mGAT1–4 (pIC50 values) in [3H]GABA uptake assays. The results are summarized 
in Table 3. All three compounds have a 1,1’-biphenyl moiety with different substituents at the 
terminal phenyl ring in common. Oxime 8av with 2’-fluoro-6’-methoxy substitution and the 2’,4’-
dichloro derivative 8bf yielded very high and similar pKi values, which amounted to 6.39 ± 0.03 
(for 8av, Table 3, entry 1) and to 6.41 ± 0.02 (for 8bf, Table 3, entry 2).  
Upon exchange of the 4’-chloro substituent in the 2’,4’-dichloro substituted oxime 8bf by a 4’-
fluoro atom, a slightly reduction of the binding affinity from 6.41 ± 0.02 (8bf, Table 3; entry 2) 
to 6.16 ± 0.03 (8bn, Table 3, entry 3) occurs. As can be seen from the remaining MS marker 
binding in the deconvolution experiment, a switch of the positions of the 2’-chloro-4’-fluoro 
substituents in 8bn resulting in 8be (2’-F,4’-Cl, Table 2; entry 9) leads to a reduced affinity 
(compare 8bn, Table 2, entry 18, 62 ± 2% with 8be, Table 2, entry 9, 78 ± 5%). The affinity of 
the latter compound, 8be, is further lowered, the remaining MS marker binding amounting then 
to 87 ± 2% when the 4’-chloro substituent still present in 8be is replaced by a fluorine atom as 
well (2’-F,4’-F, 8ao, Table 2, entry 1). Hence, a chlorine substituent in 2’-position of the studied 
oximes increases the affinity to mGAT1 to a larger extent than a fluorine residue.  
The oxime 8av bearing a methoxy group in 6’-position and a fluorine in 2’-position showed a 
high affinity (pKi = 6.39 ± 0.03, Table 3, entry 1) which, in contrast, is significantly lower when 
the fluorine residue is shifted to the meta (8as, 83 ± 2%, Table 2, entry 5) or para position (8at, 
76 ± 3%, Table 2, entry 6).   
As compared to the homologous compounds in which the pyrrolidine ring is provided with an 
acetic acid residue instead of a carboxylic acid function in 3-position14, oximes 8av, 8bf and 
8bn though possessing identical lipophilic residues showed in each case (for the individual 
pairs of compounds) lower affinities towards mGAT1. For example, the pKi value of the 2’,4’-
dichloro-substituted oxime 8bf (pKi = 6.41 ± 0.02) is approximately 1.5 log unit lower than the 
pKi value of the respective homologous oxime bearing an acetic acid moiety at the pyrrolidine 
ring (pKi = 7.87 ± 0.01)14. In other words, reduction of the acetic acid chain in 3-position of the 
pyrrolidine ring to a carboxylic acid function leads to a loss of affinity of almost 1.5 log units. 
Interestingly, in case of 2’-fluoro-6’-methoxy-substituted oxime 8av (pKi = 6.39 ± 0.03), the 
difference between its pKi value and the pKi value of the homologous 2-(pyrrolidin-3-yl)acetic 
acid derivative (pKi = 7.12 ± 0.03)14 was less pronounced implying that the presence of a 
methoxy group had a more favorable effect in 8av than in the homologous compound.  
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2.2.5. Subtype selectivity 
 
In order to characterize the potencies at mGAT1 and their subtype selectivity regarding mGAT1 
over the other murine GABA transporter subtypes mGAT2–mGAT4, the novel oximes 8av, 
8bf, and 8bn were furthermore characterized in [3H]GABA uptake assays. 
The results are given in Table 3. In those cases where [3H]GABA uptake was reduced to 50% 
or below (~ pIC50 ≥ 4.0) at a test compound concentration of 100 µM, pIC50 values were 
determined in three independent experiments for mGAT1 whereas in a single experiment for 
mGAT2–4. For less potent compounds only the percentage value of the remaining [3H]GABA 
uptake is given. As can be seen from the data in Table 3, the inhibitory potencies (pIC50 values) 
of the studied compounds at mGAT1 are approximately one log unit lower than the 
corresponding binding affinities (pKi values). This phenomenon repeatedly observed and 
reported in previous publications may be attributed to the different assay conditions used for 
MS Binding Assays as compared to the [3H]GABA uptake assays. Still the determined pIC50 
and pKi values for mGAT1 are in good accordance to each other. With the highest pIC50 value 
found for mGAT2–4 amounting to 4.30 (for 8bf at mGAT2, Table 3, entry 2) and all other 
potencies being so low that only the percentage value or remaining [3H]GABA uptake (~ pIC50 
≤ 4.0) has been determined, the hit compounds 8av, 8bf, and 8bn show a distinct subtype 
selectivity in favor of mGAT1 of more than 1.3 log units (compare e.g. data for mGAT1 with 
those for mGAT2–4 found for 8bf, Table 3, entry 2).  
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Table 3: Binding affinities (pKi) from competitive MS Binding Assays and inhibitory potencies (pIC50) from [3H]GABA uptake 
experiments determined for synthesized oximes with following substitution pattern. 
 
Entry 
compound 
(substitution pattern)a 
pKib 
pIC50c 
mGAT1 mGAT2 mGAT3 mGAT4 
1 8av (2’-F,6’-OMe) 6.39 ± 0.03 5.72 ± 0.04  86% 93% 89% 
2 8bf (2’-Cl,4’-Cl) 6.41 ± 0.02 5.64 ± 0.11 4.30 62% 56% 
3 8bn (2’-Cl,4’-F) 6.16 ± 0.03 5.32 ± 0.07 52% 75% 66% 
aIndividually synthesized oximes (see experimental section). bData points for specific binding of NO711 on mGAT1 (mean ± SD, n = 3) in the 
present of different concentrations of test compound resulted in binding curves for Ki determination by nonlinear regression. pKi values represent 
the mean ± SEM of three independent experiments, each performed in triplicate.  cpIC50 values from [3H]GABA uptake assays performed with 
murine GABA transporters expressing HEK cells. The values represent the mean ± SEM of three (mGAT1) or one (mGAT2–4) independent 
experiments, each performed in triplicates. Percentage values represent remaining [3H]GABA uptake in present of 100 µM test compound. 
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3. Conclusion 
 
In this study, the library screening concept based on competitive LC-MS/MS Binding Assays 
established in our group has been applied to oximes possessing a pyrrolidine-3-carboxylic acid 
as polar domain to identify novel inhibitors for the GABA transporter mGAT1. The studied 
oxime sub-libraries could be easily generated by reacting an excess of 1-[2-
(aminooxy)ethyl]pyrrolidine-3-carboxylic acid (6) with the respective aldehyde sub-libraries, of 
which 28 were employed, each containing eight different aldehydes representing a broad 
range of different structures. Screening of these oxime sub-libraries in competitive MS Binding 
Assays for mGAT1 revealed three sub-libraries that were able to reduce the specific binding 
of the marker under the defined limit of 20% when applied in 1µM concentration for the 
individual oximes. These sub-libraries were subsequently selected for deconvolution 
experiments performed in analogy to library screening except that only single oximes were 
applied, to identify the oxime with the highest affinities.  
The three oximes found to be the most active in the deconvolution experiments were 
resynthesized and subjected to full-scale MS Binding Assays and [3H]GABA uptake assays to 
determine their binding affinities and inhibitory potencies. Oximes with a 2’,4’-dichlorobiphenyl 
residue (8bf: pKi = 6.41 ± 0.02) and a 2’-fluoro-6’-methoxy residue (8av: pKi = 6.39 ± 0.03) 
were found to be the most affine inhibitors, representing the first submicromolar mGAT1 
inhibitors delineated from pyrrolidine-3-carboxylic acid. Interestingly, two of the three 
pyrrolidine-3-carboxylic acid derivatives with the highest affinities for mGAT1 out of 224 
different oximes studied displayed a 2’,4’-dichloro and 2’-chloro-4’-fluoro substitution pattern 
at the terminal phenylring identical to that of the most potent oximes out of a homologous series 
of compounds with a 2-(pyrrolidin-3-yl)acetic acid instead of pyrrolidine-3-carboxylic acid as 
polar subunit. But the best binding oximes from this series showed a significant lower affinity 
for mGAT than the corresponding 2-(pyrrolidin-3-yl)acetic acid derived compounds reported 
earlier14.  
Overall, variation of the amino acid motif in order to extend structure-activity-relationships were 
accomplished and three oximes with pKi values between 6.16 and 6.41 were identified 
representing mGAT1 inhibitors derived from pyrrolidine-3-carboxylic acid with the highest 
binding affinities published so far. Therefore, the concept of oxime library screening using 
competitive MS Binding Assays has again proven to be a reliable readout tool to identify the 
most potent substances out of a given set of different structures.  
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4. Experimental Section 
 
4.1. Chemistry 
 
General: Organic solvents used were of analytical grade and were freshly distilled prior to use 
except for DMSO and absolute EtOH. Purchased reagents and reactants were used without 
further purification. TLC was performed on pre-coated silica gel F254 aluminum sheets (Merck). 
Flash column chromatography was performed on Merck silica gel 60 (mesh 0.040–0.063 mm). 
NMR spectra were recorded with an Avance III HD 400 MHz Bruker BioSpin (400 MHz) 
spectrometer and Avance III HD 500 MHz Bruker BioSpin (500 MHz) spectrometer equipped 
with a CryoProbe Prodigy. 1H chemical shifts were internally referenced to tetramethylsilane 
(TMS) or 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP) for samples dissolved in 
D2O. MestreNova (Version 12.0.0) was used for further analysis of the spectra. IR spectra 
were recorded with a FT-IR spectrometer Paragon 1000 (Perkin-Elmer, Rodgau, Germany) 
and Spectrum v2.00 software (Perkin-Elmer, Rodgau, Germany) as either KBr pellets or as 
films on NaCl plates. High resolution mass spectra (HRMS) were measured on a Thermo 
Finnigan LTQ FT instrument for electrospray ionization (ESI) or on a Thermo Finnigan MAT 
95 instrument for electron impact (EI). Melting points (in °C, uncorrected) were determined with 
a Büchi melting point B-350 apparatus. Determination of the protonation state of 
hydroxylamine 6 was performed with an 888 Titrando (Metrohm). Purity was determined using 
qNMR on the Avance III HD 400 MHz Bruker BioSpin (400 MHz) spectrometer with maleic acid 
as internal standard (Sigma Aldrich, Steinheim, Germany, LOT-No.: BCBM8127V).31 Oximes 
8 and hydroxylamine 6 were ≥95% pure. For weighing, an ALC-80.4 ACCULAB and a MC 21S 
from Sartorius Group (Göttingen, Germany) were used. 
 
4.2. General procedures 
 
4.2.1. General procedure for the preparation of oximes (GP1): Aldehyde 7 (1.0 eq.) in 
absolute EtOH (c = 0.1 M) was added to a stirred solution of hydroxylamine ethylester 14 (1.0 
eq.) in absolute EtOH (c = 0.1 M) and the resulting mixture was stirred at 60 °C for 18 h. After 
removing of the solvent under reduced pressure, the residue was purified by flash column 
chromatography (silica gel, n-pentane/ether + 1% NEt3 = 9:1 to 7:3) to yield 15 as a colorless 
oil. 
 
4.2.2. General procedure for the hydrolysis of oximes (GP2): A solution of ester 15 (1.0 
eq.) in absolute EtOH (c = 0.1 M) was treated with aqueous NaOH solution (2 M, 3.0 eq.) and 
the mixture was stirred at room temperature for 18 h. After cooling to 0 °C, aqueous HCl 
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solution (1 M) was added until pH 1 was reached. The aqueous phase was extracted with 
CH2Cl2 (3 x 20 mL), the combined organic layers were dried with Na2SO4 and the solvent was 
removed under reduced pressure. The resulting oil was dissolved in double-distilled water and 
lyophilized to yield the desired product 8 as hydrochloride. 
 
4.3. Synthesized substances 
 
4.3.1. 1-[2-(Aminooxy)ethyl]pyrrolidine-3-carboxylic acid –hydrogen chloride (1/2) (6): 
14 (27 mg, 0.13 mmol) was dissolved in aqueous HCl solution (1 M, 1.33 mL, 1.33 mmol) and 
the reaction mixture was stirred at 95 °C for 4 h. After cooling to room temperature, the mixture 
was washed with CH2Cl2 (3 x 10 mL) and the aqueous layer was lyophilized to yield the product 
6. Colorless amorphous solid (32 mg, 97%): mp: 66–69°C. IR (KBr): 
~  = 3423, 2959, 2692, 
1726, 1624, 1451, 1400, 1199 cm–1. 1H NMR (400 MHz, D2O, TPS) δ = 1.92 (ddd, J = 12.8, 
10.1, 6.4 Hz, 1H), 2.05 (ddd, J = 13.1, 7.9, 5.2 Hz, 1H), 2.41–2.57 (m, 2H), 2.73 (h, J = 7.9 Hz, 
2H), 2.81–2.98 (m, 2H), 3.06 (t, J = 8.9 Hz, 1H), 3.84 (t, J = 5.6 Hz, 2H) ppm. 13C NMR (101 
MHz, D2O, TPS) δ = 30.9, 47.7, 55.8, 56.5, 60.1, 76.7, 186.5 ppm. HRMS (ESI+): [M+H]+ calcd. 
for C7H15N2O3, 175.1077; found: 175.1077. 
 
4.3.2. 1-[2-({(E)-[(2’-Fluoro-6’-methoxy[1,1’-biphenyl]-2-yl)methylidene]amino} 
oxy)ethyl]pyrrolidine-3-carboxylic acid (8av): According to GP2: 15av (38 mg, 0.092 mmol) 
and NaOH (11 mg, 0.28 mmol). Colorless, amorphous powder (27 mg, 70%). mp: 61–64°C. 
IR (KBr): 
~  = 3426, 3054, 2940, 2570, 1727, 1615, 1469, 1238, 1074, 786 cm–1. 1H NMR (500 
MHz, 0.1 M NaOD/CD3OD = 1:2, TPS) δ = 1.94–2.08 (m, 2H), 2.46 (q, J = 8.4 Hz, 1H), 2.55 
(td, J = 9.6, 1.8 Hz, 1H), 2.76 (qt, J = 13.1, 6.5 Hz, 2H), 2.81–2.93 (m, 2H), 3.05 (t, J = 9.0 Hz, 
1H), 3.75 (s, 3H), 4.22 (t, J = 5.8 Hz, 2H), 6.88 (t, J = 8.7 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 
7.23 (dd, J = 7.5, 1.3 Hz, 1H), 7.43–7.49 (m, 2H), 7.51 (td, J = 7.5, 1.6 Hz, 1H), 7.80 (s, 1H), 
7.88 (dd, J = 7.7, 1.4 Hz, 1H). ppm. 13C NMR (126 MHz, 0.1 M NaOD/CD3OD = 1:2, TPS) δ = 
31.2, 48.0, 57.0, 58.7, 60.9, 75.3, 110.1 (d, JCF = 2.8 Hz), 110.8 (d, JCF = 22.9 Hz), 118.7 (d, 
JCF = 19.3 Hz), 128.5, 131.2, 132.7, 133.4 (d, JCF = 10.5 Hz), 133.7, 134.3, 134.7, 151.4, 160.8 
(d, JCF = 6.7 Hz), 163.1 (d, JCF = 242.5 Hz), 185.2 ppm. 19F NMR (376 MHz, D2O): δ = –115.8 
ppm. HRMS (ESI+): [M+H]+ calcd. for C21H24FN2O4, 387.1715; found: 387.1715. 
 
4.3.3. 1-[2-({(E)-[(2’,4’-Dichloro[1,1’-biphenyl]-2-yl)methylidene]amino}oxy)ethyl] 
pyrrolidine-3-carboxylic acid (8bf): According to GP2: 15bf (40 mg, 0.092 mmol) and NaOH 
(11 mg, 0.28 mmol). Colorless, amorphous powder (35 mg, 86%). mp: 63–67°C. IR (KBr): 
~  
= 3431, 3060, 2949, 2560, 1728, 1585, 1466, 1443, 1203, 1101, 1069, 764 cm–1. 1H NMR (500 
MHz, 0.1 M NaOD/CD3OD = 1:2, TPS) δ = 1.91–2.09 (m, 2H), 2.46 (q, J = 8.3 Hz, 1H), 2.55 
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(t, J = 9.1 Hz, 1H), 2.73 (dddd, J = 12.9, 11.4, 9.0, 4.8 Hz, 2H), 2.83 (ddd, J = 13.3, 8.9, 4.9 
Hz, 1H), 2.89 (dtd, J = 9.7, 8.5, 7.1 Hz, 1H), 3.04 (t, J = 8.9 Hz, 1H), 4.19 (t, J = 5.8 Hz, 2H), 
7.21–7.25 (m, 1H), 7.27 (d, J = 8.2 Hz, 1H), 7.46 (dd, J = 8.2, 2.1 Hz, 1H), 7.47–7.57 (m, 2H), 
7.61 (d, J = 2.1 Hz, 1H), 7.81 (s, 1H), 7.85 (dd, J = 6.9, 1.6 Hz, 1H) ppm. 13C NMR (126 MHz, 
0.1 M NaOD/CD3OD = 1:2, TPS) δ = 31.2, 48.0, 57.0, 60.9, 75.4, 129.1, 129.1, 130.3, 131.6, 
131.9, 132.9, 133.0, 133.2, 135.4, 136.8, 137.3, 140.3, 140.9, 150.8, 185.2 ppm. HRMS (ESI+): 
[M+H]+ calcd. for C20H21Cl2N2O3, 407.0924; found: 407.0926. 
 
4.3.4. 1-[2-({(E)-[(2’-Chloro-4’-fluoro[1,1’-biphenyl]-2-yl)methylidene]amino}oxy)ethyl] 
pyrrolidine-3-carboxylic acid (8bn): According to GP2: 15bn (20 mg, 0.048 mmol) and 
NaOH (5.7 mg, 0.14 mmol). Colorless, amorphous powder (18 mg, 89%): mp: 51–53°C. IR 
(KBr): 
~  = 3424, 3054, 2947, 2561, 1726, 1601, 1500, 1474, 1445, 1389, 1257, 1198, 1059, 
897, 764 cm–1. 1H NMR (500 MHz, 0.1 M NaOD/CD3OD = 1:2, TPS) δ = 1.96–2.17 (m, 2H), 
2.64 (q, J = 8.5 Hz, 1H), 2.74 (t, J = 9.1 Hz, 1H), 2.84–2.92 (m, 2H), 2.92–2.98 (m, 2H), 3.14 
(t, J = 9.2 Hz, 1H), 4.25 (t, J = 5.6 Hz, 2H), 7.19–7.27 (m, 2H), 7.31 (dd, J = 8.5, 6.1 Hz, 1H), 
7.39 (dd, J = 8.7, 2.6 Hz, 1H), 7.47–7.58 (m, 2H), 7.82 (s, 1H), 7.87 (dd, J = 7.3, 1.4 Hz, 1H) 
ppm. 13C NMR (126 MHz, 0.1 M NaOD/CD3OD = 1:2, TPS) δ = 31.1, 47.8, 56.9, 57.0, 60.7, 
74.7, 117.2 (d, JCF = 21.3 Hz), 119.4 (d, JCF = 25.2 Hz), 128.9, 131.5, 133.0, 133.0, 133.4, 
135.6 (d, JCF = 8.9 Hz), 136.7 (d, JCF = 10.6 Hz), 137.6 (d, JCF = 3.1 Hz), 141.3, 151.3, 165.2 
(d, JCF = 249.1 Hz), 184.6 ppm. 19F NMR (376 MHz, MeOD): δ = –113.3 ppm. HRMS (ESI+): 
[M+H]+ calcd. for C20H21FClN2O3, 391.1219; found: 391.1219. 
 
4.3.5. 3-Ethyl 1-(2,2,2-trichloroethyl)pyrrolidine-1,3-dicarboxylate (10): Potassium 
carbonate (451 mg, 3.26 mmol) and 2,2,2‐trichloroethyl chloroformate (390 µL, 2.86 mmol) 
were added to a solution of 9 (475 mg, 2.04 mmol) in acetonitrile (8 mL) and the resulting 
reaction mixture was stirred at 60 °C for 3 h. After cooling to room temperature the suspension 
was diluted with EtOAc (15 mL) and was filtrated. The solvent was removed in vacuo and the 
crude product was purified by flash column chromatography (silica gel, n-pentane/ether = 8:2). 
Colorless oil (583 mg, 90%): Rf = 0.27 (n-pentane:ether = 8:2). IR (Film): 
~  = 2984, 2892, 
1727, 1417, 1181, 1125, 716 cm–1. 1H NMR (400 MHz, tetrachlorethane-d2, 100 °C, TMS) δ = 
1.25 (t, J = 7.1 Hz, 3H), 2.08–2.21 (m, 2H), 3.05 (p, J = 7.2 Hz, 1H), 3.47 (dt, J = 10.8, 7.3 Hz, 
1H), 3.58 (dt, J = 11.0, 6.8 Hz, 1H), 3.62–3.74 (m, 2H), 4.15 (q, J = 7.2 Hz, 2H), 4.71 (s, 2H) 
ppm. 13C NMR (101 MHz, tetrachlorethane-d2, 100 °C, TMS) δ = 14.2, 28.6, 43.0, 45.7, 48.5, 
61.0, 75.2, 96.0, 152.7, 172.5 ppm. HRMS (EI+): [M]+ calcd. for C10H14Cl3NO4, 316.9988; found: 
316.9972. 
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4.3.6. Ethyl pyrrolidine-3-dicarboxylate–acetic acid (11): Zinc powder (614 mg, 9.39 
mmol) was added to a solution of 10 (997 mg, 3.13 mmol) in acetic acid (7 mL) and the reaction 
mixture was stirred at room temperature for 4 h. The suspension was filtrated over Celite® and 
the solid washed with CH2Cl2 (15 mL). The solvent and excess acetic acid were removed in 
vacuo by co-evaporation with toluene (3 x 10 mL). Slightly yellow oil (552 mg, 87%): IR (Film): 
~  = 3054, 2986, 1731, 1567, 1557, 1453, 1213, 1025, 736 cm–1. 1H NMR (500 MHz, CD3OD, 
TMS) δ = 1.18 (t, J = 7.1 Hz, 3H), 1.99 (s, 3H), 2.15 (dq, J = 13.4, 7.1 Hz, 1H), 2.22–2.35 (m, 
1H), 3.18–3.29 (m, 3H), 3.35–3.44 (m, 2H), 3.61 (q, J = 7.0 Hz, 2H) ppm. 13C NMR (126 MHz, 
CD3OD, TMS) δ = 18.4, 22.5, 29.6, 43.5, 47.4, 49.5, 58.4, 175.0, 180.9 ppm. HRMS (EI+): [M]+ 
calcd. for C7H13NO2, 143.0946; found: 143.0945. 
 
4.3.7. Ethyl 1‐(2‐hydroxyethyl)pyrrolidine‐3‐carboxylate (12): K2CO3 (510 mg, 3.69 
mmol), KI (4 mg, 0.03 mmol) and 2-bromoethanol (101 µL, 1,35 mmol) were added to a solution 
of 11 (250 mg, 1.23 mmol) in THF (4 mL). The resulting mixture was heated to reflux for 20 h. 
After cooling to room temperature the solids were removed by filtration and the solvent was 
removed under reduced pressure. The residue was purified by column chromatography on 
silica gel (MeCN/NEt3 = 95:5). Yellow oil (175 mg, 76%): Rf = 0.11 (MeCN/NEt3 = 95:5). IR 
(Film): 
~  = 3406, 2954, 2805, 1733, 1448, 1372, 1198, 1177, 1056, 881 cm–1. 1H NMR (500 
MHz, CDCl3, TMS) δ = 1.27 (t, J = 7.1 Hz, 3H), 2.08–2.16 (m, 2H), 2.65 (dt, J = 9.1, 7.0 Hz, 
1H), 2.66–2.75 (m, 2H), 2.74–2.79 (m, 1H), 2.80 (dd, J = 8.5, 5.7 Hz, 1H), 2.97 (dd, J = 9.2, 
8.4 Hz, 1H), 3.04 (qd, J = 8.0, 6.5 Hz, 1H), 3.66 (t, J = 5.4 Hz, 2H), 4.15 (q, J = 7.1 Hz, 2H) 
ppm. 13C NMR (126 MHz, CDCl3, TMS) δ = 14.2, 27.7, 42.1, 53.5, 56.4, 57.0, 59.6, 60.8, 174.8 
ppm. HRMS (ESI+): [M+H]+ calcd. for C9H18NO3, 188.1281; found: 188.1281. 
 
4.3.8. Ethyl 1‐{2‐[(1,3‐dioxo‐2,3‐dihydro‐1H‐isoindol‐2‐yl)oxy]ethyl}pyrrolidine‐3‐
carboxylate (13): 12 (152 mg, 0.812 mmol), N-hydroxyphthalimide (225 mg, 1.38 mmol), 
triphenylphosphine (369 mg, 1.38 mmol) were dissolved in THF (4 mL), DMEAD (333 mg, 1.42 
mmol) was added slowly and the solution was stirred for 17 h at room temperature. After 
removing the solvent under reduced pressure, the residue was dissolved in CH2Cl2 (20 mL), 
the organic layer was washed with water (3 x 15 mL), dried over sodium sulfate and the solvent 
was again removed in vacuo. The resulting oil was purified by column chromatography on 
silica gel, which was pre-dried at 145 °C in vacuo for 5 h (Ether/NEt3 = 95:5). Colorless oil (219 
mg, 81%): Rf = 0.67 (ether/NEt3 = 95:5). IR (Film): 
~  = 2978, 2800, 1789, 1731, 1467, 1374, 
1188, 1023, 878, 702 cm–1. 1H NMR (500 MHz, CDCl3, TMS) δ = 1.26 (t, J = 7.1 Hz, 3H), 2.00–
2.09 (m, 2H), 2.54 (dt, J = 8.9, 7.7 Hz, 1H), 2.68 (dd, J = 9.1, 7.1 Hz, 1H), 2.82–3.03 (m, 4H), 
3.09 (t, J = 8.8 Hz, 1H), 4.13 (q, J = 7.2 Hz, 2H), 4.28–4.39 (m, 2H), 7.75 (dd, J = 5.5, 3.1 Hz, 
2H), 7.84 (dd, J = 5.4, 3.1 Hz, 2H) ppm. 13C NMR (126 MHz, CDCl3, TMS) δ = 14.2, 27.7, 42.1, 
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53.6, 54.0, 57.0, 60.6, 76.3, 123.5, 129.0, 134.4, 163.5, 174.9 ppm. HRMS (EI+): [M]+ calcd. 
for C17H20N2O5, 332.1372; found: 332.1366. 
 
4.3.9. Ethyl 1‐[2‐(aminooxy)ethyl]pyrrolidine‐3‐carboxylate (14): Hydrazine solution (50–
60%, 15 µL, 0.24 mmol) was added to a stirred solution of 13 (40 mg, 0.12 mmol) in EtOH 
(abs., 2 mL) and the solution was stirred for 2 h at room temperature. The resulting slurry was 
filtered, the filtrate was washed with ice-cold CH2Cl2 (5 mL) and the solvent was removed in 
vacuo. Again ice-cold CH2Cl2 (5 mL) was added to the residue and the resulting mixture was 
filtered. Evaporation under reduced pressure afforded the product 14. Colorless oil (22 mg, 
92%): IR (Film): 
~  = 2959, 2950, 2802, 1731, 1592, 1372, 1194, 1032 cm–1. 1H NMR (500 
MHz, CDCl3, TMS) δ = 1.26 (t, J = 7.1 Hz, 3H), 2.00–2.22 (m, 2H), 2.50 (dt, J = 8.6, 7.7 Hz, 
1H), 2.59–2.77 (m, 3H), 2.81 (ddd, J = 9.0, 7.0, 5.7 Hz, 1H), 2.96–3.11 (m, 2H), 3.80 (t, J = 5.5 
Hz, 2H), 4.14 (q, J = 7.1 Hz, 2H) ppm. 13C NMR (126 MHz, CDCl3, TMS) δ = 14.2, 27.7, 42.1, 
54.3, 54.4, 57.1, 60.7, 74.1, 175.0 ppm. HRMS (ESI+): [M+H]+ calcd. for C9H19N2O3, 203.1390; 
found: 203.1389. 
 
4.3.10. Ethyl 1-[2-({(E)-[(2’-fluoro-6’-methoxy[1,1’-biphenyl]-2-yl)methylidene]amino} 
oxy)ethyl]pyrrolidine-3-carboxylate (15av): According to GP1: Hydroxylamine 14 (30 mg, 
0.15 mmol) and 7av (34 mg, 0.15 mmol). Colorless oil (50 mg, 81%). Rf = 0.18 (n-pentane:ether 
= 8:2, 1% NEt3). IR (Film): 
~  = 3062, 2958, 2937, 2804, 1731, 1614, 1580, 1469, 1438, 1275, 
1239, 1196, 1175, 1083, 943 cm–1. 1H NMR (500 MHz, CD2Cl2, TMS) δ = 1.22 (t, J = 7.1 Hz, 
3H), 1.97–2.08 (m, 2H), 2.53 (dt, J = 8.7, 7.3 Hz, 1H), 2.60–2.70 (m, 2H), 2.72 (tdd, J = 5.7, 
2.4, 1.5 Hz, 2H), 2.85 (t, J = 8.9 Hz, 1H), 2.96 (qd, J = 8.2, 6.7 Hz, 1H), 3.74 (s, 3H), 4.09 (q, 
J = 7.1 Hz, 2H), 4.19 (t, J = 5.8 Hz, 2H), 6.77–6.85 (m, 2H), 7.20–7.28 (m, 1H), 7.32–7.38 (m, 
1H), 7.38–7.47 (m, 2H), 7.79 (d, J = 1.1 Hz, 1H), 7.96 (dd, J = 7.7, 1.5 Hz, 1H) ppm; 13C NMR 
(126 MHz, CD2Cl2, TMS) δ = 14.4, 28.1, 42.5, 54.6, 54.8, 56.5, 57.5, 60.9, 73.4, 107.1 (d, JCF 
= 2.8 Hz), 108.4 (d, JCF = 23.0 Hz), 116.4 (d, JCF = 19.3 Hz), 125.8, 128.5, 129.7, 130.3 (d, J 
JCF = 10.6 Hz), 131.8, 132.1, 132.1, 147.5, 158.4 (d, JCF = 6.9 Hz), 160.7 (d, JCF = 243.7 Hz), 
175.2 ppm; 19F NMR (376 MHz, CD2Cl2) δ = –114.3 ppm. HRMS (ESI+): [M+H]+ calcd. for 
C23H28FN2O4, 415.2028; found: 415.2024. 
 
4.3.11. Ethyl 1-[2-({(E)-[(2’,4’-dichloro[1,1’-biphenyl]-2-yl)methylidene]amino} 
oxy)ethyl]pyrrolidine-3-carboxylate (15bf): According to GP1: Hydroxylamine 14 (30 mg, 
0.15 mmol) and 7bf (37 mg, 0.15 mmol). Colorless oil (48 mg, 74%).  Rf = 0.24 (n-pentane:ether 
= 8:2, 1% NEt3). IR (Film): 
~  = 3061, 2970, 2936, 2804, 1732, 1466, 1444, 1192, 1176, 1036, 
761 cm–1. 1H NMR (500 MHz, CD2Cl2, TMS) δ = 1.22 (t, J = 7.1 Hz, 3H), 1.98–2.07 (m, 2H), 
2.54 (dt, J = 8.8, 7.2 Hz, 1H), 2.63 (dt, J = 8.8, 6.7 Hz, 1H), 2.67 (dd, J = 9.3, 6.6 Hz, 1H), 2.70 
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(td, J = 5.7, 1.7 Hz, 2H), 2.84 (t, J = 8.8 Hz, 1H), 2.96 (qd, J = 8.2, 6.6 Hz, 1H), 4.10 (q, J = 7.1 
Hz, 2H), 4.18 (t, J = 5.8 Hz, 2H), 7.18–7.24 (m, 2H), 7.34 (dd, J = 8.2, 2.1 Hz, 1H), 7.40–7.47 
(m, 2H), 7.51 (d, J = 2.1 Hz, 1H), 7.77 (s, 1H), 7.91–7.97 (m, 1H) ppm. 13C NMR (126 MHz, 
CD2Cl2, TMS) δ = 14.4, 28.1, 42.5, 54.6, 54.8, 57.5, 60.9, 73.6, 126.1, 127.6, 128.9, 129.7, 
129.8, 130.7, 131.1, 132.9, 134.6, 134.7, 137.5, 138.4, 146.9, 175.3 ppm. HRMS (ESI+): 
[M+H]+ calcd. for C22H25Cl2N2O3, 435.1237; found: 435.1236.  
 
4.3.12. Ethyl 1-[2-({(E)-[(2’-chloro-4’-fluoro[1,1’-biphenyl]-2-yl)methylidene]amino} 
oxy)ethyl]pyrrolidine-3-carboxylate (15bn): According to GP1: Hydroxylamine 14 (30 mg, 
0.15 mmol) and 7bn (35 mg, 0.15 mmol). Colorless oil (43 mg, 69%). Rf = 0.21 (n-
pentane:ether = 8:2, 1% NEt3). IR (Film): 
~  = 3059, 2961, 2930, 2805, 1731, 1601, 143, 1257, 
1198, 1059, 1035, 897, 762 cm–1. 1H NMR (500 MHz, CDCl3, TMS) δ = 1.25 (t, J = 7.1 Hz, 3H), 
2.00–2.18 (m, 2H), 2.51 (q, J = 8.2 Hz, 1H), 2.65 (dd, J = 12.3, 5.0 Hz, 1H), 2.72–2.88 (m, 3H), 
2.99–3.11 (m, 2H), 4.14 (q, J = 7.2 Hz, 2H), 4.26 (t, J = 5.7 Hz, 2H), 7.05 (td, J = 8.2, 2.6 Hz, 
1H), 7.16–7.25 (m, 3H), 7.38–7.45 (m, 2H), 7.81 (s, 1H), 7.94–7.99 (m, 1H) ppm. 13C NMR 
(126 MHz, CD2Cl2, TMS) δ = 14.2, 27.7, 42.1, 54.3, 54.6, 57.1, 60.7, 72.8, 114.1 (d, JCF = 21.1 
Hz), 116.9 (d, JCF = 24.6 Hz), 125.7, 128.4, 129.5, 130.5, 130.6, 132.5 (d, JCF = 8.8 Hz), 134.3 
(d, JCF = 10.3 Hz), 134.5 (d, JCF = 3.7 Hz), 138.2, 147.0, 162.1 (d, JCF = 250.5 Hz), 174.9 ppm. 
19F NMR (376 MHz, CDCl3) δ = –112.1 ppm. HRMS (ESI+): [M+H]+ calcd. for C22H25FClN2O3, 
419.1532; found: 419.1530.  
 
4.4. Oxime exchange experiment: Phosphate buffer (990 µL, pH 7.1, 12.5 mM Na2HPO4, 
12.5 mM NaH2PO4, 1 M NaCl, pH value adjusted with 1 M NaOH, 10% D2O) was added to a 
solution of oxime 8av (0.423 mg, 1 µmol) and 4-methoxybenzaldehyde 7t (0.272 mg, 2 µmol) 
in DMSO-d6 (10 µL) in an NMR tube. 1H NMR spectra (64 scans) were measured at 37 °C with 
water suppression directly after the preparation of the sample and every 4 h over a 64 h period. 
No change of the spectra could be observed over the experiment time.  
 
4.5. LC-MS/MS binding experiments 
 
4.5.1. Generation of pre-equilibrated sub-libraries: To obtain the hydroxylamine 6 as a 
free base, aqueous NaOH solution (1 M, 2.0 eq.) in phosphate buffer (pH 6.0, 12.5 mM 
Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value adjusted with 1 M HCl) was added to 
hydroxylamine 6 as dihydrochloride dissolved in phosphate buffer (pH 6.0) to a nominal 
concentration of 400 mM of 6. This solution (10 µL) was added to a mixture containing eight 
solutions of individual aldehydes in DMSO (20 mM, 5 µL each) and phosphate buffer (pH 6.0, 
50 µL). These sub-library mixtures were incubated for 20 h at 37 °C in a shaking water bath to 
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guarantee full conversion into the corresponding oximes. In case of sub-library 26, oxime 
generation was achieved at 80 °C for 45 h. Before the binding experiments, all pre-equilibrated 
sub-libraries were freshly diluted with phosphate buffer pH 7.1 (12.5 mM Na2HPO4, 12.5 mM 
NaH2PO4, 1 M NaCl, pH value adjusted with 1 M NaOH) and DMSO to obtain the generated 
oximes in final concentrations of 10 µM in phosphate buffer (pH 7.1) containing 10% DMSO 
v/v.  
 
4.5.2. Generation of pre-equilibrated single oximes for deconvolution experiments: The 
pre-equilibrated single oximes for deconvolution were obtained in the same way as described 
for pre-equilibrated sub-libraries, except that one solution of a single aldehyde in DMSO (20 
mM, 5 µL) and additional DMSO (35 µL) were used. Before the binding experiments, all pre-
equilibrated deconvolution batches were freshly diluted with phosphate buffer pH 7.1 (12.5 mM 
Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value adjusted with 1 M NaOH) and DMSO to 
obtain the generated oximes in final concentrations of 10 µM in phosphate buffer (pH 7.1) 
containing 10% DMSO.  
 
4.5.3. mGAT1 membrane preparation: Membrane preparations of HEK293 cells stably 
expressing mGAT118 were prepared as described previously and stored at –80 °C.23,32 On the 
day of the assay, an aliquot was rapidly thawed and diluted in a 20-fold volume of cold aqueous 
0.9% NaCl solution (m/v). After centrifugation at 20500 rpm and 4 °C for 20 min (CP56GII, 
P70AT, Hitachi Ltd., Tokyo, Japan), the resulting pellet was resuspended in ice-cold phosphate 
buffer pH 7.1 to a protein concentration of approximately 0.1 mg mL-1 as previously 
described.32  
 
4.5.4. Library screening: Library screening was performed in 1.2 mL polypropylene deep-
well plates (Sarstedt, Nümbrecht, Germany) in analogy to a procedure previously 
described.16,21,22 Samples (n = 4) were prepared in phosphate buffer (pH 7.1) with 1% DMSO 
in total volume of 250 µL per sample containing the mGAT1 membrane preparation (50 µL, 
approximately 20 µg protein per sample, see above), NO711 (25 µL, final concentration in the 
assay 20 nM) and the pre-equilibrated sub-libraries (25 µL, final concentration one tenth of the 
corresponding stock solution containing the pre-equilibrated sub-libraries as described above) 
and incubated for 4 h at 37 °C in a shaking water bath. Incubation was stopped by transferring 
aliquots of 200 µL of each sample onto a 96-well filter plate (Acroprep Advance, glass fiber, 
1.0 µm, 350 µL, Pall, Dreieich, Germany) with a 12-channel pipette followed by subsequent 
vacuum filtration. After washing with ice-cold aqueous NaCl solution (1 M, 5 x 150 µL per well) 
by using a 12-channel pipette, the filter plate was dried (60 min, 50 °C) and cooled to room 
temperature. Subsequently, the marker was liberated by elution of the filter plate with MeOH 
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(3 x 100 µL per well) into a 1.2 mL polypropylene 96-well plate (Sarstedt, Nümbrecht, 
Germany). Each sample was supplemented with 1 nM [2H10]NO711 (200 µL, in MeOH) as an 
internal standard. All samples were dried to completeness (17 h, 50 °C). For quantification by 
LC-MS/MS (ESI), samples were reconstituted in 200 µL of 10 mM ammonium formate buffer 
[pH 7.0/MeOH (95:5 v/v)]. In the same way, aldehyde sub-libraries (see above) and 
hydroxylamine 6 (final concentrations in the assay 40 µM, 4 µM or 400 nM) were investigated. 
Total binding and nonspecific binding of NO711 were determined in analogously constituted 
samples lacking any inhibitor or in the presence of 100 mM GABA, respectively.  
 
4.5.5. Deconvolution: The experiments were performed in the same manner as the 
experiments described for the library screening, expect that an aliquot of 25 µL of a pre-
equilibrated batch of a single oxime was employed. 
 
4.5.6. LC-MS/MS (ESI) analysis: Quantification of NO711 by LC-MS/MS (ESI) was 
performed as described by using an API 3200 triple-quadrupole mass spectrometer.23,32 To 
assure reliable quantification, each day a binding experiment was performed, also matrix 
blanks (generated analogously as described for binding samples but in the absence of NO711 
and [2H10]NO711), a zero sample (matrix blank with 1 nM [2H10]NO711) and matrix standards 
(generated by supplementing matrix blanks with different concentrations of NO711 (50 pM, 
100 pM, 200 pM, 500 pM, 1 nM, 2.5 nM and 5 nM) and 1 nM of [2H10]NO711 were investigated 
and individual calibration curves for marker quantification were generated therefrom. Derived 
from the external calibration curve, the lower limit of quantification (LLOQ) could be determined 
to 50 pM. 
 
4.5.7. Competition experiments applying isolated oximes: The experiments were 
performed as described recently23,32, but substituting the original incubation buffer for 
phosphate buffer (pH 7.1, 12.5 mM Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value adjusted 
with 2 M NaOH).  
 
4.5.8. Analysis of competitive binding experiments: Marker depletion was negligible 
(<10%) in all binding experiments. Specific binding was defined as the difference between the 
total and nonspecific binding. Nonspecific binding less than 50 pM (LLOQ) was not determined 
experimentally, but was extrapolated by linear regression from nonspecifically bound NO711 
concentrations of ≥50 pM. The concentration of a competitor that inhibited 50% of specific 
binding (IC50) was calculated from competition curves by plotting NO711 specific binding 
concentrations against the log of competitor concentration (eight different concentrations per 
competitor) with Prism 5.04 (GraphPad Software, San Diego, CA, USA) using the equation for 
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one-site competition and nonlinear curve fitting. Specific binding determined for control 
samples in the absence of any competitor was set to 100%, whereas the bottom level was set 
to 0% (corresponds to the nonspecific binding of NO711). Ki values were calculated according 
to Cheng and Prussoff33 and are expressed as pKi values. All results are expressed as the 
mean standard error of the mean ± SEM (unless stated otherwise). pKi values were determined 
in at least three separate experiments.  
 
4.5.9. GABA uptake assays: [3H]GABA uptake assays were performed as previously 
described.18 
 
Acknowledgement 
Special thanks go to Silke Duesing-Kropp and Miriam Sandner for excellent technical support.  
 
Conflict of interest 
The authors declare no conflict of interest. 
 
Keywords: LC-MS/MS binding assays, mGAT1, library screening, mass spectrometry, 
pyrrolidine-3-carboxylic acid. 
 
1. Krogsgaard-Larsen P. Med Res Rev. 1988;8:27–56.  
2. Foster AC, Kemp JA. Curr. Opin Pharmacol. 2006;6:7–17. 
3. Treiman DM. Epilepsia 2001;42(Suppl. 3):8–12.  
4. (a) Rissmann RA, De Blas AL, Armstrong DM. J. Neurochem. 2007;103:1285–1292. (b) 
Lanctôt KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. Can. J. Psychiatry 2004;49:439–
453. 
5. Kalueff AV, Nutt DJ. Depression Anxiety 2007;24:495–517. 
6. Krogsgaard-Larsen P, Falch E, Larsson OM, Schousboe A. Epilepsy Res. 1987;1:77–93. 
7. (a) Liu QR, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N. J. Biol. Chem. 
1993;268:2106–2112. (b) Madsen KK, White HS, Schousboe A. Pharmacol Ther. 
2010;125:394–401. 
8. Madsen KK, Rasmus PC, Larsson OM, Krogsgaard-Larsen P, Schousboe A, White HS. J. 
Neurochem. 2009;109:139–144. 
9. Zhou Y, Holmseth S, Guo C, Hassel B, Höfner G, Huitfeldt HS, Wanner KT, Danbolt NC. J. 
Biol. Chem. 2012;287:35733–35746. 
10. Zhou Y, Holmseth S, Hua R, Lehre AC, Olofsson AM, Poblete-Naredo I, Kempson SA, 
Danbolt NC. Am. J. Physiol. Renal. Physiol. 2012;302:F316–F328. 
11. Krogsgaard-Larsen P, Johnston GAR. J. Neurochem. 1975;25:797–802. 
Third publication 
12. Larsson OM, Thorbek P, Krogsgaard-Larsen P, Schousboe A. J. Neurochem. 
1981;37:1509–1516. 
13. Krogsgaard-Larsen P. Mol. Cell. Biochem. 1980;31:105–121. 
14. Huber SK, Wanner KT. ChemMedChem 2018;23:2488–2503. 
15. Hellenbrand T, Höfner G, Wein T, Wanner KT. Bioorg. Med. Chem. 2016;24:2072–2096. 
16. Wein T, Wanner KT. J. Mol. Model 2010;16:155–161. 
17. Wein T, Petrera M, Allmendinger L, Höfner G, Pabel J, Wanner KT. ChemMedChem 
2016;11:509–518. 
18. Kragler A, Höfner G, Wanner KT. Eur. J. Med. Chem. 2008;43:2404–2411. 
19. Hog S, Greenwood JR, Madsen KB, Larsson OM, Frolund B, Schousboe A, Krogsgaard-
Larsen P, Clausen RP. Curr. Top. Med. Chem. 2006;6:1861–1882. 
20. Soudijn W, van Wijngaarden I. Curr. Med. Chem. 2000;7:1063–1079. 
21. Kern FT, Wanner KT. ChemMedChem 2015;10:396–410. 
22. Sindelar M, Wanner KT. ChemMedChem 2012;7:1678–1690. 
23. Zepperitz C, Höfner G, Wanner KT. ChemMedChem 2006;1:208–217. 
24. Höfner G, Wanner KT. Angew. Chem Int. Ed. 2003;42:5235–5237. 
25. Johnson G, Drummond JT, Boxer PA, Bruns RF. J. Med. Chem. 1992;35:233–241. 
26. Schwarzer MF. Synthese potentieller GABA-uptake-inhibitoren mit bicyclischer Struktur 
durch 1,3-dipolare Cycloadditionen und [2+2]-Photocycloadditionen. München: Verl. Dr. Hut; 
2008. 
27. Andersen KE, Lau J, Lundt BF, Petersen H, Huusfeldt PO, Suzdak PD, Swedberg MDB: 
Bioorg. Med. Chem. 2001, 9, 2773–2785. 
28. Sindelar M, Lutz TA, Petrera M, Wanner KT. J. Med. Chem. 2013;56:1323–1340. 
29. Irngartinger H, Escher T. Tetrahedron 1999;55:10753–10760. 
30. Hauke TJ, Wein T, Höfner G, Wanner KT. J. Med. Chem. 2018;61:10310–10332. 
31. Pauli GF, Chen S-N, Simmler C, Lankin DC, Gödecke T, Jaki BU, Friesen JB, McAlpine 
JB, Napolitano JG. J. Med. Chem. 2014;57:9220–9231. 
32. Zepperitz C, Höfner G, Wanner KT. Anal. Bioanal. Chem. 2008;391:309–316. 
33. Cheng YC, Prusoff WH. Biochem. Pharmacol. 1973;22:3099–3108. 
23 
Further Experiments 
 
 
4 Further Experiments 
In the following section, kinetic experiments and stability experiments are presented in detail.  
 
4.1 Generation of Oxime Libraries – Kinetic Experiments 
Oxime libraries were pre-generated in absence of the target mGAT1 by reacting each library 
consisting of eight different aldehydes 15 (1 mM each aldehyde) with an excess of either 2-
(pyrrolidin-3-yl)acetic acid (n = 1) or pyrrolidine-3-carboxylic acid (n = 0) derived hydroxylamine 
(40 mM) at 37 °C in phosphate buffer (pH 6.0, 12.5 mM Na2HPO4, 12.5 mM NaH2PO4, 1 M 
NaCl, pH value was adjusted with 1 M HCl) with a DMSO concentration of 40 % as outlined in 
Scheme 3.  
 
Scheme 3: Synthesis of oximes 13 (n = 1) and 14 (n = 0). Conditions: phosphate buffer (pH 6.0, 12.5 
mM Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value was adjusted with 1 M HCl) + 40 % DMSO at 37 
°C.  
In order to ensure completion of oxime formation within the defined time of 20 h under these 
conditions the oxime generation reaction was exemplarily monitored by the means of 1H NMR 
spectroscopy using the aldehydes 4-nitrobenzaldehyde 15a, biphenyl-2-carbaldehyde 15b, 4-
methoxybenzaldehyde 15c and 2-methoxybenzaldehyde 15d (Figure 8). The aldehyde 15c 
was only used to examine kinetics with 2-(pyrrolidin-3-yl)acetic acid derivative 13 but not with 
the other hydroxylamine 14. Since it showed similar reaction times as biphenyl-2-carbaldehyde 
15b with 13 no new information regarding reaction time for oxime generation with 14 was 
expected.  
For simplification only one single aldehyde at once was used for these kinetic experiments so 
the analysis of the obtained spectra could be reduced to one vanishing aldehyde proton signal 
and one emerging oxime proton signal, respectively. However, to maintain the concentration 
ratio between the reactants at 1:5 one single aldehyde was applied with in a higher 
concentration of 8 mM and was reacted with 40 mM of hydroxylamine. All samples were then 
prepared in phosphate buffer (pH 6.0, 12.5 mM Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, 10 
% D2O) containing 40 % DMSO-d6 at 37 °C and the spectra were recorded with a proton pulse 
sequence including an excitation sculpting block for water suppression. The spectra were 
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recorded before the addition of hydroxylamine 13, directly after the addition of 13 and was 
repeated for 20 hours with a time increment of 10 minutes. For the sake of clarity only the 
significant signals of e. g. the aldehyde proton or the oxime proton were labeled in the spectra. 
Additionally, signals which were found to play a role within the reaction (e.g. intermediates) 
were also labeled with a rectangle.  
 
Figure 8: Applied single aldehydes for kinetic experiments.  
4.1.1 Kinetic Experiments using 2-(Pyrrolidin-3-yl)acetic acid derived Hydroxylamine 
4.1.1.1 Reaction with Single Aldehydes 
2-{1-[(2-Aminooxy)ethyl]pyrrolidine-3-yl}acetic acid 13 was applied within the first set of kinetic 
experiments to begin with 4-nitrobenzaldehyde (15a) as reactant. In the pure aldehyde 
spectrum without hydroxylamine the signal for the aldehyde proton at δ = 9.99 ppm and one 
additional signal at δ = 5.92 ppm were obtained (first spectrum of Figure 9). As the reaction 
took place in aqueous media, the formation of the hydrate of 4-nitrobenzaldehyde (15a) is 
possible and the methine proton of its hydrate could be observed (see Scheme 4). 
Five minutes after addition of hydroxylamine 13 to aldehyde 15a, analysis of the spectrum 
revealed that considerable amounts of aldehyde were still present. Besides the signal for the 
aldehyde proton (δ = 9.99 ppm) and the signal at δ = 5.92 ppm two additional signals appeared: 
one at δ = 8.31 ppm, which was considered to refer to the imine proton (E-configuration) of the 
final product 16a identified by the fact that it is increasing over time and the other one at δ = 
5.59 ppm which is the dominant signal 5 min after the addition of the hydroxylamine (Figure 
9).  
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Figure 9: 1H NMR spectra obtained from the reaction of 4-nitrobenzaldeyhde (15a, δ = 9.99 ppm, 8 mM) 
with hydroxylamine 13 (40 mM) to oxime 16a (δ = 8.31 ppm) after 1) ca. 5 min., 2) 1 h, 3) 2 h, 4) 3 h, 5) 
4 h, 6) 5 h, 7) 6 h 8) 6.5 h at 37 °C. Hydrate 18a of 4-nitrobenzaldehyde observed at δ = 5.92 ppm; 
intermediate 19a observed at δ = 5.59 ppm. 
This signal can be explained when looking at the proposed reaction mechanism depicted in 
Scheme . Aldehyde 15a and its corresponding hydrate 18a are attacked by hydroxylamine 1 
yielding hemiaminal 19a as intermediate which under dehydration finally leads to oxime 16a. 
Since 19a is formed very fast in large amounts – the signal of the methine proton from the 
hemiaminal moiety is present in the first spectrum recorded after 5 min and still detected after 
6 h when no aldehyde nor hydrate signal is detectable – the dehydration can be considered as 
the rate determining step of the overall condensation reaction.  
 
Scheme 4: Formation of hydrate 18 and condensation reaction of hydroxylamine 13 with respective 
aldehydes 15 via tetrameric intermediates 19 to the corresponding oximes 16. 
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The spectrum recorded after 6.5 h finally revealed that all hemiaminal intermediate was fully 
consumed and the signal for the oxime proton at δ = 8.31 ppm reached its maximum intensity 
indicating the complete conversion into oxime 16a (Figure 9). The decrease of the absolute 
signal integrals referring to the reactants i.e. aldehyde 15a, hydrate 18a, and intermediate 19a 
(highlighted in rectangles) as a sum and the increase of the product signal referring to the 
oxime 16a (highlighted in rectangles) are plotted versus time in one single diagram. The 
exponential decay of the reactants and the exponential growth of the product are clearly 
depicted in Figure 10.  
Figure 10: Kinetic plot of reactants and product during oxime formation 16a.  
To verify the assumption, that the mentioned species were components of the same 
equilibrium 1H 2D EXSY NMR experiments were performed. These experiments exploit exactly 
the same pulse sequence as the 2D NOESY experiment. A typical sequence is depicted in 
Figure 11. This pulse sequence consists of a first preparation 90𝑋
°  pulse that transfers all 
magnetization to the x-y-plane where the spins evolve according to their Larmor frequencies. 
Subsequent to the evolution phase t1 another 90𝑋
°  pulse is followed rebuilding z-magnetization. 
After the second pulse a very crucial delay is followed which is called the mixing time tM. During 
this period magnetization transfer is accomplished due to nuclear Overhauser effect caused 
by spatial proximity of neighbored protons. Finally, another 90𝑋
°  pulse transfers the remaining 
magnetization from z- to the x-y-plane where the resulting FID is acquired.66 In the 2D NOESY 
spectrum recorded in phase-sensitive mode the off diagonal peaks representing NOEs have 
opposite phase and sign to those of the diagonal peaks which are made apparent by the 
processing software using different colors. The transfer of magnetization between two 
neighboring spins occurs during the mixing time due to cross-relaxation, but if two spins 
exchange sites e.g. in molecules that are in an equilibrium this magnetization is also 
transferred during tM from one spin to the other. Since these spins have been labeled before 
during t1 with their Larmor frequencies i.e. chemical shifts, the cross peaks in the resulting 
spectrum marks physically identical proton exchanging sites in two different species. These 
particular cross peaks have the same phase and sign as the diagonal peaks and are therefore 
depicted in the same color. To distinguish between the two different phases of the cross peaks 
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– opposite sign to the diagonal peaks caused by NOEs and the same sign due to exchange 
signals – 2D EXSY spectra are therefore mandatorily recorded in phase-sensitive mode. 
 
Figure 11: Pulse sequence of 2D NOESY/EXSY experiments according to literature.66 
The usefulness and reliability of 2D EXSY to verify the proposed reaction mechanism which 
are the basis of the considerations regarding the results of the kinetic investigations are easily 
demonstrated with the equilibrium between free aldehyde 15a and corresponding hydrate 18a 
which reflects the situation in solution before the addition of the respective hydroxylamine. To 
slow down the exchange rate the reaction temperature of this and all following experiments 
was set to 25 °C. Figure 12 nicely depicts the equilibrium between the aldehyde 15a (δ = 9.99 
ppm) and hydrate 18a proton (δ = 5.92 ppm) and are pictured as red contours. In contrast, 
cross peaks resulting from NOEs e.g. between aldehyde proton and the aromatic protons in 
ortho position (δ = 8.06 ppm) or hydrate proton and its aromatic ortho protons (δ = 7.60 ppm) 
are shown in blue contours.  
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Figure 12: EXSY experiment of pure 4-nitrobenzaldehyde (15a) (δ = 9.99 ppm, 8 mM) at 25 °C. Mixing 
time (tM) was 1 s. F1 dimension contained 256 points, F2 dimension contained 1024 points. Number of 
scans was 4. NOE signals are characterized by contrary phases, exchange signals by the same phase 
as the diagonal line. 
 
Figure 13: EXSY experiment of the reaction of 4-nitrobenzaldehyde (15a) (δ = 9.99 ppm, 8 mM) with 
hydroxylamine 13 (40 mM) to oxime 16a at 25 °C. Mixing time (tM) was 1 s. F1 dimension contained 256 
points, F2 dimension contained 1024 points. Number of scans was 4. NOE signals are characterized by 
contrary phases, exchange signals by the same phase as the diagonal line.  
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The EXSY experiment was then applied to the whole reaction mixture using 40 mM of 
hydroxylamine 13. An equilibrium between the aldehyde 15a (δ = 9.99 ppm) and another 
species, referred to the signal at δ = 5.59 ppm was detected leading to the conclusion that this 
signal is a result of the methine proton of intermediate 19a (red contour in rectangle, Figure 
13). Additionally, the NOE signal between the methine proton and the aromatic protons in ortho 
position (δ = 7.62 ppm) of intermediate 19a were observed (blue contour in rectangle, Figure 
13). All NOEs and exchange signals which were detected in the described 1H 2D NMR 
experiments are summarized in Scheme 5.  
 
Scheme 5: Observed NOEs and exchange signals of the shown equilibrium between aldehyde 15a, its 
hydrate 18a and the intermediate 19a of the reaction with hydroxylamine 13.  
In contrast to 15a, no formation of the corresponding hydrate species was observed in the 
spectra of the pure aldehydes 15b-d (first spectrum of Figure 14, Figure 15 and Figure 16), 
but directly after the addition of the hydroxylamine 13 one new signal was detected at δ = 5.43 
ppm for 15b and 15c and δ = 5.70 ppm for 15d, respectively, which vanished over the reaction 
time. Because the shift of the intermediate 19a observed in the kinetic experiments applying 
4-nitrobenzaldehyde 15a was in the same chemical shift region (δ = 5.59 ppm), it was assumed 
that the newly observed signals are also due to the fast reaction of the aldehyde 15b-d and 
the hydroxylamine 13 to the respective hemiaminal 19b-d. Applying the other three aldehydes 
to the above mentioned conditions, reaction times of 4.5 h for biphenyl-2-carbaldehyde (15b) 
(Figure 14), 5 h for 4-methoxybenzaldehyde (15c) (Figure 15) and the fastest reaction time of 
45 minutes for 2-methoxybenzaldehyde (15d) (Figure 16) were determined.  
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Figure 14: 1H NMR spectra obtained from the reaction of biphenyl-2-carbaldehyde (15b, δ = 9.77 ppm, 
8 mM) with hydroxylamine 13 (40 mM) to oxime 16b (δ = 8.03 ppm) after 1) ca. 5 minutes, 2) 1 h, 3) 2 
h, 4) 3 h, 5) 4 h, 6) 4.5 h at 37 °C. Intermediate 19b could be observed at δ = 5.43 ppm. 
 
Figure 15: 1H NMR spectra obtained from the reaction of 4-methoxybenzaldehyde (15c, δ = 9.70 ppm, 
8 mM) with hydroxylamine 13 (40 mM) to oxime 16c (δ = 8.17 ppm) after 1) ca. 5 minutes, 2) 1 h, 3) 2 
h, 4) 3 h, 5) 4 h, 6) 5 h at 37 °C. Intermediate 19c could be observed at δ = 5.43 ppm. 
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Figure 16: 1H NMR spectra obtained from the reaction of 2-methoxybenzaldehyde (15d, δ = 10.14 ppm, 
8 mM) with hydroxylamine 13 (40 mM) to oxime 16d (δ = 8.44 ppm) after 1) ca. 5 minutes, 2) 15 min, 3) 
25 min, 4) 35 min, 5) 45 min at 37 °C. Intermediate 19d could be observed at δ = 5.70 ppm. 
Again, by plotting the sum of the decreasing absolute integral of the reactants – aldehyde and 
intermediate – and the increasing absolute integral of the oximes versus time the exponential 
character of all three reactions were observed (Figure 17).  
Figure 17: Kinetic plot of reactants and product during a) oxime formation 16b, b) oxime formation 16c, 
and c) oxime formation 16d.  
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4.1.1.2 Kinetic Experiments regarding Library 26 
 
Since the composition of library 26 (Figure 18) was different to all other libraries due to three 
extraordinary sterically demanding aldehydes (15i, 15k and 15l) as well as one alkyl aldehyde 
(15j) it was individually tested again by applying standard conditions to verify if those aldehydes 
presumably slow reacting lead to desired oximes in an appropriate time. 
 
Figure 18: Aldehydes of library 26. 
All aldehydes from library 26 were applied in a concentration level of 1 mM. Fortunately, all 
aldehyde protons could be detected as separate signals in the 1H NMR spectrum which was 
recorded before the addition of hydroxylamine 13 (first spectrum, Figure 19). After adding 
hydroxylamine 13, five aldehyde signals disappeared over the time period of approximately 11 
h, while three signals remained even after 20 h at 37 °C (Figure 19) with no noticeable 
decrease. This three signals were assumed to refer to the three aldehydes 15i, 15k and 15l.  
To verify this assumption, the solution of the kinetic experiments was subsequently spiked with 
one additional equivalent of each aldehyde recording an 1H NMR spectrum after each addition. 
After spiking experiment 1 15k (δ = 10.22 ppm), after spiking experiment 2 15i (δ = 10.18 ppm) 
and after spiking experiment 3 15l (δ = 10.10 ppm, Figure 20), respectively, were identified to 
not react sufficiently fast enough to the corresponding oximes like aldehydes 15e, 15f, 15g,15h 
and 15j from the same library. Unfortunately, no conclusion could be drawn with this 
experimental setup if the tritylaldehydes did not react at all or just incompletely to their 
corresponding oximes because the relative decrease of the integrals could not be determined. 
Therefore, in all further experiments 1,3,5-trimethoxybenzene (1 mM, δ = 6.05 ppm) was added 
as an internal standard to guarantee valid quantification of the aldehyde signals. 
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Figure 19: 1H NMR spectra obtained from the reaction of library 26 (δ = 9.80–10.22 ppm, 8 x 1 mM) 
with hydroxylamine 13 (40 mM) after 1) ca. 15 minutes, 2) 3 h, 3) 5 h, 4) 7 h, 5) 9 h, 6) 11 h, 7) 20 h at 
37 °C. First spectrum shows library 26 without hydroxylamine 13. 
 
Figure 20: Spiking experiments with reaction solution of the kinetic experiment with library 26 (8 x 1 
mM) and hydroxylamine 13 at 37 °C. Addition of one equivalent of 15k in spiking experiment 1 (δ = 
10.22 ppm), one equivalent of 15i in spiking experiment 2 (δ = 10.18 ppm) and one equivalent of 15l in 
spiking experiment 3 (δ = 10.10 ppm).  
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Hence, conditions for oxime generation of library 26 had to be adopted and therefore should 
be reacted at an elevated temperature leaving the buffer system (phosphate buffer with pH 
6.0, 40 % DMSO) and the concentration levels of the aldehydes (1 mM each aldehyde) and 
the hydroxylamine (40 mM) unchanged. Temperature of 80 °C was chosen to be tested first 
as this is the highest possible temperature without reaching the boiling point of the aqueous 
amount of the reaction media to prevent potential damage of the NMR instrument during the 
measurements.  
First, all single tritylaldehydes were tested under the newly chosen conditions alone to 
determine the time till full conversion was reached. After 45 h no aldehyde signal was detected 
in all three experiments (Figure 21 for 15k, Figure 22 for 15i, Figure 23 for 15l). Once again, 
library 26 was reacted under the new conditions with hydroxylamine – this time for 45 h – and 
full conversion to the oximes were verify by the disappearance of all aldehyde signals (Figure 
24).  
 
Figure 21: 1H NMR spectra obtained from the reaction of single aldehyde 15k (δ = 10.22 ppm, 1 mM) 
with hydroxylamine 13 (40 mM) to corresponding oximes 16k (δ = 8.38 ppm) after 1) ca. 5 minutes, 2) 
8 h, 3) 45 h at 80 °C. Internal standard is 1,3,5-trimethoxybenzene (δ = 6.05 ppm, 1 mM). 
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Figure 22: 1H NMR spectra obtained from the reaction of single aldehyde 15i (δ = 10.18 ppm, 1 mM) 
with hydroxylamine 13 (40 mM) to corresponding oximes 16i (δ = 8.37 ppm) after 1) ca. 5 minutes, 2) 8 
h, 3) 45 h at 80 °C. Internal standard is 1,3,5-trimethoxybenzene (δ = 6.05 ppm, 1 mM). 
 
Figure 23: 1H NMR spectra obtained from the reaction of single aldehyde 15l (δ = 10.10 ppm, 1 mM) 
with hydroxylamine 13 (40 mM) to corresponding oximes 16l (δ = 8.28 ppm) after 1) ca. 5 minutes, 2) 8 
h, 3) 45 h at 80 °C. Internal standard is 1,3,5-trimethoxybenzene (δ = 6.05 ppm, 1 mM). 
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Figure 24: 1H NMR spectra obtained from the reaction of library 26 (δ = 9.80–10.22 ppm, 8 x 1 mM) 
with hydroxylamine 13 (40 mM) after 1) ca. 5 minutes, 2) 1 h, 3) 6 h, 4) 12 h, 5) 20 h, 6) 32 h, 7) 45 h at 
80 °C. Internal standard is 1,3,5-trimethoxybenzene (δ = 6.05 ppm, 1 mM).  
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4.1.2 Kinetic Experiments using Pyrrolidine-3-carboxylic acid derived Hydroxylamine  
4.1.2.1 Reaction with Single Aldehydes 
The experiments utilizing 2-{1-[(2-aminooxy)ethyl]pyrrolidine-3-yl}carboxylic acid 14 was 
examined under the same conditions as used before for the oxime generation. By applying 
phosphate buffer (pH 6.0, 12.5 mM Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value adjusted 
with 1 M HCl, 10 % D2O) with 40 % DMSO-d6 at 37 °C, the three different single aldehydes 
15a, 15b and 15d were tested with an elevated concentration of 8 mM to be converted to the 
corresponding oximes within 20 h. Again, signal of the aldehyde proton and the signal of the 
oxime proton were monitored and upon the disappearance of the aldehyde signal the 
equilibrium was seen as fully on the site of the product.  
Again, the spectra were recorded with a proton pulse sequence including an excitation 
sculpting block for water suppression. The spectra were recorded before the addition of the 
hydroxylamine 14, directly after the addition of 14 and repeated for 20 hours with a time 
increment of 10 minutes. For the sake of clarity only the significant signals of e. g. the aldehyde 
proton or the oxime proton are labeled in the spectra. Additionally, signals which were found 
to play a role within the reaction (e.g. intermediates) were also labeled with a rectangle. 
For the full conversion of 4-nitrobenzaldehyde 15a with 14 to oxime 17a (δ = 8.33 ppm, Figure 
25) and of biphenyl-2-carbaldehyde 15b with 14 to oxime 17b (δ = 8.04 ppm, Figure 26) with 
reaction times of 6 h and 4 h were required, respectively and the fastest reaction time of 55 
minutes was detected for the formation of oxime 17d (δ = 8.42 ppm, Figure 27) from 2-
methoxybenzaldehyde 15d as already determined by using 2-(pyrrolidin-3-yl)acetic acid 
derivative 13. Not surprisingly, hydrate formation was again detected for 4-nitrobenzaldehyde 
(18a, δ = 5.93 ppm, Figure 25) in phosphate buffer containing 40 % DMSO and for all three 
kinetic experiments the intermediates 20 of the condensation reaction were seen in the spectra 
at δ = 5.61 ppm for 20a, δ = 5.45 ppm for 20b and δ = 5.71 ppm for 20d, respectively. The 
proposed reaction mechanism is shown in Scheme 6. 
 
Scheme 6: Formation of hydrate 18 and condensation reaction of hydroxylamine 14 with respective 
aldehydes 15 via tetrameric intermediates 20 to the corresponding oximes 17. 
  
38 
Further Experiments 
 
 
 
Figure 25: 1H NMR spectra obtained from the reaction of 4-nitrobenzaldehyde (15a, δ = 9.99 ppm, 8 
mM) with hydroxylamine 14 (40 mM) to oxime 17a (δ = 8.33 ppm) after 1) ca. 5 minutes, 2) 1 h, 3) 2 h, 
4) 3 h, 5) 4 h, 6) 5 h, 7) 6 h at 37 °C. Hydrate of 4-nitrobenzaldehyde 18a observed at 5.93 ppm; 
intermediate 20a observed at δ = 5.61 ppm. 
 
Figure 26: 1H NMR spectra obtained from the reaction of biphenyl-2-carbaldehyde (15b, δ = 9.77 ppm, 
8 mM) with hydroxylamine 14 (40 mM) to oxime 17b (δ = 8.04 ppm) after 1) ca. 5 minutes, 2) 1 h, 3) 2 
h, 4) 3 h, 5) 4 h at 37 °C. Intermediate 20b could be observed at δ = 5.45 ppm. 
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Figure 27: 1H NMR spectra obtained from the reaction of 2-methoxybenzaldehyde (15d, δ = 10.14 ppm, 
8 mM) with hydroxylamine 14 (40 mM) to oxime 17d (δ = 8.42 ppm) after 1) ca. 5 minutes, 2) 15 min, 3) 
25 min, 4) 35 min, 5) 45 min, 6) 55 min at 37 °C. Intermediate 20d could be observed at δ = 5.71 ppm. 
The sum of the decreasing absolute integrals of the signals of the aldehydes, hydrate (in the 
case of aldehyde 15a) and the intermediates and the increasing absolute integrals of the 
product signal are again plotted versus time in which the exponential decay of the reactants 
and the exponential increase of the oximes are clearly observed (Figure 28). 
Figure 28: Kinetic plot of reactants and product during a) oxime formation 17a, b) oxime formation 17b, 
and c) oxime formation 17d.  
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4.1.2.2 Kinetic Experiments regarding Library 26 
When library 26 (Figure 18, 1 mM of each aldehyde) was reacted with pyrrolidine-3-carboxylic 
acid derived hydroxylamine 14 as reactant the three sterically hindered tritylaldehydes 15k (δ 
= 10.22 ppm), 15i (δ = 10.18 ppm) and 15l (δ = 10.10 ppm) were again not fully converted to 
the corresponding oximes as all three aldehyde signals were still detected after 20 h reaction 
time at 37 °C (Figure 29). By raising the reaction temperature to 80 °C, the single oximes were 
generated within 45 h which can be seen in Figure 30 for aldehyde 15k, in Figure 31 for 15i 
and in Figure 32 for 15l, respectively. As expected full conversion of all oximes in the hole 
library could be accomplished by reacting the mentioned library 26 at 80 °C for 45 h (Figure 
33). Accordingly, this particular oxime library was generated separately from all other libraries.  
 
Figure 29: 1H NMR spectra obtained from the reaction of library 26 (δ = 9.80–10.22 ppm, 8 x 1 mM) 
with hydroxylamine 14 (40 mM) after 1) ca. 15 minutes, 2) 3 h, 3) 5 h, 4) 7 h, 5) 9 h, 6) 11 h, 7) 20 h at 
37 °C. First spectrum shows library 26 without hydroxylamine 14. 
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Figure 30: 1H NMR spectra obtained from the reaction of single aldehyde 15k (δ = 10.22 ppm, 1 mM) 
with hydroxylamine 14 (40 mM) to corresponding oximes 17k (δ = 8.38 ppm) after 1) ca. 5 minutes, 2) 
8 h, 3) 45 h at 80 °C. Internal standard is 1,3,5-trimethoxybenzene (δ = 6.05 ppm, 1 mM). 
 
Figure 31: 1H NMR spectra obtained from the reaction of single aldehyde 15i (δ = 10.18 ppm, 1 mM) 
with hydroxylamine 14 (40 mM) to corresponding oximes 17i (δ = 8.37 ppm) after 1) ca. 5 minutes, 2) 8 
h, 3) 45 h at 80 °C. Internal standard is 1,3,5-trimethoxybenzene (δ = 6.05 ppm, 1 mM). 
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Figure 32: 1H NMR spectra obtained from the reaction of single aldehyde 15l (δ = 10.10 ppm, 1 mM) 
with hydroxylamine 14 (40 mM) to corresponding oximes 17i (δ = 8.29 ppm) after 1) ca. 5 minutes, 2) 8 
h, 3) 45 h at 80 °C. Internal standard is 1,3,5-trimethoxybenzene (δ = 6.05 ppm, 1 mM). 
 
Figure 33: 1H NMR spectra obtained from the reaction of library 26 (δ = 9.80–10.22 ppm, 8 x 1 mM) 
with hydroxylamine 14 (40 mM) after 1) ca. 5 minutes, 2) 1 h, 3) 6 h, 4) 12 h, 5) 20 h, 6) 32 h, 7) 45 h at 
80 °C. Internal standard is 1,3,5-trimethoxybenzene (δ = 6.05 ppm, 1 mM).  
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4.2 Generated Libraries – Stability Experiments 
Due to the fact that after the oxime generation samples had to be diluted for the screening 
experiments stability measurement had to be performed to proof that they do not undergo 
hydrolysis and that their concentrations do not change throughout the whole biological 
evaluation. Since the final concentrations applied for screening were too low for 1H NMR 
spectroscopy measurements UV or fluorescence measurements were chosen to detect any 
decrease in concentration of formed oximes. Therefore, subsequent to the oxime generation 
the samples with eight different oximes were diluted with phosphate buffer (pH 7.1, 12.5 mM 
Na2HPO4, 12.5 mM NaH2PO4, 1 M NaCl, pH value was adjusted with 1 M NaOH) containing 1 
% DMSO for the incubation with the target mGAT1 at 37 °C for 4 h. For oximes with 2-
(pyrrolidin-3-yl)acetic acid motif three different concentration levels of 1 µM, 100 nM and 10 
nM, respectively and for pyrrolidine-3-carboxylic acid derived oximes only one concentration 
of 1 µM were used for these experiments. The samples of the kinetic experiments which were 
obtained by applying the single aldehydes 15a, 15b, 15c, 15d, 15k, 15i and 15l were used 
and the fluorescence measurements were recorded on a Spectra-Max M2e Plate Reader 
(Molecular Devices) and were analyzed by using Soft-Max Pro 5.4 software. In the case of 4-
nitrobenzaldehyde derived oxime 16a additional measurements were recorded by using Cary 
Eclipse fluorescence spectrophotometer (Varian) equipped with Cary Temperature Controller 
and were analyzed by Cary Eclipse software (version: 1.1.(132)).  
First, absorption spectra of the oxime and the corresponding aldehydes were recorded, but in 
the cases of oxime derived from 15a, 15b, 15c and 15d the spectra did not differentiate in such 
manner that only the oxime was excited when using one particular wavelength without exciting 
the aldehyde to some extent. But by using fluorescence measurements, it was possible to 
determine an emission wavelength for each oxime at which the corresponding aldehyde had 
only a small contribution to the fluorescence signal (≤5 %). For the tritylaldehyde derived 
oximes 16k, 16i, 16l, 17k, 17i and 17l absorption behavior of oximes and aldehydes were 
indeed different, but for the sake of comparability and to receive the highest possible signal for 
all concentration levels to observe changes in the fluorescence signal in a reliable manner, it 
was decided to examine the stability of the oximes resulting from tritylaldehydes in the same 
way as for the other compounds, i.e. by using fluorescence measurements. Hence, suitable 
condition for each oxime had to identified to determine the stability of the equilibrium indicated 
by a stable fluorescence signal for the incubation time of 4 h.  
To observe changes in the equilibrium towards the reactants in a reliable way, linearity 
between the fluorescence signal and concentration of the oxime had to be proven. Therefore, 
different concentration levels including the concentrations at which stability should be verified 
were measured using the determined wavelength for each oxime in triplicates.  
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After proofing linearity, the steady state of the equilibrium of the freshly diluted oximes were 
examined using the wavelengths as determined before for 4 h at 37 °C.  
 
4.2.1 Stability Experiments using 2-(Pyrrolidin-3-yl)acetic acid derived Oximes  
Absorption spectrum of oxime 16a – obtained by the reaction of 13 with 4-nitrobenzaldehyde 
15a – overlapped significantly with the spectrum of the aldehyde 15a (Figure 34a) but 
fluorescence measurements revealed the maximum excitation wavelength of λ = 305 nm and 
emission wavelength of λ = 390 nm whereas the aldehyde 15a constituted 4.3 % of the total 
emission (Figure 34b and Figure 34c). Linearity was found for concentrations between 12.5 
µM and 100 nM (Figure 35a) and by employing 10 µM and 1 µM no change of the fluorescence 
signal was detected (Figure 36a and Figure 36b), respectively. But using 100 nM concentration 
the fluorescence signal was too low (RFU = 0.09) to detect changes in the signal. To overcome 
this problem, Cary Eclipse fluorescence spectrophotometer (Varian) equipped with Cary 
Temperature Controller was used because this device was able to reveal higher signal 
intensities for the same concentrations which could be seen as linearity was limited to 
concentration levels up to 5 µM (Figure 35b). Hence, stability for sample with 100 nM 
concentration level was successfully measured with fluorescence intensity which allowed to 
detect changes of the signal (RFU = 0.4, Figure 36c).  
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Figure 34: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 260–380 nm, λem = 400 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 305 nm, λem = 335–520 nm)]. Each spectrum obtained by measurements of 4-
nitrobenzaldehyde (15a) (10 µM, red) and oxime 16a (10 µM, blue). Spectra were recorded in phosphate 
buffer (pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum of the pure 
solvent as blank.  
Figure 35: Determination of the linear range (RFU versus concentration, µM) in regard to oxime 16a at 
different concentration levels in phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 305 nm, λem 
= 390 nm). Measurements were recorded on a) Spectra-Max M2e Plate Reader or b) Cary Eclipse 
fluorescence spectrophotometer (Varian) equipped with Cary Temperature Controller. 
Figure 36: Monitoring of the fluorescence emission of oxime 16a for possible change of the reaction 
equilibrium towards the starting materials 4-nitrobenzaldehyde (15a) and hydroxylamine 13 at 37 °C for 
4 h after dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM, b) 1 
µM and c) 0.1 µM (λex = 305 nm, λem = 390 nm). 
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In the case of biphenyl-2-carbaldehyde derived oxime 16b, again no wavelength could be 
determined at which exclusively or mostly the oxime 16b was detected (Figure 37a) without 
disturbance from the aldehyde 15b. Excitation wavelength and emission wavelength was 
found to be λ = 250 nm and λ = 385 nm, respectively (Figure 37b and Figure 37c) under which 
the contribution of the aldehyde to the emission signal is 1.8%. Linearity was determined 
between 12.5 µM and 100 nM with R2 of 0.9977 (Figure 38) and on this basis, stability was 
proven at three concentration levels of 10 µM, 1 µM and 100 nM (Figure 39).  
Figure 37: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 250–360 nm, λem = 370 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 250 nm, λem = 270–470 nm)]. Each spectrum obtained by measurements of 
biphenyl-2-carbaldehyde (15b) (10 µM, red) and oxime 16b (10 µM, blue). Spectra were recorded in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum 
of the pure solvent as blank.  
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Figure 38: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9977)] in regard to 
oxime 16b in different concentration levels (12.5 µM, 10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM) in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 250 nm, λem = 385 nm). 
Figure 39: Monitoring of the fluorescence emission of oxime 16b for possible change of the reaction 
equilibrium towards the starting materials biphenyl-2-carbaldehyde (15b) and hydroxylamine 13 at 37 
°C for 4 h after dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM, 
b) 1 µM and c) 0.1 µM (λex = 250 nm, λem = 385 nm). 
 
4-Methoxybenzaldehyde 15c itself and the corresponding oxime 16c showed almost the same 
absorption maxima (Figure 40a) but excitation and emission spectra revealed maxima at λ = 
310 nm for excitation and λ = 395 nm for emission with a contribution of 1.0 % of aldehyde 15c 
to the emission intensity (Figure 40b and Figure 40c). Using concentration levels from 20 µM 
to 100 nM linearity was confirmed (Figure 41) and stability was again demonstrated for all three 
concentration levels (Figure 42). 
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Figure 40: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 260–370 nm, λem = 400 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 310 nm, λem = 330–520 nm)]. Each spectrum obtained by measurements of 4-
methoxybenzaldehyde (15c) (10 µM, red) and oxime 16c (10 µM, blue). Spectra were recorded in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum 
of the pure solvent as blank.  
 
Figure 41: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9998)] in regard to 
oxime 16c in different concentration levels (20 µM, 12.5 µM, 10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 
µM) in phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 310 nm, λem = 395 nm). 
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Figure 42: Monitoring of the fluorescence emission of oxime 16c for possible change of the reaction 
equilibrium towards the starting materials 4-methoxybenzaldehyde (15c) and hydroxylamine 13 at 37 
°C for 4 h after dilution with phosphate buffer (pH 7 + 1 % DMSO) to concentration levels of a) 10 µM, 
b) 1 µM and c) 0.1 µM (λex = 310 nm, λem = 395 nm). 
 
The overlay of both absorption spectra for oxime 16d and the corresponding aldehyde 15d 
showed again that exclusive detection of oxime 16d was not possible (Figure 43a). By using 
excitation wavelength of λ = 265 nm (Figure 43b) maximum for the emission wavelength of λ 
= 380 nm was observed, but with these conditions the aldehyde had 7.6 % contribution to the 
emission signal, which was not within the defined limit of 5 % or less contribution of the pure 
aldehyde to the fluorescence signal. So, I decided to use λ = 370 nm as emission wavelength 
to decrease the contribution to 2.1 % (Figure 43c). Subsequently, linearity was shown for 
concentration levels from 12.5 µM to 100 nM (Figure 44) and oxime 16d was proven to be 
stable after dilution to three different concentrations implied by stable fluorescence signals 
(Figure 45). 
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Figure 43: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 250–360 nm, λem = 370 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 265 nm, λem = 300–500 nm)]. Each spectrum obtained by measurements of 2-
methoxybenzaldehyde (15d) (10 µM, red) and oxime 16d (10 µM, blue). Spectra were in phosphate 
buffer (pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum of the pure 
solvent as blank.  
Figure 44: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9983)] in regard to 
oxime 16d in different concentration levels (12.5 µM, 10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM) in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 265 nm, λem = 370 nm). 
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Figure 45: Monitoring of the fluorescence emission of oxime 16d for possible change of the reaction 
equilibrium towards the starting materials 2-methoxybenzaldehyde (15d) and hydroxylamine 13 at 37 
°C for 4 h after dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM, 
b) 1 µM and c) 0.1 µM (λex = 265 nm, λem = 370 nm). 
 
For the unsubstituted tritylaldehyde 15k and its oxime derivative 16k absorption (Figure 46a), 
excitation (Figure 46b) and emission spectra (Figure 46c) were recorded to obtain maximum 
wavelength of λ = 310 nm for excitation and λ = 390 nm for emission of oxime 16k. The 
contribution of the aldehyde 15k to the emission signal is 0.5%. By applying concentration 
levels from 20 µM to 100 nM linearity was investigated (Figure 47) and measurements with 
concentrations of 10 µM, 1 µM and 100 nM confirmed the stability of the oxime 16k of 4 h, 
respectively (Figure 48).  
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Figure 46: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 250–380 nm, λem = 400 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 310 nm, λem = 335–500 nm)]. Each spectrum obtained by measurements of 
tritylaldehyde 15k (10 µM, red) and oxime 16k (10 µM, blue). Spectra were recorded in phosphate buffer 
(pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum of the pure solvent 
as blank.  
Figure 47: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9998)] in regard to 
oxime 16k in different concentration levels (20 µM,10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM) in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 310 nm, λem = 390 nm). 
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Figure 48: Monitoring of the fluorescence emission of oxime 16k for possible change of the reaction 
equilibrium towards the starting materials tritylaldehyde 15k and hydroxylamine 13 at 37 °C for 4 h after 
dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM, b) 1 µM and c) 
0.1 µM (λex = 310 nm, λem = 390 nm). 
 
Fluorescence measurements of oxime 16i resulting from fluoro-substituted tritylaldehyde 
showed excitation maximum of λ = 310 nm and emission maximum at λ = 390 nm whereas the 
aldehyde 15i constituted 0.2 % of the total emission (Figure 49b and Figure 49c). Linear range 
was determined from 20 µM to 100 nM (Figure 50) and no change of the fluorescence signal 
was observed for the employed concentrations 10 µM, 1 µM and 100nM (Figure 51). 
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Figure 49: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 260–380 nm, λem = 400 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 310 nm, λem = 330–500 nm)]. Each spectrum obtained by measurements of 
tritylaldehyde 15i (10 µM, red) and oxime 16i (10 µM, blue). Spectra were in phosphate buffer (pH 7.1) 
with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum of the pure solvent as blank.  
Figure 50: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9999)] in regard to 
oxime 6i in different concentration levels (20 µM,10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 310 nm, λem = 390 nm). 
Figure 51: Monitoring of the fluorescence emission of oxime 16i for possible change of the reaction 
equilibrium towards the starting materials tritylaldehyde 15i and hydroxylamine 13 at 37 °C for 4 h after 
dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM, b) 1 µM and c) 
0.1 µM (λex = 310 nm, λem = 390 nm).  
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In the case of oxime 16l, the maximum excitation wavelength of λ = 310 nm (Figure 52b) was 
used to observe the maximum for the emission wavelength of λ = 390 nm (Figure 52c) with 
contribution of aldehyde 15l to the fluorescence signal of 1.0 %. Thus, linearity was found for 
concentrations between 20 µM and 100 nM (Figure 53) and stability was proven at all three 
concentrations of 10 µM, 1 µM and 100 nM over the incubation time of 4 h (Figure 54). 
Figure 52: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 260–380 nm, λem = 400 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 310 nm, λem = 330–500 nm)]. Each spectrum obtained by measurements of 
tritylaldehyde 15l (10 µM, red) and oxime 16l (10 µM, blue). Spectra were recorded in phosphate buffer 
(pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum of the pure solvent 
as blank.  
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Figure 53: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9990)] in regard to 
oxime 16l in different concentration levels (20 µM,10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM) in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 310 nm, λem = 390 nm). 
Figure 1: Monitoring of the fluorescence emission of oxime 16l for possible change of the reaction 
equilibrium towards the starting materials tritylaldehyde 15l and hydroxylamine 13 at 37 °C for 4 h after 
dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM, b) 1 µM and c) 
0.1 µM (λex = 310 nm, λem = 390 nm).  
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4.2.2 Stability Experiments using Pyrrolidine-3-carboxylic acid derived Oximes  
By employing oxime 17a utilizing pyrrolidine-3-carboxylic acid and the corresponding aldehyde 
15a, overlapping absorption spectra were again observed (Figure 55a) and excitation and 
emission wavelength of λ = 310 nm (Figure 55b) and λ = 390 nm (Figure 55c) were determined, 
respectively. Under these conditions contribution of 15a is 4.9 % to the fluorescence signal.  
Using concentration levels from 20 µM to 100 nM linearity was confirmed (Figure 56) and 
stability implied by stable fluorescence signal was again demonstrated by employing 10 µM 
and 1 µM (Figure 57). 
Figure 55: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 260–375 nm, λem = 400 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 310 nm, λem = 330–520 nm)]. Each spectrum obtained by measurements of 4-
nitrobenzaldehyde (15a) (10 µM, red) and oxime 17a (10 µM, blue). Spectra were recorded in phosphate 
buffer (pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum of the pure 
solvent as blank.   
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Figure 56: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9936)] in regard to 
oxime 17a in different concentration levels (20 µM,10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 310 nm, λem = 390 nm).  
Figure 57: Monitoring of the fluorescence emission of oxime 17a for possible change of the reaction 
equilibrium towards the starting materials 4-nitrobenzaldehyde (15a) and hydroxylamine 14 at 37 °C for 
4 h after dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM and b) 
1 µM (λex = 310 nm, λem = 390 nm). 
 
For biphenyl-2-carbaldehyde (15b) and its oxime derivative 17b absorption, excitation and 
emission spectra were recorded to obtain maximum wavelength of λ = 265 nm for excitation 
(Figure 58b) and λ = 380 nm for emission (Figure 58c) of oxime 17b whereas aldehyde 15b 
contributed 1.7 % of the signal. Subsequently, linearity was demonstrated for concentration 
levels from 10 µM to 100 nM (Figure 59) and oxime 17b was proven to be stable after dilution 
to 10 µM and 1 µM (Figure 60). 
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Figure 58: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 250–350 nm, λem = 370 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 265 nm, λem = 280–480 nm)]. Each spectrum obtained by measurements of 
biphenyl-2-carbaldehyde (15b) (10 µM, red) and oxime 17b (10 µM, blue). Spectra were recorded in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum 
of the pure solvent as blank.  
Figure 59: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9979)] in regard to 
oxime 17b in different concentration levels (10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM) in phosphate 
buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 265 nm, λem = 380 nm). 
2 0 0 2 5 0 3 0 0 3 5 0 4 0 0
0 .0 0
0 .0 5
0 .1 0
0 .1 5
0 .2 0
W a v e le n g th  / n m
A
b
s
o
rp
ti
o
n
a) 
2 5 0 3 0 0 3 5 0
0
2
4
6
8
1 0
W a v e le n g th  / n m
R
F
U
b) 
3 0 0 3 5 0 4 0 0 4 5 0
0
5
1 0
W a v e le n g th  / n m
R
F
U
c) 
0 5 1 0
0
2
4
6
8
1 0
C o n c e n tra tio n  / µ M
R
F
U
𝑦 = 0.817𝑥 + 0.091 
𝑅2 = 0.9979 
60 
Further Experiments 
 
 
Figure 60: Monitoring of the fluorescence emission of oxime 17b for possible change of the reaction 
equilibrium towards the starting materials 2-methoxybenzaldehyde (15b) and hydroxylamine 14 at 37 
°C for 4 h after dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM 
and b) 1 µM (λex = 265 nm, λem = 380 nm). 
 
Absorption spectra of oxime 17d resulting from 2-methoxybenzaldehyde and the aldehyde 15d 
itself overlapped revealing that detection of only oxime 17d was not possible without exciting 
aldehyde 15d (Figure 61a). By using excitation wavelength of λ = 265 nm – the maximum of 
excitation spectra (Figure 61b) – emission wavelength of λ = 380 nm was determined (Figure 
61c). As already observed with 2-(pyrrolidin-3-yl)acetic acid derivative 16d, the contribution of 
15d to the fluorescence signal is over the set limit of 5 % and therefore, emission wavelength 
of λ = 370 nm was chosen to be used for the stability experiments decreasing contribution to 
3.7 %. Linear range was investigated within concentrations from 10 µM to 100 nM with 
correlation factor of 0.9969 (Figure 62) and oxime 17d was confirmed to be stable after dilution 
to the concentration levels 10 µM and 1 µM, respectively (Figure 63).  
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Figure 61: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 260–360 nm, λem = 370 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 265 nm, λem = 335–505 nm)]. Each spectrum obtained by measurements of 2-
methoxybenzaldehyde (15d) (10 µM, red) and oxime 17d (10 µM, blue). Spectra were recorded in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum 
of the pure solvent as blank. 
Figure 62: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9969)] in regard to 
oxime 17d in different concentration levels (10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM in phosphate 
buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 265 nm, λem = 370 nm).  
Figure 63: Monitoring of the fluorescence emission of oxime 17d for possible change of the reaction 
equilibrium towards the starting materials 2-methoxybenzaldehyde (15d) and hydroxylamine 14 at 37 
°C for 4 h after dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM 
and b) 1 µM (λex = 265 nm, λem = 370 nm).  
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Fluorescence measurements of oxime 17k resulting from unsubstituted tritylaldehyde 15k 
showed excitation maximum of λ = 310 nm (Figure 64b) and emission maximum at λ = 390 nm 
(Figure 64c) whereas the aldehyde 15k constituted 0.5 % of the total emission. Using 
concentration levels from 20 µM to 100 nM linear range was investigated (Figure 65) and 
stability was again demonstrated for the concentration levels 10 µM and 1 µM (Figure 66). 
Figure 64: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 260–380 nm, λem = 400 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 310 nm, λem = 335–500 nm)]. Each spectrum obtained by measurements of 
tritylaldehyde 15k (10 µM, red) and oxime 17k (10 µM, blue). Spectra were in phosphate buffer (pH 7.1) 
with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum of the pure solvent as blank.  
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Figure 65: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9999)] in regard to 
oxime 17k in different concentration levels (20 µM,10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM) in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 310 nm, λem = 390 nm). 
Figure 66: Monitoring of the fluorescence emission of oxime 17k for possible change of the reaction 
equilibrium towards the starting materials tritylaldehyde 15k and hydroxylamine 14 at 37 °C for 4 h after 
dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM and b) 1 µM 
(λex = 310 nm, λem = 390 nm). 
 
For the tritylaldehyde 15i and its oxime derivative 17i absorption (Figure 67a), excitation 
(Figure 67b) and emission spectra (Figure 67c) were recorded to obtain maximum wavelength 
of λ = 310 nm for excitation and λ = 390 nm for emission of oxime 17i with contribution of the 
aldehyde 15k of 0.3 % to the total emission. By applying concentration levels from 20 µM to 
100 nM linearity was examined (Figure 68) and measurements with concentrations of 10 µM 
and 1 µM confirmed the stability of the oxime 5i during the incubation time of 4 h, respectively 
(Figure 69). 
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Figure 67: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 260–380 nm, λem = 400 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 310 nm, λem = 330–500 nm)]. Each spectrum obtained by measurements of 
tritylaldehyde 15i (10 µM, red) and oxime 17i (10 µM, blue). Spectra were recorded in phosphate buffer 
(pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum of the pure solvent 
as blank.  
Figure 68: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9997)] in regard to 
oxime 17i in different concentration levels (20 µM,10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM) in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 310 nm, λem = 390 nm). 
Figure 69: Monitoring of the fluorescence emission of oxime 7i for possible change of the reaction 
equilibrium towards the starting materials tritylaldehyde 15i and hydroxylamine 14 at 37 °C for 4 h after 
dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM and b) 1 µM 
(λex = 310 nm, λem = 390 nm).   
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By employing methoxy-substituted tritylaldehyde 15l and its corresponding oxime derivative 
17l, maxima of excitation and emission of λ = 310 nm (Figure 70b) and λ = 390 nm (Figure 
70c) were found with a contribution of 1.5 % of 15l to the fluorescence signal. Using these 
conditions linearity was determined within concentrations of 20 µM and 100 nM (Figure 71) 
and subsequently, stability was confirmed utilizing two concentration levels of 10 µM and 1 
µM, respectively (Figure 72).  
Figure 70: a) UV spectra (absorption versus wavelength, nm), b) excitation spectra [RFU versus 
wavelength, nm (λex = 260–380 nm, λem = 400 nm)] and c) fluorescence spectra [RFU versus 
wavelength, nm (λex = 310 nm, λem = 330–500 nm)]. Each spectrum obtained by measurements of 
tritylaldehyde 15l (10 µM, red) and oxime 17l (10 µM, blue). Spectra were recorded in phosphate buffer 
(pH 7.1) with 1 % DMSO at 37 °C and were corrected by subtraction of the spectrum of the pure solvent 
as blank.  
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Figure 71: Determination of the linear range [RFU versus concentration, µM (R2 = 0.9989)] in regard to 
oxime 17l in different concentration levels (20 µM,10 µM, 5 µM, 2.5 µM, 1 µM, 0.5 µM, 0.1 µM in 
phosphate buffer (pH 7.1) with 1 % DMSO at 37 °C (λex = 310 nm, λem = 390 nm).  
Figure 72: Monitoring of the fluorescence emission of oxime 17l for possible change of the reaction 
equilibrium towards the starting materials tritylaldehyde 15l and hydroxylamine 14 at 37 °C for 4 h after 
dilution with phosphate buffer (pH 7.1 + 1 % DMSO) to concentration levels of a) 10 µM and b) 1 µM 
(λex = 310 nm, λem = 390 nm).  
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5 Summary of the Thesis 
Neurological disorders like epilepsy or Alzheimer’s disease are assumed to be caused by a 
distorted balance between inhibitory and excitatory neurotransmission. One possibility to treat 
the mentioned diseases is to block the GABA transporters (GATs) responsible for the reuptake 
of GABA – the most abundant inhibitory neurotransmitter in the mammalian central nervous 
system – to enhance the concentration of GABA in the synaptic cleft.  
Four different subtypes of GATs are known named mGAT1-4 when cloned from mice but only 
mGAT1 and mGAT4 are involved in the GABAergic neurotransmission whereby mGAT1 is 
mainly expressed in neurons and mGAT4 in glial cells.  
Many cyclic amino acids like nipecotic acid or guvacine are known potent inhibitors for mGAT1 
with affinities in the low micromolare range. Their application as therapeutics is limited due to 
their inability to cross the blood brain barrier. N-Substitution of the amino acids with lipophilic 
residues via an alkyl chain possessing various functionalities enhanced not only their 
lipophilicity but also their selectivity for mGAT1 with significantly increased affinity. One 
important example is tiagabine which is the (R)-enantiomer of the nipecotic acid derivative and 
is known to be more potent than the (S)-enantiomer by more than half a log unit.  
Hence, it is important to determine the enantiomeric purity of nipecotic acid when used as 
starting material for the synthesis of novel enantiopure GAT inhibitors to warrant the validity of 
the date determined in pharmacological studies. Therefore, a reliable HPLC method for the 
determination of the enantiopurity of nipecotic acid was developed and validated. To gain high 
selectivity for the detection of nipecotic acid in order to determine small impurities of the other 
enantiomer in highly enantiopure samples, derivatization with a 7-
nitrobenzo[c][1,2,5]oxadiazole unit prior to chromatography was chosen. The optimized HPLC 
method was validated regarding specificity, linearity, accuracy, precision and lower limit of 
quantification for both enantiomers. The highest possible enantiomeric excess is determined 
to be 99.87% ee for the (R)-enantiomer and 99.86% ee for the (S)-enantiomer. Additional 
spiking experiments of enantiopure samples with small amounts of racemic nipecotic acid 
revealed that even slight changes in the ee values can be detected. Hence, this HPLC method 
is well suited to determine the ee values of nipecotic acid very precisely in even high 
enantiopure samples.  
Over the years, numerous potent inhibitors for mGAT1 derived from amino acids like nipecotic 
acid have been synthesized carrying different aromatic residues with diverse substituents 
attached through linkers of various length. The majority of published studies deal with 
structure-activity-relationships (SARs) regarding different nipecotic acid and guvacine 
derivatives towards the target mGAT1 but when looking for other amino acid motifs e.g. like 2-
(pyrrolidin-3-yl)acetic acid only scattered publications are available.  
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In this study this lack of information was reduced by providing information about SARs of the 
amino acids 2-(pyrrolidin-3-yl)acetic acid and pyrrolidine-3-carboxylic by identifing new potent 
and selective inhibitors of mGAT1.  
To this end, both 5-membered cyclic amino acids were applied in the combinatorial screening 
concept which is based on the generation of oxime libraries by the reaction of hydroxylamine 
derivatives with different sets of aldehydes and the subsequent screening of these libraries by 
means of competitive LC-MS/MS binding assays. Within this assay NO711 was used as a 
native MS-marker which allows the indirect determination of the binding affinity of the applied 
library.  
First, both hydroxylamine derivatives were synthesized with good overall yields. The oxime 
library formation was performed in the absence of the target mGAT1 by reaction of an excess 
of the above mentioned hydroxylamines with 28 sub-libraries containing eight different 
aldehydes. For either 2-(pyrrolidin-3-yl)acetic acid and pyrrolidine-3-carboxylic acid derived 
oximes the full conversion from the aldehydes to the corresponding oximes were exemplarily 
verified by the means of 1H NMR experiments. All freshly prepared oxime libraries were diluted 
to concentrations suitable for MS Binding Assays, for which concentrations the stability was 
again confirmed using fluorescence measurements. After incubation of the target with the 
marker NO711 the libraries were subsequently screened. Control experiments of either the 
pure aldehyde libraries and the hydroxylamine derivative revealed no significant impact on the 
marker binding.  
The libraries which were able to reduce the specific binding of the marker below 20 % were 
selected for further characterization in deconvolution experiments. In this set of experiments 
all single oximes of the chosen libraries were generated and tested again under the conditions 
used for library screening in order to identify the oximes responsible for the affinity of the library.  
The most affine oximes were then resynthesized in order to fully characterize them regarding 
their pKi values in full-scale competitive MS Binding Assays and of their inhibitory affinities 
(pIC50 values) in [3H]GABA uptake assays18 at all four murine GABA transporters. 
For hydroxylamine delineated from 2-(pyrrolidin-3-yl)acetic acid in the library screening three 
different concentrations were tested (1 µM, 100 nM and 10 nM), whereby at 100 nM four 
libraries reduced marker binding under 20 %. Out of the 32 oximes which were individually 
generated and screened at a concentration of 100 nM eight compounds were able to decrease 
the marker binding under 50 % and were therefore selected to be resynthesized. All 
compounds contained a 1,1’-biphenyl residue and yielded pKi values from 6.97 to 7.87 with 
high subtype selectivity in favor of mGAT1. The oxime with the highest affinity carries a 2’,4’-
dichlorobiphenyl moiety.  
In case of the hydroxylamine derivatives derived from pyrrolidine-3-carboxylic acid only one 
concentration level of 1 µM was applied for the library screening and three out of 28 libraries 
were found to be able to reduce marker binding below 20 %. Deconvolution experiments with 
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these three libraries revealed only one compound reaching the limit of 50 % marker binding. 
But in order to identify a set of potent compounds, the most affine oximes of each of the three 
most active libraries were chosen for resynthesis. Again all hits possessed an 1,1’-biphenyl 
residue but in fact showed lower pKi values from 6.41 to 6.16 compared to oximes with a 2-
(pyrrolidin-3-yl)acetic acid motif. The compounds with 2’,4’-dichloro and 2’-methoxy-4’-fluoro 
substitution yielded the highest pKi values.  
A set of different highly affine oximes were identified with the highest pKi values described so 
far for either 2-(pyrrolidin-3-yl)acetic acid and pyrrolidine-3-carboxylic acid substructures and 
again the application of the library screening concept by the means of MS Binding Assays as 
a read-out tool was successfully proven for the process of drug discovery.  
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6 List of Abbreviations 
°C  degrees Celsius 
~   wave number 
δ  chemical shift 
calcd  calculated 
CNS  central nervous system 
CSP  chiral stationary phase 
d  doublet (NMR) 
DMSO  dimethyl sulfoxide 
ee  enantiomeric excess 
e. g.   exempli gratia (for example) 
equiv.  equivalent 
EI  electron ionization 
ESI  electrospray ionization 
g  gram 
GABA   γ-aminobutyric acid 
GAT  γ-aminobutyric acid transporter 
h  hour 
HEK cell human embryonic kidney cell 
HPLC  high performance liquid chromatography  
HRMS  high resolution mass spectrometry 
HUGO  Human Genome Organization 
Hz  Hertz 
IC50  half maximal inhibitory concentration 
IR  infrared spectrometry 
J  coupling constant 
Ki  inhibitory constant 
LC  liquid chromatography 
LC-MS  liquid chromatography-mass spectrometry 
LLOQ  lower limit of quantification  
LeuTAa  Aquifex aeolicus leucine transporter 
M  molar 
MeOH  Methanol 
mGAT1 murine γ-aminobutyric acid transporter subtype 1 
min  minute 
mp  melting point 
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MS   mass spectrometry 
MS/MS tandem mass spectrometry 
nm  nanometer 
NMR  nuclear magnetic resonance 
NSB  nonspecific binding 
Ppm  part per million 
q  quartet (NMR) 
qNMR  quantitative nuclear magnetic resonance 
Rf   retardation factor 
RFU  relative fluorescence unit 
rt  room temperature 
s  singlet (NMR) 
SAR  structure-activity-relationship 
SB  specific binding 
SD  standard deviation 
SEM  standard error of mean 
SLC6  solute carrier 6 
t  triplet (NMR) 
T  temperature 
tR  retention time 
TB  total binding 
THF  tetrahydrofuran 
WHO   World Health Organization 
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